UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q


☑			QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~September~~June 30, ~~2021~~2022


☐			TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File No. 1-11083

BOSTON SCIENTIFIC CORPORATION

(Exact name of registrant as specified in its charter)


Delaware						04-2695240
(State or other jurisdiction of incorporation or organization)						(I.R.S. Employer Identification No.)

300 Boston Scientific Way, Marlborough, Massachusetts 01752-1234

(Address of Principal Executive Offices) (Zip Code)

508 683-4000

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.01 per share

BSX

New York Stock Exchange

0.625% Senior Notes due 2027

BSX27

New York Stock Exchange

5.50% Mandatory Convertible Preferred Stock, Series A, par value $0.01 per share

BSX PR A

New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☑ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☑ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.


Large accelerated filer	☑	Accelerated filer	☐
Non-accelerated filer	☐	Smaller reporting company	☐
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☑

The number of shares outstanding of Common Stock, $0.01 par value per share, as of ~~October~~July 29, ~~2021~~2022 was ~~1,424,992,477.~~1,431,614,313.

Table of Contents

TABLE OF CONTENTS

Table of Contents

PART I

FINANCIAL INFORMATION

ITEM 1. CONSOLIDATED FINANCIAL STATEMENTS

BOSTON SCIENTIFIC CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)


		Three Months Ended September 30,				Nine Months Ended September 30,					Three Months Ended June 30,				Six Months Ended June 30,
(in millions, except per share data)	(in millions, except per share data)	2021		2020		2021		2020		(in millions, except per share data)	2022		2021		2022		2021

Net sales	Net sales	$	2,932	$	2,659	$	8,761	$	7,204	Net sales	$	3,244	$	3,077	$	6,270	$	5,829
Cost of products sold	Cost of products sold	900		869		2,739		2,465		Cost of products sold	1,011		945		1,966		1,839
Gross profit	Gross profit	2,032		1,790		6,022		4,740		Gross profit	2,233		2,132		4,304		3,990

Operating expenses:	Operating expenses:									Operating expenses:
Selling, general and administrative expenses	Selling, general and administrative expenses	1,066		984		3,206		2,760		Selling, general and administrative expenses	1,165		1,121		2,225		2,139
Research and development expenses	Research and development expenses	310		315		884		857		Research and development expenses	335		298		654		574
Royalty expense	Royalty expense	14		12		38		32		Royalty expense	11		12		23		24
Amortization expense	Amortization expense	184		197		549		595		Amortization expense	204		180		402		365

Intangible asset impairment charges	Intangible asset impairment charges	128		219		173		452		Intangible asset impairment charges	7		45		7		45
Contingent consideration net expense (benefit)	Contingent consideration net expense (benefit)	(26)		6		(117)		(102)		Contingent consideration net expense (benefit)	36		(85)		48		(91)
Restructuring net charges (credits)	Restructuring net charges (credits)	9		3		18		16		Restructuring net charges (credits)	11		3		14		8
Litigation-related net charges (credits)	Litigation-related net charges (credits)	—		260		302		260		Litigation-related net charges (credits)	42		298		42		302
Gain on disposal of businesses and assets	Gain on disposal of businesses and assets	(40)		—		(48)		—		Gain on disposal of businesses and assets	—		(2)		—		(9)
		1,645		1,995		5,003		4,870			1,810		1,870		3,415		3,358
Operating income (loss)	Operating income (loss)	387		(205)		1,019		(130)		Operating income (loss)	423		262		889		632

Other income (expense):	Other income (expense):									Other income (expense):
Interest expense	Interest expense	(86)		(86)		(254)		(265)		Interest expense	(64)		(86)		(343)		(168)
Other, net	Other, net	181		64		192		9		Other, net	(14)		(26)		(46)		11
Income (loss) before income taxes	Income (loss) before income taxes	483		(227)		957		(386)		Income (loss) before income taxes	345		149		501		474
Income tax expense (benefit)	Income tax expense (benefit)	64		(72)		10		(94)		Income tax expense (benefit)	85		(37)		131		(53)
Net income (loss)	Net income (loss)	419		(155)		946		(292)		Net income (loss)	260		186		370		527
Preferred stock dividends	Preferred stock dividends	(14)		(14)		(42)		(19)		Preferred stock dividends	(14)		(14)		(28)		(28)
Net income (loss) available to common stockholders	Net income (loss) available to common stockholders	$	405	$	(169)	$	905	$	(311)	Net income (loss) available to common stockholders	$	246	$	172	$	342	$	500

Net income (loss) per common share — basic	Net income (loss) per common share — basic	$	0.28	$	(0.12)	$	0.64	$	(0.22)	Net income (loss) per common share — basic	$	0.17	$	0.12	$	0.24	$	0.35
Net income (loss) per common share — assuming dilution	Net income (loss) per common share — assuming dilution	$	0.28	$	(0.12)	$	0.63	$	(0.22)	Net income (loss) per common share — assuming dilution	$	0.17	$	0.12	$	0.24	$	0.35

Weighted-average shares outstanding	Weighted-average shares outstanding									Weighted-average shares outstanding
Basic	Basic	1,423.8		1,430.9		1,421.3		1,413.0		Basic	1,429.7		1,421.3		1,428.8		1,420.0
Assuming dilution	Assuming dilution	1,435.6		1,430.9		1,433.0		1,413.0		Assuming dilution	1,437.8		1,432.5		1,438.1		1,431.7

~~See~~Refer to notes to the unaudited consolidated financial statements. Amounts may not foot due to rounding.

Table of Contents

BOSTON SCIENTIFIC CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (UNAUDITED)


		Three Months Ended September 30,				Nine Months Ended September 30,					Three Months Ended June 30,				Six Months Ended June 30,
(in millions)	(in millions)	2021		2020		2021		2020		(in millions)	2022		2021		2022		2021
Net income (loss)	Net income (loss)	$	419	$	(155)	$	946	$	(292)	Net income (loss)	$	260	$	186	$	370	$	527
Other comprehensive income (loss), net of tax:	Other comprehensive income (loss), net of tax:									Other comprehensive income (loss), net of tax:
Foreign currency translation adjustment	Foreign currency translation adjustment	(49)		84		(130)		(104)		Foreign currency translation adjustment	77		2		13		(81)
Net change in derivative financial instruments	Net change in derivative financial instruments	50		(64)		161		(15)		Net change in derivative financial instruments	134		(18)		157		111

Net change in defined benefit pensions and other items	Net change in defined benefit pensions and other items	—		—		1		—		Net change in defined benefit pensions and other items	0		0		0		1
Total other comprehensive income (loss)	Total other comprehensive income (loss)	1		20		31		(119)		Total other comprehensive income (loss)	211		(16)		170		30
Total comprehensive income (loss)	Total comprehensive income (loss)	$	420	$	(135)	$	978	$	(411)	Total comprehensive income (loss)	$	471	$	170	$	540	$	558

~~See~~Refer to notes to the unaudited consolidated financial statements. Amounts may not foot due to rounding.

Table of Contents

BOSTON SCIENTIFIC CORPORATION AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS (UNAUDITED)


		As of					As of
(in millions, except share and per share data)	(in millions, except share and per share data)	September 30, 2021		December 31, 2020		(in millions, except share and per share data)	June 30, 2022		December 31, 2021
		(unaudited)
ASSETS	ASSETS					ASSETS
Current assets:	Current assets:					Current assets:
Cash and cash equivalents	Cash and cash equivalents	$	1,947	$	1,734	Cash and cash equivalents	$	276	$	1,925
Trade accounts receivable, net	Trade accounts receivable, net	1,669		1,531		Trade accounts receivable, net	1,917		1,778
Inventories	Inventories	1,603		1,351		Inventories	1,752		1,610
Prepaid income taxes	Prepaid income taxes	217		194		Prepaid income taxes	264		205
Assets held for sale		—		1,133

Other current assets	Other current assets	792		751		Other current assets	874		799
Total current assets	Total current assets	6,229		6,694		Total current assets	5,083		6,317
Property, plant and equipment, net	Property, plant and equipment, net	2,109		2,084		Property, plant and equipment, net	2,246		2,252
Goodwill	Goodwill	11,820		9,951		Goodwill	12,883		11,988
Other intangible assets, net	Other intangible assets, net	6,227		5,917		Other intangible assets, net	6,349		6,121
Deferred tax assets	Deferred tax assets	4,049		4,210		Deferred tax assets	4,059		4,142
Other long-term assets	Other long-term assets	1,444		1,921		Other long-term assets	1,569		1,410
TOTAL ASSETS	TOTAL ASSETS	$	31,877	$	30,777	TOTAL ASSETS	$	32,189	$	32,229

LIABILITIES AND STOCKHOLDERS’ EQUITY	LIABILITIES AND STOCKHOLDERS’ EQUITY					LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:	Current liabilities:					Current liabilities:
Current debt obligations	Current debt obligations	$	261	$	13	Current debt obligations	$	170	$	261
Accounts payable	Accounts payable	674		513		Accounts payable	732		794
Accrued expenses	Accrued expenses	2,418		2,197		Accrued expenses	2,197		2,436
Other current liabilities	Other current liabilities	669		958		Other current liabilities	784		783
Total current liabilities	Total current liabilities	4,022		3,681		Total current liabilities	3,883		4,274
Long-term debt	Long-term debt	8,824		9,130		Long-term debt	8,802		8,804
Deferred income taxes	Deferred income taxes	274		330		Deferred income taxes	265		310
Other long-term liabilities	Other long-term liabilities	2,296		2,309		Other long-term liabilities	1,988		2,220

Commitments and contingencies	Commitments and contingencies	0		0		Commitments and contingencies	0		0

Stockholders’ equity	Stockholders’ equity					Stockholders’ equity
Preferred stock, $0.01 par value - authorized 50,000,000 shares - issued 10,062,500 shares as of September 30, 2021 and December 31, 2020		—		—
Common stock, $0.01 par value - authorized 2,000,000,000 shares - issued 1,688,023,638 shares as of September 30, 2021 and 1,679,911,918 shares as of December 31, 2020		17		17
Treasury stock, at cost - 263,289,848 shares as of September 30, 2021 and December 31, 2020		(2,251)		(2,251)
Preferred stock, $0.01 par value - authorized 50,000,000 shares - issued 10,062,500 shares as of June 30, 2022 and December 31, 2021						Preferred stock, $0.01 par value - authorized 50,000,000 shares - issued 10,062,500 shares as of June 30, 2022 and December 31, 2021	—		—
Common stock, $0.01 par value - authorized 2,000,000,000 shares - issued 1,693,192,785 shares as of June 30, 2022 and 1,688,810,052 shares as of December 31, 2021						Common stock, $0.01 par value - authorized 2,000,000,000 shares - issued 1,693,192,785 shares as of June 30, 2022 and 1,688,810,052 shares as of December 31, 2021	17		17
Treasury stock, at cost - 263,289,848 shares as of June 30, 2022 and December 31, 2021						Treasury stock, at cost - 263,289,848 shares as of June 30, 2022 and December 31, 2021	(2,251)		(2,251)
Additional paid-in capital	Additional paid-in capital	19,930		19,732		Additional paid-in capital	20,103		19,986
Accumulated deficit	Accumulated deficit	(1,473)		(2,378)		Accumulated deficit	(1,050)		(1,392)
Accumulated other comprehensive income (loss), net of tax	Accumulated other comprehensive income (loss), net of tax	238		207		Accumulated other comprehensive income (loss), net of tax	433		263
Total stockholders’ equity	Total stockholders’ equity	16,462		15,326		Total stockholders’ equity	17,251		16,622
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$	31,877	$	30,777	TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$	32,189	$	32,229

~~See~~Refer to notes to the unaudited consolidated financial statements. Amounts may not foot due to rounding.

Table of Contents

BOSTON SCIENTIFIC CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED)


		Three Months Ended September 30,				Nine Months Ended September 30,					Three Months Ended June 30,				Six Months Ended June 30,
(in millions, except share data)	(in millions, except share data)	2021		2020		2021		2020		(in millions, except share data)	2022		2021		2022		2021
Preferred stock shares outstanding
Preferred stock shares issued										Preferred stock shares issued
Beginning	Beginning	10,062,500		10,062,500		10,062,500		—		Beginning	10,062,500		10,062,500		10,062,500		10,062,500
Preferred stock issuance	Preferred stock issuance	—		—		—		10,062,500		Preferred stock issuance	—		—		—		—
Ending	Ending	10,062,500		10,062,500		10,062,500		10,062,500		Ending	10,062,500		10,062,500		10,062,500		10,062,500
Common stock shares outstanding
Common stock shares issued										Common stock shares issued
Beginning	Beginning	1,685,006,608		1,676,753,566		1,679,911,918		1,642,488,911		Beginning	1,692,828,987		1,683,861,226		1,688,810,052		1,679,911,918
Common stock issuance	Common stock issuance	—		—		—		29,382,500		Common stock issuance	—		—		—		—
Stock-based compensation		3,017,030		2,674,643		8,111,720		7,556,798
Impact of stock-based compensation plans										Impact of stock-based compensation plans	363,798		1,145,382		4,382,733		5,094,690
Ending	Ending	1,688,023,638		1,679,428,209		1,688,023,638		1,679,428,209		Ending	1,693,192,785		1,685,006,608		1,693,192,785		1,685,006,608

Preferred stock	Preferred stock									Preferred stock
Beginning	Beginning	$	—	$	—	$	—	$	—	Beginning	$	—	$	—	$	—	$	—
Preferred stock issuance	Preferred stock issuance	—		—		—		—		Preferred stock issuance	—		—		—		—
Ending	Ending	—		$	—	—		$	—	Ending	$	—	$	—	—		$	—
Common stock	Common stock									Common stock
Beginning	Beginning	$	17	$	17	$	17	$	16	Beginning	$	17	$	17	$	17	$	17
Common stock issuance	Common stock issuance	—		—		—		—		Common stock issuance	—		—		—		—
Stock-based compensation		—		—		—		—
Impact of stock-based compensation plans										Impact of stock-based compensation plans	—		—		—		—
Ending	Ending	$	17	$	17	$	17	$	17	Ending	$	17	$	17	$	17	$	17
Treasury Stock	Treasury Stock									Treasury Stock
Beginning	Beginning	$	(2,251)	$	(1,717)	$	(2,251)	$	(1,717)	Beginning	$	(2,251)	$	(2,251)	$	(2,251)	$	(2,251)
Repurchase of common stock	Repurchase of common stock	—		—		—		—		Repurchase of common stock	—		—		—		—
Ending	Ending	$	(2,251)	$	(1,717)	$	(2,251)	$	(1,717)	Ending	$	(2,251)	$	(2,251)	$	(2,251)	$	(2,251)
Additional Paid-In Capital	Additional Paid-In Capital									Additional Paid-In Capital
Beginning	Beginning	$	19,817	$	19,590	$	19,732	$	17,561	Beginning	$	20,043	$	19,750	$	19,986	$	19,732
Preferred stock issuance		—		—		—		975
Common stock issuance		—		—		—		975
Stock-based compensation		113		97		199		176

Impact of stock-based compensation plans										Impact of stock-based compensation plans	60		66		117		85
Ending	Ending	$	19,930	$	19,687	$	19,930	$	19,687	Ending	$	20,103	$	19,817	$	20,103	$	19,817
Accumulated Deficit	Accumulated Deficit									Accumulated Deficit
Beginning	Beginning	$	(1,878)	$	(2,405)	$	(2,378)	$	(2,253)	Beginning	$	(1,296)	$	(2,050)	$	(1,392)	$	(2,378)
Net income (loss)	Net income (loss)	419		(155)		946		(292)		Net income (loss)	260		186		370		527
Cumulative effect adjustment for adoption of ASU 2016-13		—		—		—		(10)
Preferred stock dividends	Preferred stock dividends	(14)		(14)		(42)		(19)		Preferred stock dividends	(14)		(14)		(28)		(28)
Ending	Ending	$	(1,473)	$	(2,574)	$	(1,473)	$	(2,574)	Ending	$	(1,050)	$	(1,878)	$	(1,050)	$	(1,878)
Accumulated Other Comprehensive Income (Loss), Net of Tax	Accumulated Other Comprehensive Income (Loss), Net of Tax									Accumulated Other Comprehensive Income (Loss), Net of Tax
Beginning	Beginning	$	237	$	131	$	207	$	270	Beginning	$	222	$	254	$	263	$	207
Total other comprehensive income (loss)		1		20		31		(119)
Changes in other comprehensive income (loss)										Changes in other comprehensive income (loss)	211		(16)		170		30
Ending	Ending	$	238	$	151	$	238	$	151	Ending	$	433	$	237	$	433	$	237
Total stockholders' equity	Total stockholders' equity	16,462		15,564		16,462		15,564		Total stockholders' equity	$	17,251	$	15,942	17,251		15,942

~~See~~Refer to notes to the unaudited consolidated financial statements. Amounts may not foot due to rounding.

Table of Contents

BOSTON SCIENTIFIC CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

Nine Months Ended September 30,
(in millions) 2021 2020
Net income (loss) $ 946 $ (292)
Adjustments to reconcile net income (loss) to cash provided by (used for) operating activities
Gain on disposal of businesses and assets (48) —
Depreciation and amortization 803 834
Deferred and prepaid income taxes (49) (13)
Stock-based compensation expense 145 128
Intangible asset impairment charges 173 452
Net loss (gain) on investments and notes receivable (208) (29)
Contingent consideration net expense (benefit) (117) (102)
Inventory step-up amortization 15 42
Foreign exchange (gain) loss 17 13
Other, net 32 46
Increase (decrease) in operating assets and liabilities, excluding purchase accounting:
Trade accounts receivable (131) 242
Inventories (315) (1)
Other assets (145) (119)
Accounts payable, accrued expenses and other liabilities 275 (364)
Cash provided by (used for) operating activities 1,392 835
Purchases of property, plant and equipment (288) (217)
Proceeds from sale of property, plant and equipment 10 6
Payments for acquisitions of businesses, net of cash acquired (2,014) (3)
Proceeds from royalty rights 62 66
Payments for investments and acquisitions of certain technologies (51) (130)
Proceeds from sale of investments and disposition of certain assets 329 —
Proceeds from disposal of businesses 801 15
Proceeds from settlements of hedge contracts 15 —
Cash provided by (used for) investing activities (1,136) (264)
Payment of contingent consideration previously established in purchase accounting (14) (35)
Payments for royalty rights (85) (97)
Payments on short-term borrowings — (2,950)
Proceeds from short-term borrowings, net of debt issuance costs — 2,245
Net increase (decrease) in commercial paper — (714)
Payments on borrowings from credit facilities — (1,919)
Proceeds from borrowings on credit facilities — 1,916
Payments on long-term borrowings and debt extinguishment costs — (1,000)
Proceeds from long-term borrowings, net of debt issuance costs — 1,683
Cash dividends paid on preferred stock (42) (14)
Net proceeds from issuance of preferred stock in connection with public offering — 975
Net proceeds from issuance of common stock in connection with public offering — 975
Cash used to net share settle employee equity awards (48) (59)
Proceeds from issuances of common stock pursuant to employee stock compensation and purchase plans 102 107
Cash provided by (used for) financing activities (87) 1,112
Effect of foreign exchange rates on cash (5) (8)
Net increase (decrease) in cash, cash equivalents, restricted cash and restricted cash equivalents 164 1,675
Cash, cash equivalents, restricted cash and restricted cash equivalents at beginning of period 1,995 607
Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period $ 2,159 $ 2,282

~~See~~


	Six Months Ended June 30,
(in millions)	2022		2021
Net income (loss)	$	370	$	527
Adjustments to reconcile net income (loss) to cash provided by (used for) operating activities
Gain on disposal of businesses and assets	—		(9)
Depreciation and amortization	558		531
Deferred and prepaid income taxes	(93)		(88)
Stock-based compensation expense	107		94
Goodwill and other intangible asset impairment charges	7		45
Net loss (gain) on investments and notes receivable	36		(22)
Contingent consideration net expense (benefit)	48		(91)
Inventory step-up amortization	25		8

Debt extinguishment costs	194		—
Other, net	31		35
Increase (decrease) in operating assets and liabilities, excluding purchase accounting:
Trade accounts receivable	(162)		(145)
Inventories	(180)		(100)
Other assets	(244)		(200)
Accounts payable, accrued expenses and other liabilities	(449)		340

Cash provided by (used for) operating activities	249		927

Investing activities:
Purchases of property, plant and equipment and internal use software	(226)		(181)
Proceeds from sale of property, plant and equipment	9		7
Payments for acquisitions of businesses, net of cash acquired	(1,471)		(706)
Proceeds from (payments for) investments and acquisitions of certain technologies	(14)		92
Proceeds from disposal of certain businesses and assets	5		801
Proceeds from royalty rights	36		43
Proceeds from settlements of hedge contracts	56		15
Cash provided by (used for) investing activities	(1,603)		71

Financing activities:
Payment of contingent consideration previously established in purchase accounting	(283)		(14)
Payments for royalty rights	(39)		(42)
Payments on short-term borrowings	(250)		—

Net increase (decrease) in commercial paper	154		—


Payments on long-term borrowings and debt extinguishment costs	(3,184)		—
Proceeds from long-term borrowings, net of debt issuance costs	3,270		—
Cash dividends paid on preferred stock	(28)		(28)


Cash used to net share settle employee equity awards	(47)		(47)
Proceeds from issuances of common stock pursuant to employee stock compensation and purchase plans	58		38
Cash provided by (used for) financing activities	(350)		(93)

Effect of foreign exchange rates on cash	(6)		(2)

Net increase (decrease) in cash, cash equivalents, restricted cash and restricted cash equivalents	(1,710)		903
Cash, cash equivalents, restricted cash and restricted cash equivalents at beginning of period	2,168		1,995
Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period	$	458	$	2,898

Refer to notes to the unaudited consolidated financial statements. Amounts may not foot due to rounding.

Table of Contents

BOSTON SCIENTIFIC CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

(SUPPLEMENTAL INFORMATION)


		Nine Months Ended September 30,					Six Months Ended June 30,
(in millions)	(in millions)	2021		2020		(in millions)	2022		2021
Supplemental Information	Supplemental Information					Supplemental Information
Stock-based compensation expense	Stock-based compensation expense	$	145	$	128	Stock-based compensation expense	$	107	$	94
Fair value of contingent consideration recorded in purchase accounting	Fair value of contingent consideration recorded in purchase accounting	384		—		Fair value of contingent consideration recorded in purchase accounting	—		221
Non-cash impact of transferred royalty rights	Non-cash impact of transferred royalty rights	(62)		(66)		Non-cash impact of transferred royalty rights	(36)		(43)


		As of September 30,					As of June 30,
Reconciliation to amounts in the unaudited consolidated balance sheets:		2021		2020
Reconciliation to amounts within the unaudited consolidated balance sheets:						Reconciliation to amounts within the unaudited consolidated balance sheets:	2022		2021
Cash and cash equivalents	Cash and cash equivalents	$	1,947	$	2,022	Cash and cash equivalents	$	276	$	2,675
Restricted cash and restricted cash equivalents included in Other current assets	Restricted cash and restricted cash equivalents included in Other current assets	155		214		Restricted cash and restricted cash equivalents included in Other current assets	132		167
Restricted cash equivalents included in Other long-term assets	Restricted cash equivalents included in Other long-term assets	57		46		Restricted cash equivalents included in Other long-term assets	50		57
Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period	Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period	$	2,159	$	2,282	Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period	$	458	$	2,898

~~See~~Refer to notes to the unaudited consolidated financial statements. Amounts may not foot due to rounding.

Table of Contents

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

NOTE A – BASIS OF PRESENTATION

The accompanying unaudited consolidated financial statements of Boston Scientific Corporation have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP) and with the instructions to Form 10-Q and Article 10 of Regulation S-X, and they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. When used in this report, the terms, "we," "us," "our," and "the Company" mean Boston Scientific Corporation and its divisions and subsidiaries. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for fair presentation have been included. Operating results for the three and ~~nine~~six months ended ~~September~~June 30, ~~2021~~2022 are not necessarily indicative of the results that may be expected for the year ending December 31, ~~2021.~~2022. Accordingly, our unaudited consolidated financial statements and footnotes thereto should be read in conjunction with our audited consolidated financial statements and footnotes thereto included in Item 8 of our most recent Annual Report on Form 10-K.

In the first quarter of 2022, we reorganized our operational structure in order to strengthen our category leadership in the markets we serve and, in particular, benefit our Cardiology customers and patients. Following the reorganization, we have aggregated our core businesses into 2 reportable segments: MedSurg and Cardiovascular, each of which generates revenues from the sale of medical devices. We have revised prior periods to conform to the current year presentation.

Amounts reported in millions within this Quarterly Report on Form 10-Q are computed based on the amounts in thousands. As a result, the sum of the components may not equal the total amount reported in millions due to rounding. Certain columns and rows within tables may not add due to the use of rounded numbers. Percentages presented are calculated from the underlying unrounded amounts.

Subsequent Events

We evaluate events occurring after the date of our accompanying unaudited consolidated balance sheet for potential recognition or disclosure in our financial statements. Those items requiring recognition in the financial statements have been recorded and disclosed accordingly.

Those items requiring disclosure (non-recognized subsequent events) in the financial statements have been disclosed accordingly. Refer to~~Note B – Acquisitions, Divestitures and Strategic Investments,~~ Note H – Commitments and Contingencies and Note I – Stockholders' Equity for further details.

NOTE B – ACQUISITIONS, DIVESTITURES AND STRATEGIC INVESTMENTS

Our accompanying unaudited consolidated financial statements include the operating results for acquired entities from the respective dates of acquisition. We completed ~~3 acquisitions~~1 acquisition in the first six months of 2022, and 1 acquisition and 1 divestiture in the first ~~nine~~six months of ~~2021 and did not complete any significant acquisitions or divestitures during the first nine months of 2020.~~2021. We have not presented supplemental pro forma financial information for completed acquisitions or divestitures given their results are not material to our accompanying unaudited consolidated financial statements. Further, transaction costs were immaterial to our accompanying unaudited consolidated financial statements and were expensed as incurred.

~~In addition, on September 21, 2021,~~On June 15, 2022, we announced our entry into a definitive agreement with Synergy Innovation Co, Ltd, to ~~acquire Devoro Medical, Inc. (Devoro Medical)~~purchase its majority stake of M.I. Tech Co., Ltd., (M.I. Tech), a ~~privately-held company which has developed~~publicly traded Korean manufacturer and distributor of medical devices for endoscopic and urologic procedures. The agreement, whereby we will purchase approximately 64 percent of the WOLF Thrombectomy® Platform, designed to capture and extract blood clots in arterial, venous and pulmonary embolism procedures. We have been an investor in Devoro Medical since 2019 and hold an equity stakeoutstanding shares of ~~approximately 16 percent. The transaction price~~M.I. Tech, consists of ~~an upfront cash payment~~a purchase price of ~~$320 million,~~KRW 291.2 billion or approximately ~~$269~~$230 million, ~~after adjustments for our current equity ownership, debt, and other~~subject to closing ~~adjustments; and up to $80 million upon achievement of certain clinical and regulatory milestones, or approximately $67 million after adjustments for current equity ownership.~~adjustments. The acquisition is expected to close induring the ~~fourth quarter~~second half of ~~2021,~~2022, subject to customary closing conditions. ~~Following the closing of the acquisition, we plan~~The M.I. Tech stent portfolio complements our existing Endoscopy portfolio which will give physicians more treatment options to ~~integrate the Devoro Medical business into our Peripheral Interventions division.~~meet specific patient needs.

2022 Acquisition

~~Further, on October 6, 2021,~~On February 14, 2022, we ~~announced~~completed our ~~entry into a definitive agreement to acquire~~acquisition of Baylis Medical Company Inc. (Baylis Medical), a privately-held company which has developed the ~~radiofrequcncy~~radiofrequency (RF) NRG™ and VersaCross™ Transseptal Platforms as well as a family of guidewires, sheaths and dilators used to support left heart access, which ~~will expand~~expands our electrophysiology and structural heart product portfolios. The transaction ~~consists~~consisted of an upfront cash payment of ~~$1.75~~$1.471 billion, net of cash acquired, subject to closing adjustments. ~~The acquisition is expected to close during the first quarter of 2022, subject to customary closing conditions. Following the closing of the acquisition, we plan to integrate~~We are integrating the Baylis Medical business into our ~~Electrophysiology~~Cardiology division.

~~2021 Acquisitions~~

Table of Contents

Purchase Price Allocation

The preliminary purchase price was comprised of the amounts presented below, which represent the preliminary determination of the fair value of identifiable assets acquired and liabilities assumed. The final determination of the fair value of certain assets and liabilities will be completed within the measurement period in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 805, Business Combinations (FASB ASC Topic 805).


(in millions)
Payment for acquisition, net of cash acquired	$	1,471


	$	1,471

The preliminary purchase price allocation was comprised of the following components:


(in millions)
Goodwill	$	989
Amortizable intangible assets	657

Other assets acquired	113

Liabilities assumed	(280)
Net deferred tax liabilities	(8)
	$	1,471

Goodwill was primarily established due to synergies expected to be gained from leveraging our existing operations, as well as revenue and cash flow projections associated with future technologies and is not deductible for tax purposes.

We allocated a portion of the preliminary purchase price to the specific intangible asset categories as follows:


	Amount Assigned (in millions)		Weighted Average Amortization Period (in years)	Risk-Adjusted Discount Rates used in Purchase Price Allocation

Amortizable intangible assets:
Technology-related	$	622	11	11%
Other intangible assets	36		11	11%



	$	657

2021 Acquisition

On March 1, 2021, we completed the acquisition of Preventice Solutions, Inc. (Preventice), a privately-held company which offers a full portfolio of mobile cardiac health solutions and services, ranging from ambulatory cardiac monitors, to cardiac

~~Table of Contents~~

event monitors and mobile cardiac telemetry. The transaction consisted of an upfront cash payment of $925 million and up to an additional $300 million in a potential commercial milestone payment. We ~~have~~had been an investor in Preventice since 2015 and held an equity stake of approximately 22 percent immediately prior to the acquisition date. We remeasured the fair value of our previously-held investment based on the allocation of the purchase price according to priority of equity interests, which resulted in a $195 million gain recognized within Other, net in the first quarter of 2021. The transaction price for the remaining stake consisted of an upfront cash payment of $706 million, net of cash acquired, and ~~up to approximately $230~~an additional revenue-based milestone payment of $216 million ~~in future milestone payments.~~made during the second quarter of 2022. The Preventice business is being managed by our ~~Cardiac Rhythm Management~~Cardiology division.

~~On August 6, 2021, we completed our acquisition~~Table of the remaining shares of Farapulse, Inc. (Farapulse), a privately-held company that has developed a non-thermal ablation system for the treatment of atrial fibrillation (AF) and other cardiac arrhythmias. The transaction consisted of an upfront cash payment of $450 million, up to $125 million upon achievement of certain clinical and regulatory milestones and additional revenue-based payments over the next three years. We have been an investor in Farapulse since 2014 and held an equity stake of approximately 27 percent immediately prior to the acquisition date. We remeasured the fair value of our previously-held investment based on the allocation of the purchase price according to priority of equity interests which resulted in a $222 million gain recognized within ~~Other, net~~ during the third quarter of 2021. The transaction price for the remaining stake consisted of an upfront cash payment of $268 million, net of cash acquired, and up to approximately $92 million in future milestone payments. The Farapulse business is being integrated into our Electrophysiology division.Contents

On September 1, 2021, we completed our acquisition of the global surgical business of Lumenis LTD. (Lumenis), a privately-held company that develops and commercializes energy-based medical solutions, including innovative laser systems, fibers and accessories used for urology and otolaryngology procedures. The transaction consisted of an upfront cash payment of $1.039 billion, net of cash acquired. The Lumenis business is being integrated into our Urology and Pelvic Health division.

Purchase Price Allocation

~~The preliminary purchase price~~We accounted for the ~~acquisitions completed during~~acquisition of Preventice as a business combination, and in accordance with FASB ASC Topic 805, we recorded the ~~first nine months of 2021 was comprised of the amounts presented below, which represent the preliminary determination of the fair value of identifiable~~ assets acquired and liabilities ~~assumed.~~assumed at their respective fair values as of the acquisition date. The final determination of the fair value of certain assets and liabilities, in particular those associated with our acquisition of Lumenis, will be completed within the measurement period in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 805, ~~Business Combinations. Due to the timing of the Lumenis acquisition, efforts to obtain information and complete the valuation studies necessary to determine the fair value of the various~~ purchase price ~~components are still ongoing.~~

(in millions) Preventice Lumenis Farapulse Total
Payment for acquisition, net of cash acquired $ 706 $ 1,039 $ 268 $ 2,014
Fair value of contingent consideration 221 — 162 384
Fair value of prior interest 269 — 222 491
$ 1,197 $ 1,039 $ 653 $ 2,889

~~The preliminary purchase price allocation for these acquisitions~~ was comprised of the following components:

(in millions) Preventice Lumenis Farapulse Total
Goodwill $ 926 $ 582 $ 386 $ 1,894
Amortizable intangible assets 237 459 267 964
Indefinite-lived intangible assets — — 43 43
Other assets acquired 65 115 9 190
Liabilities assumed (32) (86) (10) (127)
Net deferred tax liabilities — (32) (43) (74)
$ 1,197 $ 1,039 $ 653 $ 2,889


(in millions)
Payment for acquisition, net of cash acquired	$	706
Fair value of contingent consideration	221
Fair value of prior interest	269
	$	1,197


(in millions)
Goodwill	$	926
Amortizable intangible assets	237

Other assets acquired	65

Liabilities assumed	(32)

	$	1,197

We allocated a portion of the purchase price to the specific intangible asset categories as follows:


	Amount Assigned (in millions)		Weighted Average Amortization Period (in years)	Risk-Adjusted Discount Rates used in Purchase Price Allocation
Amortizable intangible assets:
Technology-related	$	215	9	10%

Other intangible assets	22		8		10%


	$	237

~~Table of Contents~~

~~We allocated a portion~~In the second quarter of 2022 we recorded certain measurement period adjustments related to our prior year acquisition of the ~~preliminary purchase price~~surgical business of Lumenis, LTD. (Lumenis). We recorded an accrued income tax liability within Other non-current liabilities within our accompanying unaudited consolidated balance sheets of $177 million related to uncertain tax positions assumed in connection with the acquisition. We were indemnified by the sellers for the majority of such tax obligations and recognized a corresponding indemnification asset of $172 million at the acquisition date within Other non-current assets within our accompanying unaudited consolidated balance sheets. Subsequent to the ~~specific intangible~~acquisition date, interest and penalties accrued on the tax liability are being recorded within Income tax expense (benefit) and corresponding adjustments to the indemnification asset ~~categories as follows:~~

Amount Assigned
(in millions)
Weighted Average Amortization Period
(in years)
Risk-Adjusted Discount
Rates used in Purchase Price Allocation
Preventice:
Amortizable intangible assets:
Technology-related $ 215 9 10%
Other intangible assets 22 8 10%
$ 237
Lumenis:
Amortizable intangible assets:
Technology-related $ 417 14 11%
Other intangible assets 42 13 11%
$ 459
Farapulse:
Amortizable intangible assets:
Technology-related $ 267 12 16%
Indefinite-lived intangible assets:
In-process research and development (IPR&D) 43 N/A 17%
$ 310
are being recorded in Other, net within our accompanying unaudited consolidated statements of operations. The outcome of these matters is subject to uncertainty and ultimately, the amount of tax due and the related indemnification reimbursement we receive will be dependent on the outcome of tax return examinations by relevant authorities. Refer to Note F – Supplemental Balance Sheet Information for further details regarding our indemnification asset.

2021 Divestiture

On March 1, 2021, we completed the divestiture of the Specialty Pharmaceuticals business to Stark International Lux S.A.R.L., and SERB SAS, affiliates of SERB, a European specialty pharmaceutical group, for a purchase price of approximately $800 million, ~~which was~~ subject to certain adjustments including cash on hand at the closing of the transaction. The agreement included the transfer of 5 facilities and approximately 280 employees globally.

~~We classified~~In the ~~assets~~second quarter and ~~liabilities~~first six months of 2021, we recognized a Gain on disposal of businesses and assets associated with the ~~Specialty Pharmaceuticals business (disposal group) as held for sale~~transaction of $2 million and $9 million, respectively, within our accompanying unaudited consolidated ~~balance sheet as~~statements of ~~December 31, 2020 at their respective carrying values, which approximated fair value, less costs to sell. Assets within the disposal group are presented within~~

~~Assets held for sale~~ ~~and liabilities are presented within~~ ~~Other current liabilities~~ ~~within our consolidated balance sheet as~~Table of ~~December 31, 2020.~~Contents

operations. Refer to Note C – Assets and Liabilities Held for Sale to our audited financial statements contained in Item 8 of our most recent Annual Report on Form 10-K for additional information. ~~In the first nine months of 2021, we recognized a~~ ~~Gain on disposal of businesses and assets~~ ~~associated with the transaction of $9 million within our accompanying unaudited consolidated statements of operations.~~

Contingent Consideration

Changes in the fair value of our contingent consideration liability during the first ~~nine~~six months of ~~2021~~2022 were as follows:


(in millions)
Balance as of December 31, ~~2020~~2021	$	~~196~~486
~~Amount recorded related to current year acquisitions~~	~~384~~

Contingent consideration net expense (benefit)	~~(117)~~48
Contingent consideration payments	~~(14)~~(314)
Balance as of ~~September~~June 30, ~~2021~~2022	$	~~448~~219

As of ~~September~~June 30, ~~2021,~~2022, the maximum amount of future contingent consideration (undiscounted) that we could be required to pay associated with our completed acquisitions was ~~$919 million, which includes amounts related to our recent acquisitions of~~

~~Table of Contents~~

~~Preventice and Farapulse.~~$544 million. Refer to Note B – Acquisitions and Strategic Investmentsto our audited financial statements contained in Item 8 of our most recent Annual Report on Form 10-K for additional information.

The recurring Level 3 fair value measurements of our contingent consideration liability that we expect to be required to settle include the following significant unobservable inputs:


Contingent Consideration Liability	Contingent Consideration Liability	Fair Value as of September 30, 2021	Valuation Technique	Unobservable Input	Range			Weighted Average(1)	Contingent Consideration Liability	Fair Value as of June 30, 2022	Valuation Technique	Unobservable Input	Range			Weighted Average(1)
R&D, Regulatory and Commercialization-based Milestones	R&D, Regulatory and Commercialization-based Milestones	td09 million	Discounted Cash Flow	Discount Rate	1%	-	2%	1%	R&D, Regulatory and Commercialization-based Milestones	td07 million	Discounted Cash Flow	Discount Rate	1%	-	2%	1%
				Probability of Payment	20%	-	95%	79%				Probability of Payment	80%	-	100%	90%
				Projected Year of Payment	2023	-	2027	2023				Projected Year of Payment	2022	-	2025	2023
Revenue-based Payments	Revenue-based Payments	$340 million	Discounted Cash Flow	Discount Rate	4%	-	14%	6%	Revenue-based Payments	td12 million	Discounted Cash Flow	Discount Rate	6%	-	14%	7%
				Probability of Payment	100%			100%				Probability of Payment	100%			100%
				Projected Year of Payment	2021	-	2024	2022				Projected Year of Payment	2023	-	2024	2023

(1) Unobservable inputs were weighted by the relative fair value of the contingent consideration liability. For projected year of payment, the amount represents the median of the inputs and is not a weighted average.

Projected contingent payment amounts related to research and development (R&D), regulatory and commercialization-based milestones and revenue-based ~~milestones~~payments are discounted back to the current period, primarily using a discounted cash flow model. Significant increases or decreases in projected revenues, probabilities of payment, discount rates or the time until payment is made would have resulted in a significantly lower or higher fair value measurement as of ~~September~~June 30, ~~2021.~~2022.

Strategic Investments

The aggregate carrying amount of our strategic investments was comprised of the following:


		As of					As of
(in millions)	(in millions)	September 30, 2021		December 31, 2020		(in millions)	June 30, 2022		December 31, 2021
Equity method investments	Equity method investments	$	266	$	319	Equity method investments	$	212	$	259
Measurement alternative investments(1)	Measurement alternative investments(1)	164		183		Measurement alternative investments(1)	159		142
Publicly-held equity securities(2)		4		414
Publicly-held securities(2)						Publicly-held securities(2)	5		10
Notes receivable	Notes receivable	—		2		Notes receivable	8		—
		$	434	$	918		$	384	$	412

(1) Measurement alternative investments are privately-held equity securities without readily determinable fair values that are measured at cost less impairment, if any, adjusted to fair value for any observable price changes in orderly transactions for the identical or a similar investment of the same issuer, recognized in Other, net within our accompanying unaudited consolidated statements of operations.

(2) Publicly-held ~~equity~~ securities are measured at fair value with changes in fair value recognized in Other, net within our accompanying unaudited consolidated statements of operations.

Table of Contents

These investments are classified as Other long-term assets within our accompanying unaudited consolidated balance sheets, in accordance with U.S. GAAP and our accounting policies.

~~In the third quarter and first nine months of 2021, we recorded losses of $24 million and $178 million, respectively, on our investment in Pulmonx Corporation presented in~~ ~~Other, net~~ associated with the remeasurement of our investment during the period to fair value based on observable market prices, as well as the disposition of our remaining ownership. On March 1, 2021, we completed our acquisition of Preventice, in which we previously held an equity interest of approximately 22 percent and on August 6, 2021, we completed the acquisition of the remaining shares of Farapulse, in which we previously held an equity stake of approximately 27 percent. As of ~~September~~June 30, ~~2021,~~2022, the cost of our aggregated equity method investments exceeded our share of the underlying equity in net assets by ~~$289~~$233 million, which represents amortizable intangible assets, in-process research and development (IPR&D), goodwill and deferred tax liabilities.

~~Table of Contents~~

NOTE C – GOODWILL AND OTHER INTANGIBLE ASSETS

The gross carrying amount of goodwill and other intangible assets and the related accumulated amortization for intangible assets subject to amortization and accumulated ~~write-offs of~~ goodwill impairment charges are as follows:

As of September 30, 2021 As of December 31, 2020
(in millions) Gross Carrying Amount
Accumulated Amortization/ Write-offs(1)
Gross Carrying Amount Accumulated Amortization/ Write-offs
Technology-related $ 11,787 $ (6,590) $ 11,059 $ (6,179)
Patents 497 (399) 511 (407)
Other intangible assets 1,859 (1,301) 1,775 (1,220)
Amortizable intangible assets $ 14,143 $ (8,290) $ 13,345 $ (7,806)

Goodwill $ 21,720 $ (9,900) $ 19,924 $ (9,973)
IPR&D $ 254 $ 257
Technology-related 120 120
Indefinite-lived intangible assets $ 374 $ 377

(1) In the fourth quarter of 2020, we recorded goodwill impairment charges of $73 million related to the Specialty Pharmaceuticals business and classified the remaining assets and liabilities as held for sale as of December 31, 2020. On March 1, 2021, we completed the divestiture of the Specialty Pharmaceuticals business. The goodwill impairment charges of $73 million related to the Specialty Pharmaceuticals business are no longer presented within accumulated write-offs above as of September 30, 2021.


	As of June 30, 2022				As of December 31, 2021
(in millions)	Gross Carrying Amount		Accumulated Amortization/ Write-offs		Gross Carrying Amount		Accumulated Amortization/ Write-offs
Technology-related	$	12,515	$	(7,078)	$	11,957	$	(6,754)
Patents	487		(392)		494		(398)
Other intangible assets	1,953		(1,368)		1,900		(1,325)
Amortizable intangible assets	$	14,955	$	(8,838)	$	14,351	$	(8,476)

Goodwill	$	22,783	$	(9,900)	$	21,888	$	(9,900)

IPR&D	$	112			$	126
Technology-related	120				120
Indefinite-lived intangible assets	$	232			$	246

The increase in our balance of goodwill and amortizable intangible assets is primarily related to our ~~acquisitions~~acquisition of Baylis Medical completed in the first ~~nine months~~quarter of ~~2021.~~

Our technology-related intangible assets consist of technical processes, intellectual property and institutional understanding with respect to products and processes that we intend to leverage in future products or processes and will carry forward from one product generation to the next. We used the multi-period excess earnings method, a form of the income approach, to derive the fair value of the technology-related intangible assets and are amortizing them on a straight-line basis over their assigned estimated useful lives. Our in-process research and development (IPR&D) represents intangible assets that are used in research and development activities but have not yet reached technological feasibility, regardless of whether they have alternative future use. The primary basis for determining the technological feasibility or completion of these projects is obtaining regulatory approval to market the underlying products in an applicable geographic region.2022.

The following represents our goodwill balance by global reportable segment:

(in millions) MedSurg Rhythm and Neuro Cardiovascular Total
As of December 31, 2020 $ 2,059 $ 2,194 $ 5,697 $ 9,951
Impact of foreign currency fluctuations and other changes in carrying amount (4) (1) (15) (20)
Goodwill acquired 578 1,312 — 1,890
As of September 30, 2021 $ 2,633 $ 3,506 $ 5,682 $ 11,820


(in millions)	MedSurg		Cardiovascular		Total
As of December 31, 2021	$	4,246	$	7,741	$	11,988


Impact of foreign currency fluctuations and other changes in carrying value	(5)		(88)		(93)
Goodwill acquired	—		989		989

As of June 30, 2022	$	4,241	$	8,642	$	12,883

~~Prior~~In the first quarter of 2022, we reorganized our operational structure in order to strengthen our category leadership in the markets we serve and, in particular, benefit our Cardiology customers and patients. Following the reorganization, we have aggregated our core businesses into 2 reportable segments: MedSurg and Cardiovascular, each of which generates revenues from the sale of medical devices. We have revised prior periods to conform to the ~~divestiture on March 1, 2021, we presented the Specialty Pharmaceuticals business as a standalone operating segment alongside our reportable segments.~~current year presentation.

~~Table of Contents~~

Goodwill and Intangible Asset Impairments

We did not record any goodwill impairment charges in the ~~third quarter or~~ first ~~nine~~six months of ~~2021~~2022 or ~~2020.~~2021. We test our goodwill balances in the second quarter of each year as of April 1 for impairment, or more frequently if impairment indicators are present or changes in circumstances suggest an impairment may exist. In the second quarter of 2021, we performed our annual goodwill impairment test for all of our reporting units and concluded that the fair value of each reporting unit exceeded its carrying value. There were no impairment indicators in the third quarter of 2021 that necessitated an interim impairment test.

We assess goodwill for impairment at the reporting unit level, which is defined as an operating segment or one level below an operating segment, referred to as a component. WeFollowing the reorganization of our operational structure in the first quarter of 2022, we identified the following reporting units infor purposes of our ~~2021~~ annual goodwill impairment test: Interventional Cardiology, ~~Peripheral Interventions, Cardiac~~ Rhythm Management, ~~Electrophysiology,~~Peripheral Interventions, Endoscopy, Urology and Pelvic Health and Neuromodulation. ~~We aggregated the Cardiac Rhythm Management and Electrophysiology reporting units, components of the Rhythm Management operating segment, based~~Based on the criteria prescribed in FASB ASC Topic 350, Intangibles - Goodwill and ~~Other.~~Other (FASB ASC Topic 350), we aggregated the Interventional Cardiology Therapies and Watchman components of our Cardiology operating segment into a

Table of Contents

single Interventional Cardiology reporting unit, and aggregated the Cardiac Rhythm Management and Electrophysiology components into a single Rhythm Management reporting unit.

In the second quarter of 2022, we performed our annual goodwill impairment test utilizing both the qualitative and quantitative approach described in FASB ASC Topic 350. The qualitative approach was used for testing reporting units where fair value has historically exceeded carrying value by greater than 100 percent, and all other reporting units were tested using the quantitative approach. For those tested using the qualitative approach, after assessing the totality of events, it was determined that it was not more likely than not that the fair value of the reporting units was less than their carrying value, and it was not deemed necessary to proceed to the quantitative test. For all reporting units tested using the quantitative approach, we determined that the fair value of each reporting unit exceeded their carrying value and concluded that goodwill was not impaired or at risk of impairment.

We recorded Intangible asset impairment charges of ~~$128~~$7 million in the ~~third~~second quarter and first six months of ~~2021, $219~~2022, and $45 million in the ~~third~~second quarter ~~of 2020, $173 million in the~~and first ~~nine~~six months of ~~2021 and $452 million in the first nine months of 2020.~~2021. We review intangible assets subject to amortization quarterly to determine if any adverse conditions exist or a change in circumstances has occurred that would indicate impairment or a change in the remaining useful life. We test our indefinite-lived intangible assets at least annually during the third quarter for impairment and reassess their classification as indefinite-lived assets. In addition, we review our indefinite-lived intangible assets for classification and impairment more frequently if impairment indicators exist. InDuring the ~~third~~second quarter of 2021, we ~~performed our annual IPR&D impairment test and evaluated~~determined it was more likely than not that one of our indefinite-lived ~~core technology~~intangible assets ~~using the optional~~was impaired based on our qualitative assessment ~~approach~~of impairment indicators. We tested the intangible asset for recoverability and ~~concluded that~~recorded an impairment charge associated with incremental time and cost to complete the ~~assets were not impaired. We also verified that the classification of IPR&D projects~~associated in-process research and ~~our indefinite-lived core technology assets recognized within our unaudited consolidated balance sheets continues to be appropriate.~~development (IPR&D) project.

The impairment charges recorded in the third quarter of 2021 were primarily associated with amortizable technology-related intangible assets that were initially established following our acquisition of VENITI, Inc., and in the first nine months of 2021 also included the partial impairment of one of our acquired IPR&D assets. In the third quarter of 2020, impairment charges were primarily associated with IPR&D acquired with Apama Medical, Inc. and in the first nine months of 2020 also included charges primarily associated with amortizable technology-related intangible assets that were initially established following our acquisition of nVision Medical Corporation. Each of these charges were recorded as a result of management’s decision to change commercial launch plans or discontinue certain commercial or R&D programs based on cost to complete or remediate, time to market, overall economic viability or, specific to nVision, our understanding of the clinical evidence necessary to commercialize the technology. Refer to Note A – ~~Significant Accounting Policies~~Basis of Presentation to our audited financial statements contained in Item 8 of our most recent Annual Report on Form 10-K for further discussion of our annual goodwill and intangible asset impairment testing.

~~Table of Contents~~

NOTE D – HEDGING ACTIVITIES AND FAIR VALUE MEASUREMENTS

Derivative Instruments and Hedging Activities

We address market risk from changes in foreign currency exchange rates and interest rates through risk management programs which include the use of derivative and nonderivative financial instruments. We operate these programs pursuant to documented corporate risk management policies and do not enter into derivative transactions for speculative purposes. Our derivative instruments do not subject our earnings to material risk, as the gains or losses on these derivatives generally offset losses or gains recognized on the hedged item.

We manage concentration of counterparty credit risk by limiting acceptable counterparties to major financial institutions with investment grade credit ratings, limiting the amount of credit exposure to individual counterparties and by actively monitoring counterparty credit ~~ratings and the amount of individual credit exposure.~~ratings. We also employ master netting arrangements that limit the risk of counterparty non-payment on a particular settlement date to the net gain that would have otherwise been received from the counterparty. Although not completely eliminated, we do not consider the risk of counterparty default to be significant as a result of these protections. Further, none of our derivative instruments are subject to collateral or other security arrangements, nor do they contain provisions that are dependent on our credit ratings from any credit rating agency.

Currency Hedging Instruments

~~Risk Management Strategy~~

Our risk from changes in currency exchange rates consists primarily of monetary assets and liabilities, forecasted intercompany and third-party transactions, and net investments in certain subsidiaries. We manage currency exchange rate risk at a consolidated level to reduce the cost of hedging by taking advantage of offsetting transactions. We employ derivative and nonderivative instruments, primarily forward currency contracts, to reduce the risk to our earnings and cash flows associated with changes in currency exchange rates.

The success of our currency risk management program depends, in part, on forecast transactions denominated primarily in ~~Euro,~~euro, British pound sterling, Japanese yen, Chinese renminbi and Australian dollar. We may experience unanticipated currency exchange gains or losses to the extent the actual activity is different than forecast. In addition, changes in currency exchange rates related to any unhedged transactions may impact our earnings and cash flows.

~~Hedge Designations and Relationships~~

Certain of our currency derivative instruments are designated as cash flow hedges under FASB ASC Topic 815, Derivatives and Hedging (FASB ASC Topic 815), and are intended to protect the U.S. dollar value of forecasted transactions. ~~The gain or loss on a derivative instrument designated as a cash flow hedge is recorded in the~~ ~~Net change in derivative financial instruments~~ ~~component of~~ ~~Other comprehensive income (loss), net of tax (OCI)~~ within our accompanying unaudited consolidated statements of comprehensive income (loss) until the underlying third-party transaction occurs. When the underlying third-party transaction occurs, we recognize the gain or loss in earnings within ~~Cost of products sold~~ in our accompanying unaudited consolidated statements of operations. In the event the hedging relationship is no longer effective, or if the occurrence of the hedged forecast transaction becomes no longer probable, we reclassify the gains or losses within ~~Accumulated other comprehensive income (loss), net of tax (AOCI)~~ ~~to earnings at that time.~~

We also designate certain forward currency contracts as net investment hedges to hedge a portion of our net investments in certain of our entities with functional currencies denominated in the Swiss franc, Japanese yen, British pound sterling, South Korean won and Taiwan dollar. For these derivative instruments, we elected to use the spot method to assess hedge effectiveness. We also elected to exclude the spot-forward difference, referred to as the excluded component, from the assessment of hedge effectiveness and are amortizing this amount separately, as calculated at the date of designation, on a straight-line basis over the term of the currency forward contracts. As such, we defer recognition of foreign currency gains and losses within the ~~Foreign currency translation adjustment (CTA)~~ ~~component of~~ ~~OCI, and we reclassify amortization of the excluded component from~~ ~~AOCI~~ ~~to current period earnings within~~ ~~Interest expense~~ ~~in our accompanying unaudited consolidated statements of operations.~~

We designate certain euro-denominated debt as net investment hedges to hedge a portion of our net investments in certain of our entities with functional currencies denominated in the Euro. As of ~~September~~June 30, ~~2021~~2022 and December 31, ~~2020,~~2021, we designated as a net investment hedge a portion of our €900 million in aggregate principal amount of 0.625% euro-denominated senior notes issued in November 2019 and due in ~~2027.~~2027 (2027 Notes). For these nonderivative instruments, we defer recognition of the ~~foreign currency~~

1514

Table of Contents

foreign currency remeasurement gains and losses within the CTA component of OCI. We reclassify these gains and losses to current period earnings within Other, net in our accompanying unaudited consolidated statements of operations only when the hedged item affects earnings, which would occur upon disposal or substantial liquidation of the underlying foreign subsidiary.

We also use forward currency contracts that are not part of designated hedging relationships ~~under FASB ASC Topic 815~~ as a part of our strategy to manage our exposure to currency exchange rate risk related to monetary assets and liabilities and related forecast transactions. These non-designated currency forward contracts have an original time to maturity consistent with the hedged currency transaction exposures, generally less than one year, and are marked-to-market with changes in fair value recorded to earnings within Other, net inwithin our accompanying unaudited consolidated statements of operations.

Interest Rate Hedging Instruments

~~Risk Management Strategy~~

Our interest rate risk relates primarily to U.S. dollar borrowings partially offset by U.S. dollar cash investments. We use interest rate derivative instruments to mitigate the risk to our earnings and cash flows associated with exposure to changes in interest rates. Under these agreements, we and the counterparty, at specified intervals, exchange the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional principal amount. We designate these derivative instruments either as fair value or cash flow hedges in accordance with FASB ASC Topic 815.

~~Hedge Designations and Relationships~~

We had no interest rate derivative instruments designated as cash flow hedges outstanding as of ~~September~~June 30, ~~2021~~2022 or December 31, ~~2020.~~2021. Prior to 2020, we terminated interest rate derivative instruments that were designated as cash flow hedges and are continuing to recognize the amortization of the gains or losses originally recorded within AOCI to earnings as a component of Interest expense over the same period that the hedged item affects earnings, provided the hedge relationship remains effective. If we determine the hedge relationship is no longer effective, or if the occurrence of the hedged forecast transaction becomes no longer probable, we reclassify the amount of gains or losses from AOCI to earnings at that time.

In the event that we designate outstanding interest rate derivative instruments as cash flow hedges, we record the changes in the fair value of the derivatives within OCI until the underlying hedged transaction occurs. The balance of the deferred amounts on our terminated cash flow hedges within AOCI was a ~~$25~~$9 million loss as of ~~September~~June 30, ~~2021~~2022 and a ~~$29~~$24 million loss as of December 31, ~~2020. We recognized immaterial gains and losses in~~ 2021.~~Interest expense~~ ~~relating to the amortization of our terminated cash flow hedges in the current and prior periods.~~

We had no interest rate derivative instruments designated as fair value hedges outstanding as of September 30, 2021 or December 31, 2020. Prior to 2018, we terminated interest rate derivative instruments that were designated as fair value hedges and are continuing to recognize the amortization of the gains or losses originally recorded within ~~Long-term debt~~ ~~in our accompanying unaudited consolidated balance sheets into earnings as a component of~~ ~~Interest expense~~ over the same period that the discount or premium associated with the hedged items affects earnings. In the event that we designate outstanding interest rate derivative instruments as fair value hedges, we record the changes in the fair values of interest rate derivatives designated as fair value hedges and of the underlying hedged debt instruments in ~~Interest expense, which generally offset. The balance of the deferred gains on our terminated fair value hedges within~~ ~~Long-term debt~~ ~~was immaterial as of September 30, 2021 and December 31, 2020. We recognized immaterial gains in~~ ~~Interest expense~~ ~~relating to the amortization of the terminated fair value hedges in the current and prior periods.~~

~~Table of Contents~~

The following table presents the contractual amounts of our hedging instruments outstanding:


(in millions)	(in millions)	FASB ASC Topic 815 Designation	As of				(in millions)	FASB ASC Topic 815 Designation	As of
			September 30, 2021		December 31, 2020				June 30, 2022		December 31, 2021
Forward currency contracts	Forward currency contracts	Cash flow hedge	$	4,344	$	4,531	Forward currency contracts	Cash flow hedge	$	3,527	$	3,996
Forward currency contracts	Forward currency contracts	Net investment hedge	493		1,004		Forward currency contracts	Net investment hedge	365		493
Foreign currency-denominated debt(1)	Foreign currency-denominated debt(1)	Net investment hedge	997		868		Foreign currency-denominated debt(1)	Net investment hedge	997		997
Forward currency contracts	Forward currency contracts	Non-designated	4,838		4,946		Forward currency contracts	Non-designated	3,029		3,892

Total Notional Outstanding	Total Notional Outstanding		$	10,672	$	11,349	Total Notional Outstanding		$	7,917	$	9,378

(1) Foreign currency-denominated debt is the portion of the €900 million debt principal associated with our 2027 Notes designated as a net investment hedge.

The remaining time to maturity as of ~~September~~June 30, ~~2021~~2022 is within 60 months for all forward currency contracts designated as cash flow hedges and generally less than one year for all non-designated forward currency contracts. The forward currency contracts designated as net investment hedges generally mature ~~within the next year.~~between one and three years. The euro-denominated debt principal designated as a net investment hedge has a contractual maturity of December 1, 2027.

The following presents the effect of our derivative and nonderivative instruments designated as cash flow and net investment hedges under FASB ASC Topic 815 in our accompanying unaudited consolidated statements of operations. Refer to Note M – Changes in Other Comprehensive Income for the total amounts relating to derivative and nonderivative instruments presented within our accompanying unaudited consolidated statements of comprehensive income (loss).

Effect of Hedging Relationships on Accumulated Other Comprehensive Income
Amount Recognized in OCI on Hedges
Unaudited Consolidated Statements of Operations(1)
Amount Reclassified from AOCI into Earnings
(in millions) Pre-Tax Gain (Loss) Tax Benefit (Expense) Gain (Loss) Net of Tax Location of Amount Reclassified and Total Amount of Line Item Pre-Tax (Gain) Loss Tax (Benefit) Expense (Gain) Loss Net of Tax
Three Months Ended September 30, 2021
Forward currency contracts
Cash flow hedges $ 79 $ (18) $ 61 Cost of products sold $ 900 $ (16) $ 3 $ (12)
Net investment hedges(2)
7 (2) 6 Interest expense 86 (2) — (2)
Foreign currency-denominated debt
Net investment hedges(3)
25 (6) 20 Other, net (181) — — —
Interest rate derivative contracts
Cash flow hedges — — — Interest expense 86 1 — 1
Effect of Hedging Relationships on Accumulated Other Comprehensive Income
Amount Recognized in OCI on Hedges
Unaudited Consolidated Statements of Operations(1)
Amount Reclassified from AOCI into Earnings
(in millions) Pre-Tax Gain (Loss) Tax Benefit (Expense) Gain (Loss) Net of Tax Location of Amount Reclassified and Total Amount of Line Item Pre-Tax (Gain) Loss Tax (Benefit) Expense (Gain) Loss Net of Tax
Three Months Ended September 30, 2020
Forward currency contracts
Cash flow hedges $ (64) $ 14 $ (50) Cost of products sold $ 869 $ (20) $ 4 $ (15)
Net investment hedges(2)
(21) 5 (16) Interest expense 86 (6) 1 (5)
Foreign currency-denominated debt
Net investment hedges(3)
(46) 10 (36) Other, net (64) — — —
Interest rate derivative contracts
Cash flow hedges — — — Interest Expense 86 1 — 1
Effect of Hedging Relationships on Accumulated Other Comprehensive Income
Amount Recognized in OCI on Hedges
Unaudited Consolidated Statements of Operations(1)
Amount Reclassified from AOCI into Earnings
(in millions) Pre-Tax Gain (Loss) Tax Benefit (Expense) Gain (Loss) Net of Tax Location of Amount Reclassified and Total Amount of Line Item Pre-Tax (Gain) Loss Tax (Benefit) Expense (Gain) Loss Net of Tax
Nine Months Ended September 30, 2021
Forward currency contracts
Cash flow hedges $ 234 $ (53) $ 182 Cost of products sold $ 2,739 $ (31) $ 7 $ (24)
Net investment hedges (2) 50 (11) 39 Interest expense 254 (11) 3 (9)
Foreign currency-denominated debt
Net investment hedges (3) 60 (14) 47 Other, net (192) — — —
Interest rate derivative contracts
Cash flow hedges — — — Interest expense 254 4 (1) 3
Effect of Hedging Relationships on Accumulated Other Comprehensive Income
Amount Recognized in OCI on Hedges
Unaudited Consolidated Statements of Operations(1)
Amount Reclassified from AOCI into Earnings
(in millions) Pre-Tax Gain (Loss) Tax Benefit (Expense) Gain (Loss) Net of Tax Location of Amount Reclassified and Total Amount of Line Item Pre-Tax (Gain) Loss Tax (Benefit) Expense (Gain) Loss Net of Tax
Nine Months Ended September 30, 2020
Forward currency contracts
Cash flow hedges $ 47 $ (11) $ 36 Cost of products sold $ 2,465 $ (70) $ 16 $ (55)
Net investment hedges (2) (4) (21) (25) Interest expense 265 (18) 4 (14)
Foreign currency-denominated debt
Net investment hedges (3) (44) 13 (31) Other, net (9) — — —
Interest rate derivative contracts
Cash flow hedges — — — Interest expense 265 4 (1) 3

Table of Contents


	Effect of Hedging Relationships on Accumulated Other Comprehensive Income
	Amount Recognized in OCI on Hedges						Unaudited Consolidated Statements of Operations(1)			Amount Reclassified from AOCI into Earnings
(in millions)	Pre-Tax Gain (Loss)		Tax Benefit (Expense)		Gain (Loss) Net of Tax		Location of Amount Reclassified and Total Amount of Line Item			Pre-Tax (Gain) Loss		Tax (Benefit) Expense		(Gain) Loss Net of Tax
Three Months Ended June 30, 2022
Forward currency contracts
Cash flow hedges	$	213	$	(48)	$	165	Cost of products sold	$	1,011	$	(41)	$	9	$	(32)
Net investment hedges(2)	34		5		39		Interest expense	64		(3)		1		(2)
Foreign currency-denominated debt
Net investment hedges(3)	62		(14)		48		Other, net	14		—		—		—
Interest rate derivative contracts
Cash flow hedges	—		—		—		Interest expense	64		1		—		1


	Effect of Hedging Relationships on Accumulated Other Comprehensive Income
	Amount Recognized in OCI on Hedges						Unaudited Consolidated Statements of Operations(1)			Amount Reclassified from AOCI into Earnings
(in millions)	Pre-Tax Gain (Loss)		Tax Benefit (Expense)		Gain (Loss) Net of Tax		Location of Amount Reclassified and Total Amount of Line Item			Pre-Tax (Gain) Loss		Tax (Benefit) Expense		(Gain) Loss Net of Tax
Three Months Ended June 30, 2021
Forward currency contracts
Cash flow hedges	$	(15)	$	3	$	(12)	Cost of products sold	$	945	$	(10)	$	2	$	(7)
Net investment hedges(2)	(8)		2		(7)		Interest expense	86		(3)		1		(3)
Foreign currency-denominated debt
Net investment hedges(3)	(12)		3		(10)		Other, net	26		—		—		—
Interest rate derivative contracts
Cash flow hedges	—		—		—		Interest Expense	86		1		—		1


	Effect of Hedging Relationships on Accumulated Other Comprehensive Income
	Amount Recognized in OCI on Hedges						Unaudited Consolidated Statements of Operations(1)			Amount Reclassified from AOCI into Earnings
(in millions)	Pre-Tax Gain (Loss)		Tax Benefit (Expense)		Gain (Loss) Net of Tax		Location of Amount Reclassified and Total Amount of Line Item			Pre-Tax (Gain) Loss		Tax (Benefit) Expense		(Gain) Loss Net of Tax
Six Months Ended June 30, 2022
Forward currency contracts
Cash flow hedges	$	259	$	(58)	$	200	Cost of products sold	$	1,966	$	(71)	$	16	$	(55)
Net investment hedges (2)	49		2		50		Interest expense	343		(5)		1		(4)
Foreign currency-denominated debt
Net investment hedges (3)	86		(19)		66		Other, net	46		—		—		—
Interest rate derivative contracts
Cash flow hedges	—		—		—		Interest expense	343		15		(3)		11

Table of Contents


	Effect of Hedging Relationships on Accumulated Other Comprehensive Income
	Amount Recognized in OCI on Hedges						Unaudited Consolidated Statements of Operations(1)			Amount Reclassified from AOCI into Earnings
(in millions)	Pre-Tax Gain (Loss)		Tax Benefit (Expense)		Gain (Loss) Net of Tax		Location of Amount Reclassified and Total Amount of Line Item			Pre-Tax (Gain) Loss		Tax (Benefit) Expense		(Gain) Loss Net of Tax
Six Months Ended June 30, 2021
Forward currency contracts
Cash flow hedges	$	156	$	(35)	$	121	Cost of products sold	$	1,839	$	(16)	$	4	$	(12)
Net investment hedges (2)	43		(10)		33		Interest expense	168		(9)		2		(7)
Foreign currency-denominated debt
Net investment hedges (3)	35		(8)		27		Other, net	(11)		—		—		—
Interest rate derivative contracts
Cash flow hedges	—		—		—		Interest expense	168		3		(1)		2

(1) In all periods presented in the table above, the pre-tax (gain) loss amounts reclassified from AOCI to earnings represent the effect of the hedging relationships on earnings. ~~All other amounts included in earnings related to hedging relationships were immaterial.~~

(2) For our outstanding forward currency contracts designated as net investment hedges, the net gain or loss reclassified from AOCI to earnings as a reduction of Interest expense represents the straight-line amortization of the excluded component as calculated at the date of designation. This initial value of the excluded component has been excluded from the assessment of effectiveness in accordance with FASB ASC Topic 815. In the current and prior period, we did not recognize any gains or losses on the components included in the assessment of hedge effectiveness in earnings.

(3) For our outstanding euro-denominated debt principal designated as a net investment hedge, the change in fair value attributable to changes in the spot rate is recorded in the CTA component of OCI. No amounts were reclassified from AOCI to current period earnings.

As of ~~September~~June 30, ~~2021,~~2022, pre-tax net gains or losses for our derivative instruments designated, or previously designated, as cash flow and net investment hedges under FASB ASC Topic 815 that may be reclassified from AOCI to earnings within the next twelve months are presented below (in millions):

Designated Hedging Instrument

FASB ASC Topic 815 Designation

Location on Unaudited Consolidated Statements of Operations

Amount of Pre-Tax Gain (Loss) that may be Reclassified to Earnings

Forward currency contracts

Cash flow hedge

Cost of products sold

~~108~~251

Forward currency contracts

Net investment hedge

Interest expense

510

Interest rate derivative contracts

Cash flow hedge

Interest expense

~~(5)~~(3)

~~Table of Contents~~

Net gains and losses on currency hedge contracts not designated as hedging instruments offset by net gains and losses from currency transaction exposures are presented below:


		Location on Unaudited Consolidated Statements of Operations		Three Months Ended September 30,								Nine Months Ended September 30,									Location on Unaudited Consolidated Statements of Operations		Three Months Ended June 30,								Six Months Ended June 30,
(in millions)	(in millions)		2021			2020				2021				2020		(in millions)						2022			2021				2022				2021
Net gain (loss) on currency hedge contracts	Net gain (loss) on currency hedge contracts		Other, net			$	(15)			$	29			$	(17)			$	20	Net gain (loss) on currency hedge contracts		Other, net			$	(34)			$	(1)			$	(63)			$	(2)
Net gain (loss) on currency transaction exposures	Net gain (loss) on currency transaction exposures	Other, net		7				(30)				1				(33)		Net gain (loss) on currency transaction exposures			Other, net		35				(5)				56				(6)
Net currency exchange gain (loss)	Net currency exchange gain (loss)			$	(8)			$	(1)			$	(17)			$	(13)	Net currency exchange gain (loss)					$	1			$	(7)			$	(7)			$	(9)

Fair Value Measurements

FASB ASC Topic 815 requires all derivative and nonderivative instruments to be recognized at their fair values as either assets or liabilities on the balance sheet. We determine the fair value of our derivative and nonderivative instruments using the framework prescribed by FASB ASC Topic 820, Fair Value Measurements and Disclosures (FASB ASC Topic 820) and considering the estimated amount we would receive or pay to transfer these instruments at the reporting date with respect to current currency exchange rates, interest rates, the creditworthiness of the counterparty for unrealized gain positions and our own creditworthiness for unrealized loss positions. In certain instances, we may utilize financial models to measure fair value of our derivative and nonderivative instruments. In doing so, we use inputs that include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, other

Table of Contents

observable inputs for the asset or liability and inputs derived principally from, or corroborated by, observable market data by correlation or other means. The following are the balances of our derivative and nonderivative assets and liabilities:


		Location on Unaudited Consolidated Balance Sheets(1)		As of							Location on Unaudited Consolidated Balance Sheets(1)		As of
(in millions)	(in millions)		September 30, 2021			December 31, 2020	(in millions)					June 30, 2022			December 31, 2021
Derivative and Nonderivative Assets:	Derivative and Nonderivative Assets:									Derivative and Nonderivative Assets:
Designated Hedging Instruments	Designated Hedging Instruments								Designated Hedging Instruments
Forward currency contracts	Forward currency contracts	Other current assets		$	152		$	53	Forward currency contracts		Other current assets		$	246		$	183
Forward currency contracts	Forward currency contracts	Other long-term assets		176			109		Forward currency contracts		Other long-term assets		252			169
				328			162						498			352
Non-Designated Hedging Instruments	Non-Designated Hedging Instruments								Non-Designated Hedging Instruments
Forward currency contracts	Forward currency contracts	Other current assets		41			79		Forward currency contracts		Other current assets		40			42

Total Derivative and Nonderivative Assets	Total Derivative and Nonderivative Assets			$	369		$	242	Total Derivative and Nonderivative Assets				$	538		$	394

Derivative and Nonderivative Liabilities:	Derivative and Nonderivative Liabilities:								Derivative and Nonderivative Liabilities:
Designated Hedging Instruments	Designated Hedging Instruments								Designated Hedging Instruments
Forward currency contracts	Forward currency contracts	Other current liabilities		$	24		$	44	Forward currency contracts		Other current liabilities		$	10		$	32
Forward currency contracts	Forward currency contracts	Other long-term liabilities		5			54		Forward currency contracts		Other long-term liabilities		1			6
Foreign currency-denominated debt(2)	Foreign currency-denominated debt(2)	Other long-term liabilities		1,033			1,094		Foreign currency-denominated debt(2)		Long-term debt		926			1,011

				1,063			1,191						938			1,049
Non-Designated Hedging Instruments	Non-Designated Hedging Instruments								Non-Designated Hedging Instruments
Forward currency contracts	Forward currency contracts	Other current liabilities		57			71		Forward currency contracts		Other current liabilities		28			22
Total Derivative and Nonderivative Liabilities	Total Derivative and Nonderivative Liabilities			$	1,120		$	1,262	Total Derivative and Nonderivative Liabilities				$	966		$	1,071

(1) We classify derivative and nonderivative assets and liabilities as current when the settlement date of the contract is one year or less.

(2) Foreign currency-denominated debt is the portion of the €900 million debt principal associated with our 2027 Notes designated as a net investment hedge. A portion of this notional is subject to de-designation and re-designation based on changes in the underlying hedged item.

~~Table of Contents~~

Recurring Fair Value Measurements

On a recurring basis, we measure certain financial assets and financial liabilities at fair value based upon quoted market prices. Where quoted market prices or other observable inputs are not available, we apply valuation techniques to estimate fair value. FASB ASC Topic 820 establishes a three-level valuation hierarchy for disclosure of fair value measurements. The category of a financial asset or a financial liability within the valuation hierarchy is based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy are defined as follows:

•Level 1 – Inputs to the valuation methodology are quoted market prices for identical assets or liabilities.

•Level 2 – Inputs to the valuation methodology are other observable inputs, including quoted market prices for similar assets or liabilities and market-corroborated inputs.

•Level 3 – Inputs to the valuation methodology are unobservable inputs based on management’s best estimate of inputs market participants would use in pricing the asset or liability at the measurement date, including assumptions about risk.

Table of Contents

Assets and liabilities measured at fair value on a recurring basis consist of the following:


		As of																	As of
		September 30, 2021								December 31, 2020									June 30, 2022								December 31, 2021
(in millions)	(in millions)	Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total		(in millions)	Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
Assets	Assets																	Assets
Money market funds and time deposits	Money market funds and time deposits	$	1,537	$	—	$	—	$	1,537	$	1,584	$	—	$	—	$	1,584	Money market funds and time deposits	$	36	$	—	$	—	$	36	$	1,632	$	—	$	—	$	1,632
Publicly-held equity securities	Publicly-held equity securities	4		—		—		4		414		—		—		414		Publicly-held equity securities	5		—		—		5		10		—		—		10
Hedging instruments	Hedging instruments	—		369		—		369		—		242		—		242		Hedging instruments	—		538		—		538		—		394		—		394
Licensing arrangements	Licensing arrangements	—		—		280		280		—		—		365		365		Licensing arrangements	—		—		182		182		—		—		246		246
		$	1,541	$	369	$	280	$	2,190	$	1,998	$	242	$	365	$	2,605		$	40	$	538	$	182	$	760	$	1,642	$	394	$	246	$	2,282
Liabilities	Liabilities																	Liabilities
Hedging instruments	Hedging instruments	$	—	$	1,120	$	—	$	1,120	$	—	$	1,262	$	—	$	1,262	Hedging instruments	$	—	$	966	$	—	$	966	$	—	$	1,071	$	—	$	1,071
Contingent consideration liability	Contingent consideration liability	—		—		448		448		—		—		196		196		Contingent consideration liability	—		—		219		219		—		—		486		486
Licensing arrangements	Licensing arrangements	—		—		297		297		—		—		407		407		Licensing arrangements	—		—		215		215		—		—		281		281
		$	—	$	1,120	$	745	$	1,865	$	—	$	1,262	$	603	$	1,865		$	—	$	966	$	434	$	1,400	$	—	$	1,071	$	767	$	1,838

Our investments in money market funds and time deposits are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices. These investments are classified as Cash and cash equivalents within our accompanying unaudited consolidated balance sheets, in accordance with U.S. GAAP and our accounting policies. In addition to ~~$1.537 billion~~$36 million invested in money market funds and time deposits as of ~~September~~June 30, ~~2021~~2022 and ~~$1.584~~$1.632 billion as of December 31, ~~2020,~~2021, we held ~~$410~~$240 million in interest-bearing and non-interest-bearing bank accounts as of ~~September~~June 30, ~~2021~~2022 and ~~$150~~$293 million as of December 31, ~~2020.~~2021.

Our recurring fair value measurements using Level 3 inputs include those related to our contingent consideration liability. Refer to Note B – Acquisitions, Divestitures and Strategic Investments for a discussion of the changes in the fair value of our contingent consideration liability. In addition, our recurring fair value measurements using Level 3 inputs related to our licensing arrangements, including the contractual right to receive future royalty payments related to the Zytiga™ Drug. We ~~recognized~~maintain a financial asset and associated liability for our licensing arrangements measured at fair value in our accompanying unaudited consolidated balance sheets ~~using the fair value option~~ in accordance with FASB ASC Topic 825, Financial Instruments.

~~Table of Contents~~

~~We own the contractual right~~ Refer to ~~receive 50 percent of the future royalty payments from the licensee~~Note E – Hedging Activities and ~~remit such payments to the inventors associated with the intellectual property. Royalty payments we receive reduce the fair value of the financial asset and are presented within~~ Fair Value Measurements~~Proceeds from royalty rights, and payments we remit to inventors reduce the fair value of the financial liability and are presented within~~ ~~Payments for royalty rights~~ within our unaudited consolidated statements of cash flows. We sold our right to receive and retain the other 50 percent of the future royalty payments in 2019 for an upfront cash payment, which we accounted for as a secured borrowing in accordance with FASB ASC Topic 860, ~~Transfers and Servicing~~. Although we sold these rights, we continue to recognize at fair value the future royalty payments as a financial asset and associated liability. Royalty payments associated with the rights we sold no longer impact our cash flows, and we present this activity as ~~Non-cash impact of transferred royalty rights~~ ~~in the supplemental information~~ to our ~~unaudited consolidated~~audited financial statements contained in Item 8 of ~~cash flows. We reduce the fair value of the financial asset and associated liability when such non-cash activity occurs.~~

We have recorded the fair value of the financial asset and associated liability using a discounted cash flow approach considering the probability-weighted expected future cash flows to be generated by the royalty stream. The fair value of the financial liability also considers the related contractual provisions that govern our payment obligations. Significant increases or decreases in projected cash flows of the royalty stream and the related contractual provisions that govern our payment obligations, discount rates or the time until payment is made would have resulted in a significantly lower or higher fair value measurement of the licensing arrangements' financial asset and liability as of September 30, 2021. However, increases or decreases in the financial asset would be offset by increases or decreases in the financial liability, other thanmost recent Annual Report on Form 10-K for ~~timing of receipt and remittance; as such our earnings are not subject to material gains and losses from the licensing arrangement.~~additional information.

The recurring Level 3 fair value measurements of our licensing arrangements recognized in our accompanying unaudited consolidated balance sheets as of ~~September~~June 30, ~~2021~~2022 include the following significant unobservable inputs:


Licensing Arrangements	Licensing Arrangements	Fair Value as of September 30, 2021	Valuation Technique	Unobservable Input	Range				Weighted Average (1)	Licensing Arrangements	Fair Value as of June 30, 2022		Valuation Technique		Unobservable Input		Range						Weighted Average (1)
Financial Asset	Financial Asset	td80 million	Discounted Cash Flow	Discount Rate	15%				15%	Financial Asset	td82 million		Discounted Cash Flow		Discount Rate		15%						15%

				Projected Year of Payment	2021		-	2025	2023						Projected Year of Payment		2022		-		2025		2024
Financial Liability	Financial Liability	td97 million	Discounted Cash Flow	Discount Rate	12	%	-	15%	13%						Financial Liability	td15 million		Discounted Cash Flow		Discount Rate		12		%	-	15%	13%

				Projected Year of Payment	2021		-	2026	2023	Projected Year of Payment		2022		-						2026		2024

(1) Unobservable inputs relate to a single financial asset and liability. As such, unobservable inputs were not weighted by the relative fair value of the instruments. For projected year of payment, the amount represents the median of the inputs and is not a weighted average.

Table of Contents

Changes in the fair value of our licensing arrangements' financial asset were as follows:


(in millions)
Balance as of December 31, ~~2020~~2021	$	~~365~~246

Proceeds from royalty rights	~~(62)~~

~~Non-cash impact of transferred royalty rights~~	~~(62)~~(72)
Fair value adjustment (expense) benefit	409
Balance as of ~~September~~June 30, ~~2021~~2022	$	~~280~~182

Changes in the fair value of our licensing arrangements' financial liability were as follows:


(in millions)
Balance as of December 31, ~~2020~~2021	$	~~407~~281

Payments for royalty rights	~~(85)~~


~~Non-cash impact of transferred royalty rights~~	~~(62)~~(75)
Fair value adjustment expense (benefit)	379
Balance as of ~~September~~June 30, ~~2021~~2022	$	~~297~~215

~~Table of Contents~~

Non-Recurring Fair Value Measurements

We hold certain assets and liabilities that are measured at fair value on a non-recurring basis in periods after initial recognition. The fair value of a measurement alternative investment is not estimated if there are no identified events or changes in circumstances that may have a significant adverse effect on the fair value of the investment. Refer to Note B – Acquisitions, Divestitures and Strategic Investments for a discussion of our strategic investments and Note C – Goodwill and Other Intangible Assets for a discussion of the fair values of our intangible assets including goodwill.

The fair value of our outstanding debt obligations was ~~$10.372~~$8.517 billion as of ~~September~~June 30, ~~2021, including $1.056 billion relating to our euro-denominated December 2027 Notes,~~2022 and ~~$10.774~~$10.196 billion as of December 31, ~~2020, including $1.118 billion relating to our euro-denominated December 2027 Notes.~~2021. We determined fair value by using quoted market prices for our publicly registered senior notes, classified as Level 1 within the fair value hierarchy, and face value for commercial paper, term loans and credit facility borrowings outstanding. Refer to Note E – Contractual Obligations and Commitments for a discussion of our debt obligations.

Table of Contents

NOTE E – CONTRACTUAL OBLIGATIONS AND COMMITMENTS

Borrowings and Credit Arrangements

We had total debt outstanding of ~~$9.085~~$8.971 billion as of ~~September~~June 30, ~~2021~~2022 and ~~$9.143~~$9.065 billion as of December 31, ~~2020,~~2021, with current maturities of ~~$261~~$170 million as of ~~September~~June 30, ~~2021~~2022 and ~~$13~~$261 million as of December 31, ~~2020.~~2021. The debt maturity schedule for our long-term debt obligations is presented below:

(in millions, except interest rates) Issuance Date Maturity Date As of
Coupon Rate(1)
September 30,
2021 December 31,
2020
May 2022 Notes(3)
May 2015 May 2022 $ — $ 250 3.375%
October 2023 Notes August 2013 October 2023 244 244 4.125%
March 2024 Notes February 2019 March 2024 850 850 3.450%
May 2025 Notes May 2015 May 2025 523 523 3.850%
June 2025 Notes May 2020 June 2025 500 500 1.900%
March 2026 Notes February 2019 March 2026 850 850 3.750%
December 2027 Notes November 2019 December 2027 1,043 1,105 0.625%
March 2028 Notes February 2018 March 2028 434 434 4.000%
March 2029 Notes February 2019 March 2029 850 850 4.000%
June 2030 Notes May 2020 June 2030 1,200 1,200 2.650%
November 2035 Notes(2)
November 2005 November 2035 350 350 7.000%
March 2039 Notes February 2019 March 2039 750 750 4.550%
January 2040 Notes December 2009 January 2040 300 300 7.375%
March 2049 Notes February 2019 March 2049 1,000 1,000 4.700%
Unamortized Debt Issuance Discount
and Deferred Financing Costs
2022 - 2049 (79) (88)
Unamortized Gain on Fair Value Hedges 2023 4 5
Finance Lease Obligation Various 6 7
Long-term debt $ 8,824 $ 9,130


(in millions, except interest rates)	Issuance Date	Maturity Date	As of				Coupon Rate(1)
			June 30, 2022		December 31, 2021

October 2023 Senior Notes(4)	August 2013	October 2023	—		244		4.125%
March 2024 Senior Notes(4)	February 2019	March 2024	504		850		3.450%
March 2025 Senior Notes(3)	March 2022	March 2025	1,039		—		0.750%
May 2025 Senior Notes(4)	May 2015	May 2025	—		523		3.850%
June 2025 Senior Notes	May 2020	June 2025	500		500		1.900%
March 2026 Senior Notes(4)	February 2019	March 2026	255		850		3.750%
December 2027 Senior Notes(3)	November 2019	December 2027	935		1,021		0.625%
March 2028 Senior Notes(3)	March 2022	March 2028	779		—		1.375%
March 2028 Senior Notes(4)	February 2018	March 2028	344		434		4.000%
March 2029 Senior Notes(4)	February 2019	March 2029	272		850		4.000%
June 2030 Senior Notes	May 2020	June 2030	1,200		1,200		2.650%
March 2031 Senior Notes(3)	March 2022	March 2031	779		—		1.625%
March 2034 Senior Notes(3)	March 2022	March 2034	520		—		1.875%
November 2035 Senior Notes(2)	November 2005	November 2035	350		350		6.750%
March 2039 Senior Notes(4)	February 2019	March 2039	450		750		4.550%
January 2040 Senior Notes	December 2009	January 2040	300		300		7.375%
March 2049 Senior Notes(4)	February 2019	March 2049	650		1,000		4.700%
Unamortized Debt Issuance Discount and Deferred Financing Costs		2023 - 2049	(82)		(76)
Unamortized Gain on Fair Value Hedges		2022	—		3
Finance Lease Obligation		Various	5		6
Long-term debt			$	8,802	$	8,804

Note: The table above does not include unamortized amounts related to interest rate contracts designated as cash flow hedges.

(1) Coupon rates are semi-annual, except for the euro-denominated ~~December 2027 Notes,~~senior notes, which bear an annual coupon.

(2) Corporate credit rating improvements may result in a decrease in the adjusted interest rate on our November 2035 Notes to the extent that our lowest credit rating is above BBB- or Baa3. The interest rates on our November 2035 Notes will be permanently reinstated to the issuance rate if the lowest credit ratings assigned to these senior notes is either A- or A3 or higher. ~~Effective November 15, 2021, the interest rate payable will decrease by 0.25 percent and begin accruing at a rate of 6.75 percent following recent upgrades to our credit ratings.~~

(3) AsThese notes are euro-denominated and presented in U.S. dollars based on the exchange rate in effect as of ~~September~~June 30, 2022 and December 31, 2021, respectively.

(4) Amounts repaid, or partially repaid as the case may be, in connection with the March 2022 tender offer and early redemption of certain of our outstanding ~~balance is presented~~senior notes are described below. In addition, in the first quarter of 2022, we repaid $250 million of 3.375% May 2022 Senior Notes classified within Current Debt Obligations within our ~~unaudited~~ consolidated balance ~~sheet.~~

~~Table~~sheets as of ~~Contents~~December 31, 2021.

Revolving Credit Facility

On May 10, 2021, we entered into a new $2.750 billion revolving credit facility (2021 Revolving Credit Facility) with a global syndicate of commercial banks and terminated our previous facility (2018 Revolving Credit Facility). The 2021 Revolving Credit Facility will mature on May 10, 2026, with one-year extension options, subject to certain conditions. This facility provides backing for our commercial paper program, and outstanding commercial paper directly reduces borrowing capacity under the 2021 Revolving Credit Facility. There were no amounts outstanding under the 2021 Revolving Credit Facility as of ~~September~~

Table of Contents

June 30, ~~2021~~2022 or December 31, 2021; however, outstanding commercial paper directly reduces borrowing capacity under the ~~2018~~2021 Revolving Credit ~~Facility as of December 31, 2020.~~Facility.

Financial Covenant

As of ~~and through September~~June 30, ~~2021,~~2022, we were in compliance with the financial covenant required by the ~~credit facilities described above:~~2021 Revolving Credit Facility.

Covenant Requirement

Actual

as of ~~September~~June 30, ~~2021~~2022

Maximum permitted leverage ratio(1)

~~4.00~~3.75 times

~~2.89~~2.61 times

(1)Ratio of total debt to consolidated EBITDA, as defined by the credit agreements, as amended.

The 2021 Revolving Credit Facility includes the ~~following~~ financial covenant requirement for all of our credit arrangements ~~(i)~~that we maintain the maximum permitted leverage ratio of ~~4.00 times for the third quarter of 2021, with a step-down to~~ 3.75 times ~~for the fourth quarter of 2021 and~~ through the remaining term. The agreement provides for higher leverage ratios, at our election, for the period following a qualified acquisition ~~at our election,~~ for which consideration exceeds $1.000 billion. In the event of such an acquisition, for the four succeeding quarters immediately following, including the quarter in which the acquisition occurs, the maximum permitted leverage ratio is 4.75 times. The maximum permitted ratio steps down for the fifth, sixth and seventh succeeding quarters to 4.50 times, 4.25 times and 4.00 times, respectively. Thereafter, a maximum leverage ratio of 3.75 times is required through the remaining term of the 2021 Revolving Credit Facility. We have not elected to increase the maximum permitted leverage ratio for the recently completed ~~acquisition of Lumenis~~qualified acquisitions due to the funding ~~of the acquisition~~ using cash on hand.

The financial covenant requirement provides for an exclusion from the calculation of consolidated EBITDA, as defined by the agreement, through maturity, of any non-cash charges and up to $500 million in restructuring charges and restructuring-related expenses related to our current or future restructuring plans. As of ~~September~~June 30, ~~2021,~~2022, we had ~~$428~~$311 million of the restructuring charge exclusion remaining. In addition, any cash litigation payments (net of any cash litigation receipts), as defined by the ~~agreements,~~agreement, are excluded from the calculation of consolidated EBITDA, as defined by the ~~agreements,~~agreement, provided that the sum of any excluded net cash litigation payments do not exceed $1.455 billion in the aggregate. As of ~~September~~June 30, ~~2021,~~2022, we had ~~$1.243~~$1.080 billion of the litigation exclusion remaining.

Any inability to maintain compliance with this covenant could require us to seek to renegotiate the terms of our credit arrangements or seek waivers from compliance with this covenant, both of which could result in additional borrowing costs. Further, there can be no assurance that our lenders would agree to such new terms or grant such waivers on terms acceptable to us. In this case, all 2021 Revolving Credit Facility commitments would terminate, and any amounts borrowed under the facility would become immediately due and payable. Furthermore, any termination of our 2021 Revolving Credit Facility may negatively impact the credit ratings assigned to our commercial paper program, which may impact our ability to refinance any then outstanding commercial paper as it becomes due and payable.

Commercial Paper

Our commercial paper program is backed by the 2021 Revolving Credit ~~Facility, as discussed above, and outstanding commercial paper directly reduces borrowing capacity under the 2021 Revolving Credit~~ Facility. We ~~did not have any~~had $155 million of commercial paper outstanding as of ~~September~~June 30, ~~2021 or~~2022 and none as of December 31, ~~2020.~~2021.


	As of
(in millions, except maturity and yield)	June 30, 2022			December 31, 2021
Commercial paper outstanding (at par)	$	155		$	—
Maximum borrowing capacity	2,750			2,750
Borrowing capacity available	2,595			2,750
Weighted average maturity	7 days			0 days
Weighted average yield	1.93		%	—		%

Table of Contents

Senior Notes

We had senior notes outstanding of ~~$9.143~~$8.878 billion as of ~~September~~June 30, ~~2021~~2022 and ~~$9.205~~$9.121 billion as of December 31, ~~2020.~~2021. Our senior notes were issued in public offerings, are redeemable prior to maturity and are not subject to sinking fund requirements. Our senior notes are unsecured, unsubordinated obligations and rank on parity with each other. These notes are effectively junior to liabilities of our subsidiaries ~~(see~~(refer to Other Arrangements below).

~~Table~~In March 2022, American Medical Systems Europe B.V. (AMS Europe), an indirect, wholly owned subsidiary of ~~Contents~~Boston Scientific, completed a registered public offering (the Offering) of €3.000 billion in aggregate principal amount of euro-dominated senior notes comprised of €1.000 billion of 0.750% Senior Notes due 2025, €750 million of 1.375% Senior Notes due 2028, €750 million of 1.625% Senior Notes due 2031 and €500 million of 1.875% Senior Notes due 2034 (collectively, the Eurobonds). Boston Scientific has fully and unconditionally guaranteed all of AMS Europe's obligations under the Eurobonds, and no other subsidiary of Boston Scientific will guarantee these obligations. AMS Europe is a “finance subsidiary” as defined in Rule 13-01(a)(4)(vi) of Regulation S-X. The financial condition, results of operations and cash flows of AMS Europe are consolidated in the financial statements of Boston Scientific. The Offering resulted in cash proceeds of $3.270 billion, net of investor discounts and issuance costs.

We used the net proceeds from the Offering to fund the tender offer and early redemption of combined aggregate principal amount of $3.275 billion of certain of our outstanding senior notes, as well as to pay accrued interest, tender premiums, fees and expenses. We recorded associated debt extinguishment charges of $194 million in the first quarter of 2022 presented in Interest expense within our accompanying unaudited consolidated statements of operations.

Other Arrangements

We have accounts receivable factoring programs in certain European countries and with commercial banks in China and Japan which include promissory notes discounting programs. We account for our factoring programs as sales under FASB ASC Topic 860, Transfers and Servicing. We have no retained interest in the transferred receivables, other than collection and administration, and once sold, the accounts receivable are no longer available to satisfy creditors in the event of bankruptcy. Amounts de-recognized for accounts and notes receivable, which are excluded from Trade accounts receivable, net inwithin our accompanying unaudited consolidated balance sheets, are aggregated by contract denominated currency below (in millions):


Factoring Arrangements	Factoring Arrangements	As of September 30, 2021				As of December 31, 2020				Factoring Arrangements	As of June 30, 2022				As of December 31, 2021
		Amount De-recognized		Weighted Average Interest Rate		Amount De-recognized		Weighted Average Interest Rate			Amount De-recognized		Weighted Average Interest Rate		Amount De-recognized		Weighted Average Interest Rate
Euro denominated	Euro denominated	$	152	2.1	%	$	148	1.9	%	Euro denominated	$	147	1.9	%	$	141	2.1	%
Yen denominated	Yen denominated	203		0.5	%	240		0.6	%	Yen denominated	177		0.6	%	223		0.6	%
Renminbi denominated	Renminbi denominated	—		3.1	%	—		3.5	%	Renminbi denominated	—		3.1	%	—		3.2	%

Other Contractual Obligations and Commitments

We had outstanding letters of credit of ~~$135~~$128 million as of ~~September~~June 30, ~~2021~~2022 and ~~$124~~$134 million as of December 31, ~~2020,~~2021, which consisted primarily of bank guarantees and collateral for workers' compensation insurance arrangements. As of ~~September~~June 30, ~~2021~~2022 and December 31, ~~2020, none of the beneficiaries~~2021 we had ~~drawn upon the letters of credit or guarantees, and accordingly, we have~~ not recognized a related liability for ~~our~~any outstanding letters of credit inwithin our accompanying unaudited consolidated balance ~~sheets as of September 30, 2021 and December 31, 2020.~~sheets.

Refer to Note F – Contractual Obligations and Commitments to our audited financial statements contained in Item 8 of our most recent Annual Report on Form 10-K for additional information on our borrowings and credit agreements.

Table of Contents

NOTE F – SUPPLEMENTAL BALANCE SHEET INFORMATION

Components of selected captions inwithin our accompanying unaudited consolidated balance sheets are as follows:

Trade accounts receivable, net


		As of					As of
(in millions)	(in millions)	September 30, 2021		December 31, 2020		(in millions)	June 30, 2022		December 31, 2021
Trade accounts receivable	Trade accounts receivable	$	1,778	$	1,637	Trade accounts receivable	$	2,034	$	1,886
Allowance for credit losses	Allowance for credit losses	(108)		(105)		Allowance for credit losses	(117)		(108)
		$	1,669	$	1,531		$	1,917	$	1,778

The following is a ~~rollforward~~roll forward of our Allowance for credit losses:


		Three Months Ended September 30,				Nine Months Ended September 30,					Three Months Ended June 30,				Six Months Ended June 30,
(in millions)	(in millions)	2021		2020		2021		2020		(in millions)	2022		2021		2022		2021
Beginning balance	Beginning balance	$	107	$	94	$	105	$	74	Beginning balance	$	113	$	101	$	108	$	105
Cumulative effect adjustment(1)		n/a		n/a		n/a		10
Credit loss expense	Credit loss expense	9		16		20		39		Credit loss expense	9		9		20		11
Write-offs	Write-offs	(7)		(7)		(17)		(19)		Write-offs	(5)		(4)		(11)		(10)
Ending balance	Ending balance	$	108	$	103	$	108	$	103	Ending balance	$	117	$	107	$	117	$	107

~~(1) Effective January 1, 2020, we adopted~~

In accordance with FASB ASC Topic 326, Financial Instruments - Credit Losses using the modified retrospective method, which requires that we recognize credit loss reserves when financial assets are established if credit losses are expected over the asset’s contractual life. Refer to ~~Note R – New Accounting Pronouncements~~ ~~to our audited financial statements contained in Item 8 of our most recent Annual Report on Form 10-K for additional information.~~

~~Table of Contents~~

~~In accordance with FASB~~(FASB ASC Topic ~~326,~~326), we record credit loss reserves to Allowance for credit losses when we establish Trade accounts receivable if credit losses are expected over the asset's contractual life. We base our estimates of credit loss reserves on historical experience and adjust, as necessary, to reflect current conditions using reasonable and supportable forecasts not already reflected in the historical loss information. We utilize an accounts receivable aging approach to determine the reserve to record at accounts receivable commencement for certain customers, applying country or region-specific factors. In performing the assessment of outstanding accounts receivable, regardless of country or region, we may consider significant factors relevant to collectability, including those specific to a customer such as bankruptcy, lengthy average payment cycles and type of account.

We closely monitor outstanding receivables for potential collection risks, including those that may arise from economic and geopolitical conditions. Our sales to government-owned or supported customers, particularly in southern Europe, are subject to an increased number of days outstanding prior to payment relative to other entities, and, in southern Europe, relative to those in other countries. More recently, we have seen an increase in the volume of our U.S. business conducted in ambulatory surgery centers and office-based laboratories. Many of these customers are smaller than those we have historically done business with and may have more limited liquidity. We have adjusted our estimates of credit loss reserves for these customers, regions and conditions based on collection trends.

Inventories

As of
(in millions) September 30, 2021 December 31, 2020
Finished goods $ 1,039 $ 893
Work-in-process 127 109
Raw materials 436 349
$ 1,603 $ 1,351

~~Other current assets~~

As of
(in millions) September 30, 2021 December 31, 2020
Restricted cash and restricted cash equivalents $ 155 $ 208
Derivative assets 192 133
Licensing arrangements 142 148
Other 302 263
$ 792 $ 751

~~Property, plant and equipment, net~~

As of
(in millions) September 30, 2021 December 31, 2020
Land $ 103 $ 104
Buildings and improvements 1,340 1,292
Equipment, furniture and fixtures 3,515 3,465
Capital in progress 465 446
5,423 5,308
Less: accumulated depreciation 3,314 3,224
$ 2,109 $ 2,084

Depreciation expense was $88 million for the third quarter of 2021, $84 million for the third quarter of 2020, $254 million for the first nine months of 2021 and $238 million for the first nine months of 2020.


	As of
(in millions)	June 30, 2022		December 31, 2021
Finished goods	$	1,082	$	1,029
Work-in-process	144		128
Raw materials	526		452
	$	1,752	$	1,610

Table of Contents

Other current assets


	As of
(in millions)	June 30, 2022		December 31, 2021
Restricted cash and restricted cash equivalents	$	132	$	188
Derivative assets	286		226
Licensing arrangements	94		132
Other	362		254
	$	874	$	799

Property, plant and equipment, net


	As of
(in millions)	June 30, 2022		December 31, 2021
Land	$	118	$	109
Buildings and improvements	1,406		1,335
Equipment, furniture and fixtures	3,453		3,475
Capital in progress	537		605
	5,514		5,525
Less: accumulated depreciation	3,268		3,273
	$	2,246	$	2,252

Depreciation expense was $80 million for the second quarter of 2022, $83 million for the second quarter of 2021, $156 million for the first six months of 2022, and $166 million for the first six months of 2021.

Other long-term assets


		As of					As of
(in millions)	(in millions)	September 30, 2021		December 31, 2020		(in millions)	June 30, 2022		December 31, 2021
Restricted cash equivalents	Restricted cash equivalents	$	57	$	52	Restricted cash equivalents	$	50	$	55
Operating lease right-of-use assets	Operating lease right-of-use assets	415		458		Operating lease right-of-use assets	400		435
Derivative assets	Derivative assets	176		109		Derivative assets	252		169
Investments	Investments	434		918		Investments	384		412
Licensing arrangements	Licensing arrangements	138		218		Licensing arrangements	88		114
Indemnification asset						Indemnification asset	163		—
Other	Other	223		166		Other	230		225
		$	1,444	$	1,921		$	1,569	$	1,410

Accrued expenses

As of
(in millions) September 30, 2021 December 31, 2020
Legal reserves $ 357 $ 505
Payroll and related liabilities 884 681
Rebates 351 331
Contingent consideration liability 253 26
Other 574 656
$ 2,418 $ 2,197

~~Other current liabilities~~

As of
(in millions) September 30, 2021 December 31, 2020
Deferred revenue $ 160 $ 138
Licensing arrangements 142 153
Taxes payable 113 158
Liabilities held for sale — 200
Other 255 307
$ 669 $ 958

~~Other long-term liabilities~~

As of
(in millions) September 30, 2021 December 31, 2020
Accrued income taxes $ 541 $ 547
Legal reserves 191 64
Contingent consideration liability 195 171
Licensing arrangements 155 253
Operating lease liabilities 377 401
Deferred revenue 296 257
Other 542 615
$ 2,296 $ 2,309


	As of
(in millions)	June 30, 2022		December 31, 2021
Legal reserves	$	359	$	264
Payroll and related liabilities	754		848
Rebates	335		350
Contingent consideration	133		289
Other	615		686
	$	2,197	$	2,436

Table of Contents

Other current liabilities


	As of
(in millions)	June 30, 2022		December 31, 2021
Deferred revenue	$	222	$	208
Licensing arrangements	112		138
Taxes payable	257		209

Other	193		228
	$	784	$	783

Other long-term liabilities


	As of
(in millions)	June 30, 2022		December 31, 2021
Accrued income taxes	$	550	$	442
Legal reserves	155		284
Contingent consideration	86		197
Licensing arrangements	103		143
Operating lease liabilities	357		389
Deferred revenue	279		276
Other	458		489
	$	1,988	$	2,220

As a result of our 2019 acquisition of BTG plc. (BTG), we assumed a benefit obligation related to a defined benefit pension plan sponsored by BTG for eligible United Kingdom employees. During the second quarter of 2022, we transferred the benefit obligation and associated assets of the pension plan to third party insurers, and as a result, were relieved from primary responsibility of the benefit obligation and the related plan assets. The transaction did not have a material impact on our financial position or results of operations.

NOTE G – INCOME TAXES

Our effective tax rate from continuing operations is presented below:


		Three Months Ended September 30,				Nine Months Ended September 30,					Three Months Ended June 30,				Six Months Ended June 30,
		2021		2020		2021		2020			2022		2021		2022		2021
Effective tax rate from continuing operations	Effective tax rate from continuing operations	13.2	%	31.7	%	1.1	%	24.3	%	Effective tax rate from continuing operations	24.7	%	(24.9)	%	26.1	%	(11.2)	%

The ~~change~~changes in our reported tax rates for the ~~third~~second quarter and first ~~nine~~six months of ~~2021,~~2022, as compared to the same periods in ~~2020, relates~~2021, relate primarily to the impact of certain receipts and charges that are taxed at different rates than our effective tax rate. These include acquisition/divestiture-related charges and receipts, charges and ~~charges include~~receipts on investment portfolio net losses (gains), litigation-related ~~net charges (credits), intangible asset impairment charges, acquisition/divestiture-related~~ net charges, as well as certain discrete tax items primarily related to ~~an IRS audit settlement~~changes in ~~the third quarter of 2020.~~tax laws, unrecognized tax benefits, changes in valuation allowance and foreign return-to-provision adjustments.

As of ~~September~~June 30, ~~2021,~~2022, we had ~~$277~~$411 million of gross unrecognized tax benefits, of which a net ~~$195~~$333 million, if recognized, would affect our effective tax rate. As of December 31, ~~2020,~~2021, we had ~~$261~~$255 million of gross unrecognized tax benefits, of which a net ~~$183~~$177 million, if recognized, would affect our effective tax rate. The change in our gross unrecognized tax benefit is primarily related to positions on new entities we acquired through recent acquisitions and restructuring activities.

It is reasonably possible that within the next 12 months, we will resolve multiple issues with foreign, federal and state taxing authorities, resulting in a reduction in our balance of unrecognized tax benefits of up to ~~$23~~$55 million.

Economic stimulus legislation has been enacted in many countries in response to the COVID-19 pandemic. In the U.S., the CARES Act, enacted on March 27, 2020, provided an estimated $2.2 trillion in COVID-19 pandemic-related relief, and included tax relief and government loans, subsidies and other relief for entities in affected industries. While we have not applied for government loans, we have taken advantage

Table of the benefits offered in multiple jurisdictions, including the U.S. provision allowing taxpayers to defer payment of the employer portion of certain payroll taxes incurred in 2020. This allowed us to preserve cash generated from operations to service our debt obligations and other near-term commitments and is expected to be paid in full by the end of 2022 as permitted by the legislation.Contents

NOTE H – COMMITMENTS AND CONTINGENCIES

The medical device market in which we participate is largely technology driven. As a result, intellectual property rights, particularly patents and trade secrets, play a significant role in product development and differentiation. Over the years, there has been litigation initiated against us by others, including our competitors, claiming that our current or former product offerings infringe patents owned or licensed by them. Intellectual property litigation is inherently complex and unpredictable. In addition, competing parties frequently file multiple suits to leverage patent portfolios across product lines, technologies and geographies and to balance risk and exposure between the parties. In some cases, several competitors are parties in the same proceeding, or in a series of related proceedings, or litigate multiple features of a single class of devices. These dynamics frequently drive settlement not only for individual cases, but also for a series of pending and potentially related and unrelated cases. Although monetary and injunctive relief is typically sought, remedies and restitution are generally not determined until the conclusion of the trial court proceedings and can be modified on appeal. Accordingly, the outcomes of individual cases are difficult to time, predict or quantify and are often dependent upon the outcomes of other cases in other geographies.

During recent years, we successfully negotiated closure of several long-standing legal matters and have received favorable rulings in several other matters; however, there continues to be outstanding intellectual property litigation. Adverse outcomes in one or more of these matters could have a material adverse effect on our ability to sell certain products and on our operating margins, financial position, results of operations and/or liquidity.

In the normal course of business, product liability, securities and commercial claims are asserted against us. Similar claims may be asserted against us in the future related to events not known to management at the present time. We maintain an insurance policy providing limited coverage against securities claims and we are substantially self-insured with respect to product liability claims and fully self-insured with respect to intellectual property infringement claims. The absence of significant third-party insurance coverage increases our potential exposure to unanticipated claims or adverse decisions. Product liability claims, securities and commercial litigation and other legal proceedings in the future, regardless of their outcome, could have a material adverse effect on our ability to sell certain products and on our operating margins, financial position, results of operations and/or liquidity.

~~Table of Contents~~

In addition, like other companies in the medical device industry, we are subject to extensive regulation by national, state and local government agencies in the U.S. and other countries in which we operate. From time to time we are the subject of qui tam actions and governmental investigations often involving regulatory, marketing and other business practices. These qui tam actions and governmental investigations could result in the commencement of civil and criminal proceedings, substantial fines, penalties and administrative remedies and have a material adverse effect on our financial position, results of operations and/or liquidity. For additional information, refer to Note K – Commitments and Contingencies to our audited financial statements contained in Item 8 of our most recent Annual Report on Form 10-K.

In accordance with FASB ASC Topic 450, Contingencies, we accrue anticipated costs of settlement, damages, losses for product liability claims and, under certain conditions, costs of defense, based on historical experience or to the extent specific losses are probable and estimable. Otherwise, we expense these costs as incurred. If the estimate of a probable loss is a range and no amount within the range is more likely, we accrue the minimum amount of the range.

Our accrual for legal matters that are probable and estimable was $548 million as of September 30, 2021 and $569 million as of December 31, 2020 and includes certain estimated costs of settlement, damages and defense primarily related to product liability cases or claims related to our transvaginal surgical mesh products. A portion of this accrual is already funded through our qualified settlement fund (QSF), which is included in restricted cash and restricted cash equivalents in ~~Other current assets~~ ~~of $155 million as of September 30, 2021 and $208 million as of December 31, 2020. Refer to~~ ~~Note F – Supplemental Balance Sheet Information~~ ~~for additional information.~~

We did not record any litigation-related net charges during the third quarter of 2021 and recorded $302 million during the first nine months of 2021, and $260 million during the third quarter and first nine months of 2020, primarily related to transvaginal mesh products, inclusive of a reserve related to claims made by a coalition of state attorneys general. These settlements were finalized in March of 2021 as described further below.

We record certain legal and product liability charges, credits and costs of defense, which we consider to be unusual or infrequent and significant as Litigation-related net charges (credits) inwithin our accompanying unaudited consolidated financial statements. All other legal and product liability charges, credits and costs are recorded within Selling, general and administrative expenses inwithin our accompanying unaudited consolidated statements of operations. We continue to assess certain litigation and claims to determine the amounts, if any, that management believes will be paid as a result of such claims and litigation and, therefore, additional losses may be accrued and paid in the future, which could materially adversely impact our operating results, cash flows and/or our ability to comply with our financial covenant.

Our accrual for legal matters that are probable and estimable was $514 million as of June 30, 2022 and $548 million as of December 31, 2021 and includes certain estimated costs of settlement, damages and defense primarily related to product liability cases or claims related to our transvaginal surgical mesh products. A portion of this accrual is already funded through our qualified settlement fund (QSF), which is included in restricted cash and restricted cash equivalents in Other current assets of $132 million as of June 30, 2022 and $188 million as of December 31, 2021. Refer to Note F – Supplemental Balance Sheet Information for additional information. We recorded litigation-related net charges of $42 million during the second quarter and first six months of 2022, $298 million during the second quarter of 2021 and $302 million during the first six months of 2021.

During recent years, we successfully negotiated closure of several long-standing legal matters and have received favorable rulings in several other matters; however, there continues to be outstanding litigation. Adverse outcomes in one or more of these matters could have a material adverse effect on our ability to sell certain products and on our operating margins, financial position, results of operations and/or liquidity.

In management's opinion, we are not currently involved in any legal proceedings other than those disclosed in our most recent Annual Report on Form 10-K and those specifically identified below, which, individually or in the aggregate, could have a material adverse effect on our financial condition, operations and/or cash flows. Unless included in our legal accrual or otherwise indicated below, a range of loss associated with any individual material legal proceeding cannot be reasonably estimated.

Patent Litigation

On October 28, 2015, the Company filed suit against Cook Group Limited and Cook Medical LLC (collectively, ~~“Cook”)~~Cook) in the United States District Court for the District of Delaware (1:15-cv-00980) alleging infringement of certain Company patents regarding Cook’s Instinct™ Endoscopic Hemoclip. The Company seeks lost profits, a reasonable royalty and a permanent injunction. The case was transferred to the District Court for the Southern District of Indiana. Cook filed ~~seven~~ Inter Partes Review ~~(“IPR”)~~(IPR) requests with the U.S. Patent and Trademark Office (USPTO) against four then-asserted patents, which resulted in the ~~four asserted patents.~~court staying the case until 2020. All IPRs ~~have~~ concluded and ~~Cook and~~confirmed the ~~Company both appealed the Patent Office’s IPR decisions to the Federal Circuit Court~~validity of ~~Appeals. On April 30, 2020, the U.S. Court~~certain claims of Appeals ruled that claims from two of the Company's patents remain valid, remanding two of the patents for further review by the USPTO’s Patent Trial and Appeal Board. In November 2020, the Patent Office issued remand rulings invalidating several additional claims. The district court stayed the case pending the appeals court decision on the IPRs, which is now complete.each challenged patent. The case is proceeding before the United States District Court for the Southern District of Indiana, with the Company asserting three patents against Cook. Trial is anticipated in February 2023.

~~On November 20, 2017,~~ The ~~Board of Regents, University of Texas System (UT)~~Company has also asserted patents against Cook in Germany and TissueGen. Inc., served a lawsuit against us in the Western District of Texas. The complaint against us alleges patent infringement of two U.S. patents owned by UT, relating to “Drug Releasing Biodegradable Fiber Implant” and “Drug Releasing Biodegradable Fiber for Delivery of Therapeutics,” and affects the manufacture, use and sale of our Synergy™ Stent System. On March 12, 2018, the District Court for the Western District of Texas dismissed the action and transferred it to the United ~~States District~~Kingdom. In January 2022, the Düsseldorf Regional Court, ~~for~~Patent Litigation Chamber ruled that Cook’s Instinct Endoscopic Clip technology infringes the ~~District of Delaware. On September 5, 2019,~~Company’s patent, EP 3 023 061. The Düsseldorf Court granted an ex parte preliminary injunction giving the ~~Court of Appeals for~~Company the ~~Federal Circuit affirmed the dismissal of the District Court for~~right to enjoin Cook (Cook Medical EUDC GmbH, Germany, Cook

Table of Contents

~~the Western District of Texas. In April 2020, the United States Supreme Court denied the University’s Petition for Certiorari. UT is proceeding with its case against BSC~~Deutschland GmbH, Germany and Cook Medical Europe Ltd., Ireland) from offering and selling Instinct Endoscopic Clips in ~~Delaware. Trial is scheduled for November 14, 2022.~~

On December 9, 2016, the Company and Boston Scientific Neuromodulation Corporation filed a patent infringement action against Nevro in United States District Court for the District of Delaware (16-cv-1163) alleging that ten U.S. patents owned by Boston Scientific Neuromodulation Corporation are infringed by Nevro's Senza™ Spinal Cord Stimulation (SCS) System. At a trial held in October and November 2021 regarding six of Boston Scientific's originally asserted patent claims, a jury granted Boston Scientific a monetary award, finding that each asserted claim is valid, that four of the six claims are infringed by Nevro, and that two of the claims are willfully infringed by Nevro.

On April 21, 2018, the Company and Boston Scientific Neuromodulation Corporation filed a patent infringement, theft of trade secrets and tortious interference with a contract action against Nevro in United States District Court for the District of Delaware (18-cv-664), and amended the complaint on July 18, 2018, alleging that nine U.S. patents owned by Boston Scientific Neuromodulation Corporation are infringed by Nevro’s Senza™ I and Senza™ II SCS Systems. On December 9, 2019, Nevro filed an answer and counterclaims, in which it alleged that our SCS systems infringe five Nevro patents. No trial date has been set for the theft of trade secrets and patent counterclaims. The patent infringement claims from case 18-cv-664 were stayed pending IPRs. On January 6, 2021, the court stayed one of the patent infringement claims from case 16-cv-1163, such that it will proceed with the stayed patent infringement claims from case 18-cv-664.Germany.

Product Liability Litigation

As of ~~October 20, 2021,~~June 30, 2022, in the United States, approximately ~~54,500~~55,000 product liability cases or claims related to transvaginal surgical mesh products designed to treat stress urinary incontinence and pelvic organ prolapse have been asserted against us. Outside the United States, approximately 2,700 cases or claims have been asserted, predominantly in Canada, the United Kingdom, Ireland and Australia. Plaintiffs generally seek monetary damages based on allegations of personal injury associated with the use of our transvaginal surgical mesh products, including design and manufacturing claims, failure to warn, breach of warranty, fraud, violations of state consumer protection laws and loss of consortium claims.

As of ~~October 20, 2021,~~June 30, 2022, we have entered into master settlement agreements in principle or are in the final stages of entering one with certain plaintiffs' counsel to resolve an aggregate of approximately ~~52,500~~53,000 cases and claims in the United States, adjusted to reflect the ~~Company’s~~Company's analysis of expected non-participation and duplicate claims. These master settlement agreements provide that the settlement and distribution of settlement funds to participating claimants are conditional upon, among other things, achieving minimum required claimant participation thresholds. Of the approximately ~~52,500~~53,000 cases and claims, approximately ~~50,500~~52,000 have met the conditions of the settlement and are final. In Canada, we have settled approximately 300 claims. In Australia, the Company has reached a settlement, subject to court approval, that resolves the approximately 2,300 claims asserted in the consolidated class action filed against the Company in the first quarter of 2021. All settlement agreements were entered into solely by way of compromise and without any admission or concession by us of any liability or wrongdoing. ~~The pending cases are in various federal and state courts in~~

As of June 30, 2022, the U.S. Generally, the plaintiffs allege personal injury associated with use of our transvaginal surgical mesh products. The plaintiffs assert design and manufacturing claims, failure to warn, breach of warranty, fraud, violations of state consumer protection laws and loss of consortium claims. Over 3,100 of the cases were specially assigned to one judge in state court in Massachusetts. On February 7, 2012, the Judicial Panel on Multi-District Litigation (MDL) established MDL-2326 in the U.S. District Court for the Southern District of West Virginia and transferred the federal court transvaginal surgical mesh cases to MDL-2326 for coordinated pretrial proceedings. The Court issued an Order closing the MDL on February 11, 2021, as all cases that had been pending were dismissed or remanded to courts of primary jurisdiction. Outside the United States, there arecompany is facing fewer than 8090 cases and claims in the United Kingdom and ~~Ireland.~~ Canada.

In April 2021 the ~~first quarter~~Company's Board of ~~2021, 2 class actions were filed against~~Directors received a shareholder demand under section 220 of the Delaware General Corporation Law, for inspection of books and records. The Company ~~in Australia. In~~has notified our insurer and retained counsel to respond to the second quarter of 2021, one class action was permanently stayed, while the other is proceeding. The registration process for the class action closed on October 29, 2021. Complete registration information is not yet available but preliminary information indicates that fewer than 300 women have completed registration forms alleging they had Boston Scientific implants. There are also fewer than 10 cases in Canada, inclusive of 1 certified class action, which has settled and received Court approval. demand.

On April 16, 2019, the U.S. Food and Drug Administration (FDA) ordered that all manufacturers of surgical mesh products indicated for the transvaginal repair of pelvic organ prolapse stop selling and distributing their products in the United States immediately, stemming from the FDA’s 2016 reclassification of these devices to class III (high risk) devices, and as a result, the Company ceased global sales and distribution of surgical mesh products indicated for transvaginal pelvic organ prolapse. In ~~April~~February 2021, the ~~Company's Board~~Multi-District Litigation (MDL) established in February 2012 by the United States Federal Courts was closed after all pending cases were dismissed or remanded to courts of Directors received a shareholder demand under section 220 of the Delaware General Corporation Law, for inspection of books and records. The Company has notified our insurer and retained counsel to respond to the demand.primary jurisdiction.

We have established a product liability accrual for known and estimated future cases and claims asserted against us as well as with respect to the actions that have resulted in verdicts against us and the costs of defense thereof associated with our transvaginal surgical mesh products. In the second quarter of 2021, we increased the accrual associated with this matter by $298 million to account for increased, post-COVID-19 pandemic settlement and litigation activity related to the remaining cases and claims the Company faces, our revision of the per-case settlement amount for these cases based on recent settlement and litigation activity and changes to our expectations regarding the rate of incoming cases and claims. We continue to engage in discussions with plaintiffs’ counsel regarding potential resolution of pending cases and claims. We continue to vigorously contest the cases and claims asserted against us that do not settle, and expect that more cases will go to trial through 2023. The final resolution of the cases and claims is uncertain and could have a material impact on our results of operations, financial

~~Table of Contents~~

condition and/or liquidity. Trials involving our transvaginal surgical mesh products have resulted in both favorable and unfavorable judgments for us. We do not believe that the judgment in any one trial is representative of potential outcomes of all cases or claims related to our transvaginal surgical mesh products.

We are currently named a defendant in 67127 filed product liability cases involving our Greenfield Vena Cava Filter, which we discontinued marketing and ~~active~~actively selling in the fourth quarter of ~~2018, alleging various~~2018. The plaintiffs assert they are entitled to monetary damages related to alleged injuries, including perforation of the vena cava, post-implant deep vein thrombosis, fracture, and other injuries. Most of the filed cases are part of a consolidated matter in Middlesex County, Massachusetts. We have received notice of ~~an additional 377~~approximately 325 claims, none of which have been filed. As of ~~October 20, 2021,~~June 30, 2022, we have entered into master settlement agreements ~~in principle or are in the final stages of entering~~ with certain ~~plaintiffs’~~plaintiffs' counsel to resolve approximately ~~200~~225 cases.

Governmental Investigations and Qui Tam Matters

On December 1, 2015, the Brazilian governmental entity known as CADE (the Administrative Council of Economic Defense), served a search warrant on the offices of our Brazilian subsidiary, as well as on the Brazilian offices of several other major medical device makers who do business in Brazil, in furtherance of an investigation into alleged anti-competitive activity with respect to certain tender offers for government contracts. On June 20, 2017, CADE, through the publication of a “technical note,” announced that it was launching a formal administrative proceeding against Boston Scientific’s Brazilian subsidiary,

Table of Contents

Boston Scientific do Brasil Ltda. (BSB), as well as against the Brazilian operations of Medtronic, Biotronik and St. Jude Medical, two Brazilian associations, ABIMED and AMBIMO and 29 individuals for alleged anti-competitive behavior. Under applicable guidance, BSB could be fined a percentage of BSB’s 2016 gross revenues. In August 2021, the investigating commissioner issued a preliminary recommendation of liability against all of the involved companies, and also recommended that CADE impose fines and penalties. However, on October 25, 2021, the CADE Attorney General's office recommended dismissal of the charges and allegations against BSB and the individual BSB employees who were still individual defendants. Subsequently, on March 30, 2022, the Federal Prosecutor’s office issued a non-binding recommendation that is contrary to the Attorney General’s recommendation.The full Commission is considering ~~this recommendation~~both of these recommendations but has not yet issued its decision. We continue to deny the allegations, intend to defend ourselves vigorously and will appeal any decision of liability by the full Commission to the Brazilian courts. During such an appeal, the decision would have no force and effect, and the Court would consider the case without being bound by CADE’s decision.

In March 2022, the Company received a whistleblower letter alleging Foreign Corrupt Practices Act violations in Vietnam. The Company is cooperating with government agencies while investigating these allegations.

Matters Concluded Since December 31, 2021

On May 16, 2018, Arthur Rosenthal et al., filed a plenary summons against Boston Scientific Corporation and Boston Scientific Limited with the High Court of Ireland alleging that payments were due pursuant a transaction agreement regarding Labcoat Limited, a company Boston Scientific purchased in 2008 that provided coating technology for drug-eluting stents. Labcoat sought monetary damages related to an earn-out provision. On March 25, 2022, the parties agreed to a confidential settlement which resolves the dispute. The settlement did not have a material impact on our financial position or results of operations.

On December ~~21, 2017, Janssen Biotech, Inc., Janssen Oncology, Inc, Janssen Research & Development, LLC,~~9, 2016, the Company and ~~Johnson & Johnson (collectively, Janssen) were served with~~Boston Scientific Neuromodulation Corporation filed a ~~qui tam complaint filed on behalf of the United States, 29 states, and the District of Columbia. The complaint, which was filed~~patent infringement action against Nevro Corp. (Nevro) in the United States District Court for the Northern District of California, alleges that Janssen violated the federal False Claims Act and state law when providing pricing information for ZYTIGA to the government in connection with direct government sales and government-funded drug reimbursement programs. The case has been transferred to United States District Court for the District of ~~New Jersey.~~Delaware (16-cv-1163) alleging that ten U.S. patents owned by Boston Scientific Neuromodulation Corporation are infringed by Nevro's Senza™ Spinal Cord Stimulation (SCS) System. The company sought lost profits, a reasonable royalty and a permanent injunction. At a trial held in October and November 2021 regarding six of Boston Scientific's originally asserted patent claims, a jury granted Boston Scientific a monetary award, finding that each asserted claim was valid, that four of the six claims were infringed by Nevro, and that two of the claims were willfully infringed by Nevro. On ~~June 20, 2019,~~July 29, 2022, the ~~complaint was amended~~parties reached a confidential settlement agreement, pursuant to ~~include BTG International Limited as~~which the Company agreed to make a ~~defendant. In May 2020, a class action complaint was filed in New Jersey federal court against Janssen~~payment to Nevro of $85 million to resolve all pending litigation between the parties, including this matter and ~~BTG by a direct purchaser of Zytiga on behalf of similarly situated entities. The complaint was amended in February 2021~~the 18-cv-664 and alleges that BTG and Janssen violated antitrust laws by attempting to enforce certain patents against potential generic competitors. On October 12, 2021, the court granted BTG and Janssen’s motion to compel arbitration in the direct purchaser action and stayed all direct purchaser proceedings. On October 27, 2021, the court granted BTG and Janssen's motion to dismiss all claims in the indirect purchaser action. A motion to dismiss the indirect purchaser and qui tam actions are pending.

~~Refer to~~ ~~Note G – Income Taxes~~ ~~for information regarding our tax litigation.~~

~~Matters Concluded Since December 31, 2020~~21-cv-258 matters described below.

On February 23, 2015, a judge for the Court of Modena (Italy) ordered a trial for Boston Scientific and three of its employees, as well as numerous other defendants charged in criminal proceedings. The charges arise from allegations that the defendants made improper donations to certain healthcare providers and other employees of the Hospital of Modena in order to induce them to conduct unauthorized clinical trials, as well as related government fraud in relation to the financing of such clinical trials. A trial began on February 24, 2016. On November 10, 2017, the Court issued a ruling that convicted one Boston Scientific employee but acquitted two others and levied a fine of €245 thousand against us and imposed joint and several civil damages of €620 thousand on all defendants. We continue to deny these allegations, and timely appealed the decision on May 10, 2018. On November 9, 2020, the Court of Appeal in Bologna reversed the judgements against Boston Scientific and its employee and acquitted them of all charges. This judgment of acquittal became final as toApril 21, 2018, the Company and ~~its employee on April 15, 2021 when the prosecution chose not to appeal.~~

During the fourth quarter of 2013, we received written discovery requests from certain state attorneys general regarding our transvaginal surgical mesh products and related alleged violations of states’ consumer protection statutes. On December 12,

~~Table of Contents~~

2019, the Mississippi Attorney General filed suit against us in a Mississippi state court alleging violations of the Mississippi Consumer Protection Act. In the fourth quarter of 2020 and the first quarter of 2021, we reached settlements with 48 states, including Mississippi, and the District of Columbia. These settlements were finalized in March of 2021.

~~On September 6, 2019,~~ Boston Scientific Neuromodulation Corporation ~~Boston Scientific Scimed, Inc., and Fortis Advisors, LLC, as a Securityholder Representative for the former Securityholders of nVision Medical Corp.~~ filed a ~~declaratory judgment~~patent infringement, theft of trade secrets and tortious interference with a contract action against ~~BioCardia, Inc.~~Nevro in the United States District Court for the Northern District of California to address threats and allegations by BioCardia challenging inventorship and ownership of various patents that Boston Scientific Corporation acquired through an April 13, 2018 merger with nVision as well as related threats and allegations by BioCardia of trade secret misappropriation and unjust enrichment. On December 11, 2019, BioCardia filed an amended answer and counterclaims. On April 23, 2020, BioCardia filed a complaint against nVision, which had not been named as a defendant in the original case. On May 22, 2020, BioCardia amended its complaint against nVision to add twenty former nVision shareholders as defendants. On August 20, 2020, BioCardia again amended its complaint against Boston Scientific Corporation/Boston Scientific Scimed, Inc./Fortis Advisors, LLC and its complaint against nVision/nVision shareholders. On April 8, 2021, the parties settled the dispute, and, on April 12, 2021, the parties filed stipulations with the court to dismiss the remaining legal proceedings. We expect the settlement will not result in any material benefit or liability to the Company.

On May 5, 2014, we were served with a subpoena from the U.S. Department of Health and Human Services, Office of the Inspector General. The subpoena seeks information relating to the launch of the Cognis™ CRT-D and Teligen™ ICD line of devices in 2008, the performance of those devices from 2007 to 2009 and the operation of our Physician Guided Learning Program. We are cooperating with this request. On May 6, 2016, a qui tam lawsuit in this matter was unsealed in the United States District Court for the District of ~~Minnesota. At~~Delaware (18-cv-664), and amended the ~~same time, we learned that the U.S. federal government and the State of California had earlier declined to intervene in that lawsuit on April 15, 2016. The~~ complaint ~~was served on us~~ on July ~~21, 2016.~~18, 2018, alleging that nine U.S. patents owned by Boston Scientific Neuromodulation Corporation were infringed by Nevro’s Senza™ I and Senza™ II SCS Systems. On ~~October 7, 2016, the plaintiff/relator served~~December 9, 2019, Nevro filed an ~~amended complaint~~answer and counterclaims, in which it alleged that ~~dropped the allegations relating to~~ our ~~Physician Guided Learning Program. We filed~~SCS systems infringed five Nevro patents. Nevro sought lost profits, a ~~motion to dismiss the amended complaint on December 7, 2016~~reasonable royalty and ~~the court heard our motion to dismiss on April 5, 2017. On August 29, 2017, the Court granted the motion to dismiss, without prejudice and on September 19, 2017, the relator filed~~ a ~~Second Amended Complaint. We filed a motion to dismiss the Second Amended Complaint on October 10, 2017 and the Court denied that motion on December 13, 2017.~~permanent injunction. On July 31, 2018, the relator filed a motion seeking leave to file a Third Amended Complaint. The Court denied the motion on October 30, 2018. In February 2021, we filed a motion for summary judgment, which the relator opposed, and on August 13, 2021, the Court granted the motion in its entirety. Subsequently,29, 2022, the parties ~~resolved the matter, effective October 4, 2021, and the matter is now concluded. The resolution did not result in any material liability~~agreed to ~~the Company.~~a confidential settlement, described above.

On ~~November 2, 2020, Koninklijke Philips N.V. and IP2IPO Innovations, Ltd. (“Philips”) served~~February 23, 2021, Nevro filed a complaint against the Company in the United States District Court for the District of ~~Delaware.~~Delaware (21-cv-258). The complaint alleges ~~that~~infringement of five Nevro patents by certain ~~BSC cardiovascular diagnostic devices infringe six Philips patents. The~~of the Company’s spinal cord stimulation systems. Nevro sought lost profits, a reasonable royalty and a permanent injunction. On July 29, 2022, the parties ~~have settled the dispute through~~agreed to a confidential settlement, ~~agreement.~~

described above.

NOTE I – STOCKHOLDERS' EQUITY

Preferred Stock

We are authorized to issue 50 million shares of preferred stock in one or more series and to fix the powers, designations, preferences and relative participating, option or other rights thereof, including dividend rights, conversion rights, voting rights, redemption terms, liquidation preferences and the number of shares constituting any series, without any further vote or action by our stockholders.

On May 27, 2020, we completed an offering of 10,062,500 shares of 5.50% Mandatory Convertible Preferred Stock (MCPS), Series A at a price to the public and liquidation preference of $100 per share. The net proceeds from the MCPS offering were

Table of Contents

approximately $975 million after deducting underwriting discounts and commissions and offering expenses. As of ~~September~~June 30, ~~2021,~~2022, our MCPS had an aggregate liquidation preference of $1.006 billion.

Holders of MCPS will be entitled to receive, when, as and if declared by our Board of Directors, or an authorized committee thereof, out of funds legally available for payment, cumulative dividends at the annual rate of 5.50% of the liquidation preference of $100 per share, payable in cash or, subject to certain limitations, by delivery of shares of common stock or any combination of cash and shares of common stock, at our election; provided, however, that any unpaid dividends on the MCPS will continue to accumulate as described in the Certificate of Designations.

~~Table of Contents~~

Subject to certain exceptions, no dividend or distribution will be declared or paid on shares of our common stock, and no common stock will be purchased, redeemed or otherwise acquired for consideration by us or any of our subsidiaries unless, in each case, all accumulated and unpaid dividends for all preceding dividend periods have been declared and paid, or a sufficient amount of cash or number of shares of common stock has been set apart for the payment of such dividends, on all outstanding shares of MCPS. In the event of our voluntary or involuntary liquidation, winding-up or dissolution, no distribution of our assets may be made to holders of our common stock until we have paid holders of our MCPS, each of which will be entitled to receive a liquidation preference in the amount of $100 per share plus accumulated and unpaid dividends.

Unless earlier converted, each share of MCPS will automatically convert on June 1, 2023, subject to postponement for certain market disruption events, into between 2.3834 and 2.9197 shares of common stock, subject to customary anti-dilution adjustments. The number of shares of common stock issuable upon conversion will be determined based on the average volume-weighted average price per share of common stock over the 20 consecutive trading day period beginning on, and including, the 21st scheduled trading day immediately preceding June 1, 2023.

The MCPS is not subject to any redemption, sinking fund or other similar provisions. However, at our option, we may purchase or exchange the MCPS from time to time in the open market, by tender or exchange offer or otherwise, without the consent of, or notice to, holders of MCPS. The holders of the MCPS will not have any voting rights, with limited exceptions.

In the ~~third~~second quarter of ~~2021,~~2022, the Audit Committee of our Board of Directors (the Committee), pursuant to authority delegated to such committee by our Board of Directors, declared, and we paid, a cash dividend of $1.375 per MCPS share to holders of our MCPS as of ~~August~~May 15, ~~2021,~~2022, representing a dividend period from ~~June~~March 2022 through ~~August 2021.~~May 2022. On ~~October 26, 2021,~~July 25, 2022 the Committee declared a cash dividend of $1.375 per MCPS share to holders of our MCPS as of ~~November~~August 15, ~~2021,~~2022, representing a dividend period from ~~September~~June through ~~November 2021.~~August 2022. We have presented cumulative, unpaid dividends within Accrued expenses within our accompanying unaudited consolidated balance sheet as of ~~September~~June 30, ~~2021.~~2022.

Refer to Note L – Stockholders' Equity to our audited financial statements contained in Item 8 of our most recent Annual Report on Form 10-K for information on the pertinent rights and privileges of our outstanding common stock.

NOTE J – WEIGHTED AVERAGE SHARES OUTSTANDING


		Three Months Ended September 30,		Nine Months Ended September 30,			Three Months Ended June 30,		Six Months Ended June 30,
(in millions)	(in millions)	2021	2020	2021	2020	(in millions)	2022	2021	2022	2021
Weighted average shares outstanding — basic	Weighted average shares outstanding — basic	1,423.8	1,430.9	1,421.3	1,413.0	Weighted average shares outstanding — basic	1,429.7	1,421.3	1,428.8	1,420.0
Net effect of common stock equivalents	Net effect of common stock equivalents	11.8	—	11.7	—	Net effect of common stock equivalents	8.1	11.2	9.3	11.7
Weighted average shares outstanding - assuming dilution	Weighted average shares outstanding - assuming dilution	1,435.6	1,430.9	1,433.0	1,413.0	Weighted average shares outstanding - assuming dilution	1,437.8	1,432.5	1,438.1	1,431.7

The following securities were excluded from the calculation of weighted average shares outstanding - assuming dilution because their effect in the periods presented below would have been anti-dilutive:

Three Months Ended September 30, Nine Months Ended September 30,
(in millions) 2021 2020 2021 2020
Common stock equivalents(1)
0 14 0 14
Stock options outstanding(2)
0 6 3 6
MCPS(3)
24 24 24 11


	Three Months Ended June 30,		Six Months Ended June 30,
(in millions)	2022	2021	2022	2021
Stock options outstanding(1)	7	3	6	6
MCPS(2)	24	24	24	24

(1) ~~Represents common stock equivalents pursuant to our employee stock-based compensation plans, which are anti-dilutive in the third quarter and first nine months of 2020 due to our~~ ~~Net loss~~ ~~position in those periods.~~

~~(2)~~ Represents stock options outstanding pursuant to our employee stock-based compensation plans with exercise prices that were greater than the average fair market value of our common stock for the related periods.

~~(3)~~(2) Represents common stock issuable upon the conversion of MCPS. Refer to Note I – Stockholders' Equity for additional information.

~~Table of Contents~~

We base Net income (loss) per common share - assuming dilution upon the weighted-average number of common shares and common stock equivalents outstanding during each year. Potential common stock equivalents are determined using the treasury stock method. We exclude stock options, stock awards and MCPS from the calculation if the effect would be anti-dilutive. The dilutive effect of MCPS is calculated using the if-converted method. The if-converted method assumes that these securities were converted to shares of common stock at the beginning of the reporting period to the extent that the effect is dilutive.

For the ~~third~~second quarter and first ~~nine~~six months of 2022 and 2021, the effect of assuming the conversion of MCPS into shares of common stock was anti-dilutive, and therefore excluded from the calculation of earnings per share (EPS). Accordingly, Net income was reduced by cumulative Preferred stock dividends, as presented inwithin our accompanying unaudited consolidated statements of operations, for purposes of calculating Net income available to common stockholders.

We issued ~~approximately 3000000~~less than 1000000 shares of our common stock in the ~~third quarters~~second quarter of ~~2021 and 2020 and 8000000~~2022, approximately 4000000 shares in the first ~~nine~~six months of 2022, approximately 1000000 shares in the second quarter of 2021, and ~~2020~~approximately 5000000 shares in the first six months of 2021, following the exercise of stock options, vesting of ~~deferred~~restricted stock units or purchases under our employee stock purchase plan. We did not repurchase any shares of our common stock in the first ~~nine~~six months of ~~2021~~2022 or ~~2020.~~2021. On December 14, 2020, our Board of Directors approved a ~~new~~ stock repurchase program authorizing the repurchase of up to $1.000 billion of our common stock. As of ~~September~~June 30, ~~2021,~~2022, we had the full amount remaining available under the authorization.

Table of Contents

NOTE K – SEGMENT REPORTING

~~Our 7~~In the first quarter of 2022, we reorganized our operational structure in order to strengthen our category leadership in the markets we serve and, in particular, benefit our Cardiology customers and patients. Following the reorganization, we have aggregated our core businesses ~~are organized~~ into 32 reportable segments: MedSurg ~~Rhythm and Neuro,~~ and Cardiovascular, each of which ~~represent an aggregation of our operating segments that generate~~generates revenues from the sale of medical devices. There was no impact to the reporting units identified for purposes of our annual goodwill impairment testing.

We measure and evaluate our reportable segments based on their respective net sales, ~~of reportable segments,~~ operating income, ~~of reportable segments,~~ excluding intersegment profits, and operating income ~~of reportable segments~~ as a percentage of net sales, all excluding the impact of reportable segments. Operating income of reportable segments as a percentage of net sales of reportable segments is defined as operating income of reportable segments divided by net sales of reportable segments.foreign currency. We exclude from operating income of reportable segments certain corporate-related expenses and certain transactions or adjustments that our chief operating decision maker (CODM) considers to be non-operational, such as amounts related to amortization expense, goodwill and other intangible asset impairment charges, acquisition/divestiture-related net charges (credits), restructuring and restructuring-related net charges (credits); and certain litigation-related net charges (credits) and European Union (EU) Medical Device Regulation (MDR) implementation costs. Although we exclude these amounts from operating income of reportable segments, they are included in reported Income (loss) before income taxes inwithin our accompanying unaudited consolidated statements of operations and are included in the reconciliation below. Refer to Note L – Revenue for net sales by reportable segment presented in accordance with U.S. GAAP.

A reconciliation of the totals reported for the reportable segments to the applicable line items within our accompanying unaudited consolidated statements of operations is as follows (in millions, except percentages):
Three Months Ended
September 30, Nine Months Ended
September 30,
2021 2020 2021 2020
MedSurg $ 917 $ 825 $ 2,725 $ 2,175
Rhythm and Neuro 819 757 2,436 1,985
Cardiovascular 1,196 1,002 3,588 2,862
Total net sales of reportable segments 2,932 2,584 8,748 7,021
All other (Specialty Pharmaceuticals)(1)
— 74 13 183
Net sales $ 2,932 $ 2,659 $ 8,761 $ 7,204
. We have revised prior periods to conform to the current year presentation.


	Three Months Ended June 30,				Six Months Ended June 30,
Net Sales	2022		2021		2022		2021



MedSurg	$	1,278	$	1,185	$	2,442	$	2,233



Cardiovascular	2,066		1,865		3,967		3,526
Total net sales of reportable segments	3,344		3,050		6,410		5,758
Specialty Pharmaceuticals(1)	—		—		—		13

Impact of foreign currency fluctuations	(100)		27		(140)		58
	$	3,244	$	3,077	$	6,270	$	5,829



Income (loss) before income taxes
MedSurg	$	398	$	403	$	769	$	748
Cardiovascular	543		529		1,020		989
Total operating income of reportable segments	941		932		1,789		1,736
Specialty Pharmaceuticals(1)	—		—		—		4
Unallocated amounts:
Corporate expenses, including hedging activities and impact of foreign currency fluctuations on operating income of reportable segments	(123)		(159)		(189)		(298)
Intangible asset impairment charges, acquisition/divestiture-related net charges (credits), restructuring and restructuring-related net charges (credits), and certain litigation-related net charges (credits) and EU MDR implementation costs	(192)		(331)		(308)		(445)
Amortization expense	(204)		(180)		(402)		(365)
Operating income (loss)	423		262		889		632
Other expense, net	(78)		(113)		(388)		(157)
Income (loss) before income taxes	$	345	$	149	$	501	$	474

(1) On March 1, 2021, we completed the divestiture of the Specialty Pharmaceuticals business. Prior to the divestiture, we presented the Specialty Pharmaceuticals business as a standalone operating segment alongside our reportable segments.

Table of Contents

Three Months Ended
September 30, Nine Months Ended
September 30,
2021 2020 2021 2020
MedSurg $ 338 $ 307 $ 1,033 $ 738
Rhythm and Neuro 160 165 476 296
Cardiovascular 361 208 1,117 593
Total operating income of reportable segments 859 680 2,626 1,628
All other (Specialty Pharmaceuticals)(1)
— 49 4 124
Unallocated amounts:
Corporate expenses, including hedging activities (109) (108) (438) (330)
Intangible asset impairment charges, acquisition/divestiture-related net charges (credits), restructuring and restructuring-related net charges (credits), and certain litigation-related net charges (credits) and EU MDR implementation costs (178) (629) (624) (957)
Amortization expense (184) (197) (549) (595)
Operating income (loss) 387 (205) 1,019 (130)
Other expense, net 95 (22) (62) (256)
Income (loss) before income taxes $ 483 $ (227) $ 957 $ (386)
(1) On March 1, 2021, we completed the divestiture of the Specialty Pharmaceuticals business. Our consolidated net sales and income (loss) before income taxes for the first nine months of 2021 include Specialty Pharmaceuticals up to the date of the closing of the transaction.

Operating income margin of reportable segments Three Months Ended
September 30, Nine Months Ended
September 30,
2021 2020 2021 2020
MedSurg 36.8 % 37.2 % 37.9 % 33.9 %
Rhythm and Neuro 19.5 % 21.9 % 19.5 % 14.9 %
Cardiovascular 30.2 % 20.8 % 31.1 % 20.7 %


	Three Months Ended June 30,				Six Months Ended June 30,
Operating income margin of reportable segments	2022		2021		2022		2021
MedSurg	31.2	%	34.0	%	31.5	%	33.5	%
Cardiovascular	26.3	%	28.4	%	25.7	%	28.0	%

NOTE L – REVENUE

We generate revenue primarily from the sale of single-use medical devices and present revenue net of sales taxes inwithin our accompanying unaudited consolidated statements of operations. ~~The following tables disaggregate~~In the first quarter of 2022, we reorganized our ~~revenue from contracts with customers by~~ business structure into 5 operating segments and ~~geographic region (in millions):~~

Three Months Ended September 30,
2021 2020
Businesses U.S. Int'l Total U.S. Int'l Total
Endoscopy $ 306 $ 227 $ 533 $ 270 $ 205 $ 475
Urology and Pelvic Health 275 109 384 251 99 350
Cardiac Rhythm Management 312 199 512 275 190 465
Electrophysiology 32 55 86 33 43 76
Neuromodulation 175 46 221 176 41 216
Interventional Cardiology 376 368 744 255 331 586
Peripheral Interventions 250 202 452 236 179 416
Specialty Pharmaceuticals — — — 65 10 74
Net Sales $ 1,726 $ 1,206 $ 2,932 $ 1,560 $ 1,098 $ 2,659

Onon March 1, 2021, we completed the divestiture of the Specialty Pharmaceuticals business. Our consolidated net sales for the first ~~nine~~six months of 2021 include Specialty Pharmaceuticals up to the date of the closing of the transaction. The following tables disaggregate our revenue from contracts with customers by component and geographic region (in millions). We have revised prior periods to conform to current year presentation:


	Three Months Ended June 30,
	2022						2021
Businesses	U.S.		Int'l		Total		U.S.		Int'l		Total
Endoscopy	$	338	$	221	$	560	$	316	$	235	$	551
Urology and Pelvic Health	320		130		450		285		112		397
Neuromodulation	186		53		239		194		53		247
MedSurg	844		404		1,248		794		400		1,195
Interventional Cardiology Therapies	192		382		574		206		369		574
Watchman	225		25		250		192		24		216
Cardiac Rhythm Management	342		199		541		314		210		524
Electrophysiology	73		79		152		34		62		95
Cardiology	832		685		1,517		746		664		1,410
Peripheral Interventions	257		221		478		260		213		473
Cardiovascular	1,089		906		1,996		1,005		877		1,883

Total Net Sales	$	1,933	$	1,311	$	3,244	$	1,800	$	1,277	$	3,077


	Six Months Ended June 30,
	2022						2021
Businesses	U.S.		Int'l		Total		U.S.		Int'l		Total
Endoscopy	$	650	$	441	$	1,091	$	596	$	454	$	1,050
Urology and Pelvic Health	606		257		863		542		216		758
Neuromodulation	346		101		448		345		99		444
MedSurg	1,602		799		2,402		1,483		769		2,252
Interventional Cardiology Therapies	378		740		1,118		400		699		1,100
Watchman	428		48		476		341		45		386
Cardiac Rhythm Management	667		394		1,061		590		403		993
Electrophysiology	123		147		270		64		115		179
Cardiology	1,596		1,329		2,925		1,395		1,263		2,658
Peripheral Interventions	513		430		944		498		407		906
Cardiovascular	2,109		1,760		3,868		1,893		1,670		3,564
Specialty Pharmaceuticals	—		—		—		10		4		13
Total Net Sales	$	3,711	$	2,559	$	6,270	$	3,386	$	2,443	$	5,829

Refer to Note K- Segment Reporting for information on our reportable segments.

3332

Table of Contents

Nine Months Ended September 30,
2021 2020
Businesses U.S. Int'l Total U.S. Int'l Total
Endoscopy $ 902 $ 681 $ 1,583 $ 715 $ 550 $ 1,265
Urology and Pelvic Health 817 325 1,142 650 260 910
Cardiac Rhythm Management 903 603 1,505 738 515 1,253
Electrophysiology 96 169 265 86 116 202
Neuromodulation 520 145 666 426 103 529
Interventional Cardiology 1,117 1,113 2,230 741 973 1,714
Peripheral Interventions 748 609 1,358 649 499 1,148
Specialty Pharmaceuticals 10 4 13 162 21 183
Net Sales $ 5,112 $ 3,649 $ 8,761 $ 4,167 $ 3,037 $ 7,204


	Three Months Ended June 30,				Six Months Ended June 30,
Regions	2022		2021		2022		2021
U.S.	$	1,933	$	1,800	$	3,711	$	3,376
Europe, Middle East and Africa	660		662		1,284		1,266
Asia-Pacific	530		520		1,047		994
Latin America and Canada	120		95		228		180
Medical Devices	3,244		3,077		6,270		5,816
U.S.	—		—		—		10
International	—		—		—		4
Specialty Pharmaceuticals	—		—		—		13
Total Net Sales	$	3,244	$	3,077	$	6,270	$	5,829

Emerging Markets(1)	$	427	$	359	$	817	$	676

(1)

Three Months Ended September 30, Nine Months Ended September 30,
Geographic Regions 2021 2020 2021 2020
U.S. $ 1,726 $ 1,496 $ 5,103 $ 4,005
EMEA (Europe, Middle East and Africa) 590 540 1,855 1,507
APAC (Asia-Pacific) 517 472 1,511 1,292
LACA (Latin America and Canada) 99 77 279 217
Medical Devices 2,932 2,584 8,748 7,021
U.S. — 65 10 162
International — 10 4 21
Specialty Pharmaceuticals — 74 13 183
Net Sales $ 2,932 $ 2,659 $ 8,761 $ 7,204
Emerging Markets(1)
$ 354 $ 291 $ 1,030 $ 832

~~(1)~~ We define Emerging Markets as the 20 countries that we believe have strong growth potential based on their economic conditions, healthcare sectors and our global capabilities. Periodically, we assess our list of Emerging Markets countries, ~~and effective January 1, 2021, modified our list to include~~which currently includes the following countries: Brazil, Chile, China, Colombia, Czech Republic, India, Indonesia, Malaysia, Mexico, Philippines, Poland, Russia, Saudi Arabia, Slovakia, South Africa, South Korea, Taiwan, Thailand, Turkey and Vietnam. ~~We have revised prior period amounts to conform to the current year's presentation which had an immaterial impact on previously reported Emerging Markets net sales.~~

Deferred Revenue

Contract liabilities are classified within Other current liabilities and Other long-term liabilities inwithin our accompanying unaudited consolidated balance sheets. Our deferred revenue balance was ~~$455~~$501 million as of ~~September~~June 30, ~~2021~~2022 and ~~$395~~$484 million as of December 31, ~~2020.~~2021. Our contractual liabilities are primarily composed of deferred revenue related to the LATITUDE™ Patient Management System within our ~~Cardiac Rhythm Management (CRM)~~Cardiology business, for which revenue is recognized over the average service period based on device and patient longevity. Our contractual liabilities also include deferred revenue related to the LUX-Dx™ Insertable Cardiac Monitor (ICM) system, also within our ~~CRM~~Cardiology business, for which revenue is recognized over the average service period based on device longevity and usage. We recognized revenue of ~~$39~~$35 million in the ~~third~~second quarter and ~~$113~~$76 million in the first ~~nine~~six months of ~~2021~~2022 that was included in the above contract liability balance as of December 31, ~~2020.~~2021. We have elected not to disclose the transaction price allocated to unsatisfied performance obligations when the original expected contract duration is one year or less. In addition, we have not identified material unfulfilled performance obligations for which revenue is not currently deferred.

~~Table of Contents~~

Variable Consideration

~~We generally allow~~For additional information on variable consideration, refer to Note A – Significant Accounting Policies to our ~~customers to return defective, damaged and,~~audited financial statements contained in ~~certain cases, expired products for credit. We base~~Item 8 of our estimate for sales returns upon historical trends and record the amount as a reduction to revenue when we sell the initial product. In addition, we may allow customers to return previously purchased products for next-generation product offerings. For these transactions, we defer recognition of revenuemost recent Annual Report on the sale of the earlier generation product based upon an estimate of the amount of product to be returned when the next-generation products are shipped to the customer. Uncertain timing of next-generation product approvals, variability in product launch strategies, product recalls and variation in product utilization all affect our estimates related to sales returns and could cause actual returns to differ from these estimates.

Form 10-K.

We also offer sales rebates and discounts to certain customers. We treat sales rebates and discounts as a reduction of revenue and classify the corresponding liability as current. We estimate rebates for products where there is sufficient historical information available to predict the volume of expected future rebates. If we are unable to reasonably estimate the expected rebates, we record a liability for the maximum rebate percentage offered. We have entered certain agreements with group purchasing organizations to sell our products to participating hospitals at negotiated prices. We recognize revenue from these agreements following the same revenue recognition criteria discussed above.

NOTE M – CHANGES IN OTHER COMPREHENSIVE INCOME

The following tables provide the reclassifications out of Other comprehensive income (loss), net of tax:

~~Three Months Ended September 30~~

(in millions) Foreign Currency Translation Adjustments Net Change in Derivative Financial Instruments Net Change in Defined Benefit Pensions and Other Items Total
Balance as of June 30, 2021 $ 136 $ 146 $ (46) $ 237
Other comprehensive income (loss) before reclassifications (47) 61 — 14
(Income) loss amounts reclassified from accumulated other comprehensive income (2) (11) — (13)
Total other comprehensive income (loss) (49) 50 — 1
Balance as of September 30, 2021 $ 88 $ 196 $ (46) $ 238

(in millions) Foreign Currency Translation Adjustments Net Change in Derivative Financial Instruments Net Change in Defined Benefit Pensions and Other Items Total
Balance as of June 30, 2020 $ (46) $ 222 $ (45) $ 131
Other comprehensive income (loss) before reclassifications 88 (50) — 38
(Income) loss amounts reclassified from accumulated other comprehensive income (5) (14) — (19)
Total other comprehensive income (loss) 84 (64) — 20
Balance as of September 30, 2020 $ 38 $ 158 $ (45) $ 151


(in millions)	Foreign Currency Translation Adjustments		Net Change in Derivative Financial Instruments		Net Change in Defined Benefit Pensions and Other Items		Total
Balance as of March 31, 2022	$	29	$	229	$	(36)	$	222
Other comprehensive income (loss) before reclassifications	79		165		—		245
(Income) loss amounts reclassified from accumulated other comprehensive income	(2)		(31)		0		(34)
Total other comprehensive income (loss)	77		134		—		211
Balance as of June 30, 2022	$	106	$	363	$	(36)	$	433

3533

Table of Contents

~~Nine Months Ended September 30~~


(in millions)	Foreign Currency Translation Adjustments		Net Change in Derivative Financial Instruments		Net Change in Defined Benefit Pensions and Other Items		Total
Balance as of March 31, 2021	$	134	$	165	$	(45)	$	254
Other comprehensive income (loss) before reclassifications	5		(12)		(0)		(8)
(Income) loss amounts reclassified from accumulated other comprehensive income	(3)		(6)		—		(9)
Total other comprehensive income (loss)	2		(18)		—		(16)
Balance as of June 30, 2021	$	136	$	146	$	(46)	$	237

(in millions) Foreign Currency Translation Adjustments Net Change in Derivative Financial Instruments Net Change in Defined Benefit Pensions and Other Items Total
Balance as of December 31, 2020 $ 218 $ 36 $ (47) $ 207
Other comprehensive income (loss) before reclassifications 5 182 1 188
(Income) loss amounts reclassified from accumulated other comprehensive income(1)
(135) (21) — (157)
Total other comprehensive income (loss) (130) 161 1 31
Balance as of September 30, 2021 $ 88 $ 196 $ (46) $ 238

(1) In connection with the completion of the divestiture of the Specialty Pharmaceuticals business in the first quarter of 2021, we released $127 million of cumulative translation adjustments associated with the disposed business from ~~Accumulated other comprehensive income (loss), net of tax~~.


(in millions)	(in millions)	Foreign Currency Translation Adjustments		Net Change in Derivative Financial Instruments		Net Change in Defined Benefit Pensions and Other Items		Total		(in millions)	Foreign Currency Translation Adjustments		Net Change in Derivative Financial Instruments		Net Change in Defined Benefit Pensions and Other Items		Total
Balance as of December 31, 2019		$	142	$	173	$	(45)	$	270
Balance as of December 31, 2021										Balance as of December 31, 2021	$	93	$	206	$	(36)	$	263
Other comprehensive income (loss) before reclassifications	Other comprehensive income (loss) before reclassifications	(90)		36		—		(54)		Other comprehensive income (loss) before reclassifications	17		200		0		217
(Income) loss amounts reclassified from accumulated other comprehensive income	(Income) loss amounts reclassified from accumulated other comprehensive income	(14)		(52)		—		(65)		(Income) loss amounts reclassified from accumulated other comprehensive income	(4)		(43)		0		(47)
Total other comprehensive income (loss)	Total other comprehensive income (loss)	(104)		(15)		—		(119)		Total other comprehensive income (loss)	13		157		—		170
Balance as of September 30, 2020		$	38	$	158	$	(45)	$	151
Balance as of June 30, 2022										Balance as of June 30, 2022	$	106	$	363	$	(36)	$	433


(in millions)	Foreign Currency Translation Adjustments		Net Change in Derivative Financial Instruments		Net Change in Defined Benefit Pensions and Other Items		Total
Balance as of December 31, 2020	$	218	$	36	$	(47)	$	207
Other comprehensive income (loss) before reclassifications	53		121		1		174
(Income) loss amounts reclassified from accumulated other comprehensive income(1)	(134)		(10)		—		(144)
Total other comprehensive income (loss)	(81)		111		1		30
Balance as of June 30, 2021	$	136	$	146	$	(46)	$	237
(1) In connection with the completion of the divestiture of the Specialty Pharmaceuticals business in the first quarter of 2021, we released $127 million of cumulative translation adjustments associated with the disposed business from Accumulated other comprehensive income (loss), net of tax.

Refer to Note D – Hedging Activities and Fair Value Measurements for further detail on our net investment hedges recorded in Foreign currency translation adjustments and our cash flow hedges recorded in Net change in derivative financial instruments.

~~The gains and losses on defined benefit and pension items before reclassifications and gains and losses on defined benefit and pension items reclassified from~~ ~~Accumulated other comprehensive income (loss), net of tax~~ ~~were reduced by immaterial income tax impacts in the third quarter and first nine months of 2021 and 2020.~~

~~Table of Contents~~

NOTE N – NEW ACCOUNTING PRONOUNCEMENTS

Periodically, new accounting pronouncements are issued by the FASB or other standard setting bodies. Recently issued standards typically do not require adoption until a future effective date. Prior to their effective date, we evaluate the pronouncements to determine the potential effects of adoption on our accompanying unaudited consolidated financial statements. During the first ~~quarter~~six months of ~~2021,~~2022, we implemented the following standards, which did not have a material impact on our financial position ~~and results of operations.~~

~~ASC Update No. 2020-10~~

~~In October 2020, the FASB issued ASC Update No. 2020-10,~~ ~~Codification Improvements~~. Update No. 2020-10 amends a wide variety of Topics in the Codification in order to improve the consistency of the Codification and the application thereof, while leaving Generally Accepted Accounting Principles unchanged.

~~ASC Update No. 2020-06~~

~~In August 2020, the FASB issued ASC Update No. 2020-06,~~ ~~Debt - Debt with Conversion and Other Options~~ ~~(Subtopic 470-20)~~ ~~and Derivatives and Hedging - Contracts in Entity’s Own Equity~~ ~~(Subtopic 815-40):~~ ~~Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity~~. The amendments in Update No. 2020-06 simplify the complexity associated with applying U.S. GAAP for certain financial instruments with characteristics of liabilities and equity. More specifically, the amendments focus on the guidance for convertible instruments and derivative scope exception for contracts in an entity’s own equity.

~~ASC Update No. 2019-12~~

~~In December 2019, the FASB issued ASC Update No. 2019-12,~~ ~~Income Taxes~~ ~~(Topic 740):~~ ~~Simplifying the Accounting for Income Taxes~~. The purpose of Update No. 2019-12 is to continue the FASB’s Simplification Initiative to reduce complexity in accounting standards. The amendments in Update No. 2019-12 simplify the accounting for income taxes by removing certain exceptions related to the incremental approach for intraperiod tax allocation, the requirement to recognize or derecognize deferred tax liabilities related to equity method investments that are also foreign subsidiaries, and the methodology for calculating income taxes in an interim period. In addition to removing these exceptions, Update No. 2019-12 also clarifies and simplifies other aspects of the accounting for income taxes.

~~Standards to be Implemented~~

~~ASC Update No. 2021-08~~

~~In October 2021, the FASB issued ASC Update No. 2021-08,~~ ~~Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers.~~ The amendments in Update No. 2021-08 improve the accounting for acquired revenue contracts with customers in a business combination by addressing diversity in practice and inconsistency related to recognition of an acquired contract liability and payment terms and their effect on subsequent revenue recognized by the acquirer. Update No. 2021-08 is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Early adoption is permitted, and we plan to adopt Update No. 2021-08 during the fourth quarter of 2021. We have the option to apply the amendments retrospectively to all business combinations for which the acquisition date occurs on or after the beginning of the fiscal year that includes the interim period of early adoption, or prospectively. We do not expect the adoption to have a material effect on our financial position or results of operations.

ASC Update No. 2021-05

In July 2021, the FASB issued ASC Update No. 2021-05, Leases (Topic 842): Lessors—Certain Leases with Variable Lease Payments. The amendments in Update No. 2021-05 revise lessor lease classification guidance and require accounting for certain leases with variable lease payments that do not depend on a reference index or rate as operating leases. Such

Table of Contents

classification is required if the lease would have been classified as a sales-type or direct financing lease in accordance with guidance in FASB ASC Topic 842 and the lessor would have otherwise recognized a day-one loss. Update No. 2021-05 is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. We ~~have~~adopted Update No. 2021-05 in the ~~option~~first quarter of 2022 on a prospective basis.

Standards to ~~apply~~be Implemented

In March 2022, the ~~amendments retrospectively~~FASB issued ASC Update No. 2022-01, Derivatives and Hedging (Topic 815): Fair Value Hedging - Portfolio Layer Method. Update No. 2022-01 expands the current single-layer method to ~~leases that commenced or were modified~~allow multiple hedged layers of a single closed portfolio under the method, among other updates to these methods. Update No. 2022-01 is effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years. Early adoption is permitted on any date on or after the issuance of this update for any entity that has adopted the amendments in Update No. 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities, for the corresponding period. We do not expect the adoption to have a material impact on our financial position or results of operations.

In March 2022, the FASB issued ASC Update No. 2022-02, Financial Instruments- Credit Losses (Topic 326: Troubled Debt Restructurings and Vintage Disclosures. Update No. 2022-02 makes amendments related to troubled debt restructurings for entities that have adopted Update No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, as well as amendments related to vintage disclosures for entities with investments in financing receivables that have adopted Update No. 2016-13. Update No. 2022-02 is effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years. Update No. 2022-02 should be applied prospectively, with the option of modified retrospective adoption for the recognition and measurement of troubled debt restructurings. Early adoption is permitted on any date on or after the issuance of this update for any entity that has adopted the amendments in Update No. 2016-13. We do not expect the adoption to have a material impact on our financial position or results of operations.

In June 2022, the FASB issued ASC Update No. 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions. Update No. 2022-03 clarifies the guidance in Topic ~~842,~~820 related to measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of an equity security, as well as introduces new disclosure requirements for these types of equity securities. Update No. 2022-03 is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted for both interim and annual financial statements that have not yet been issued or made available for issuance and the amendments in this update should be applied prospectively. We do not expect the adoption to have a material impact on our financial position or results of operations.

~~Table of Contents~~

No other new accounting pronouncements issued or effective in the period had or are expected to have a material impact on our accompanying unaudited consolidated financial statements.

3835

Table of Contents

ITEM 2.MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Introduction

Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a broad range of interventional medical specialties. Our mission is to transform lives through innovative medical solutions that improve the health of patients around the world. As a medical technology leader for more than 40 years, we have advanced the practice of less-invasive medicine by helping physicians and other medical professionals diagnose and treat a wide range of diseases and medical conditions and improve patients’ quality of life by providing alternatives to surgery and other medical procedures that are typically traumatic to the body. Our net sales have increased substantially since our formation, fueled in part by strategic acquisitions designed to improve our ability to take advantage of growth opportunities in the medical device industry and to build diversified portfolios within our core businesses. We advance science for life by providing a broad range of high performance solutions to address unmet patient needs and reduce the cost of healthcare. When used in this report, the terms "we," "us," ~~"our,"~~"our" and "the Company" mean Boston Scientific Corporation and its divisions and subsidiaries.

COVID-19 Pandemic

In December 2019, the novel strain of coronavirus (SARS-Cov-2), and its disease commonly known as COVID-19 (COVID-19), was reported in China and has since widely impacted the global public health and economic environment. In March 2020, the World Health Organization ~~(WHO)~~ declared COVID-19, including all additional variations and strains thereof, a global pandemic (COVID-19 pandemic). While the majority of procedures using our products are deferrable, most of the conditions that we treat are generally fairly acute and cannot be deferred for extended periods. As the pandemic spread worldwide and with COVID-19 cases confirmed in all major geographies, many elective and semi-emergent procedures were postponed, enabling hospital staff to focus critical resources on caring for COVID-19 patients.

The ongoing COVID-19 pandemic and accompanying restrictions negatively impacted our net sales and our results of operations beginning in March 2020. We experienced improvement in our global sales trends beginning in the third quarter of 2020 which continued through the third quarter of 2021, as procedure volumes resumed and referral rates improved. During the third quarter of 2021, as the more contagious Delta variant strain surged globally, elective procedures were unfavorably impacted in certain regions, particularly in the U.S., while they improved in many parts of the globe as COVID-19 vaccines were increasingly made available. However, COVID-19 cases persist in many locations around the world where vaccination rates remain low and new, more contagious variant strains of COVID-19 have emerged, resulting in continued restrictions. In particular, certain countries within our Asia Pacific region, including India and Japan, as well as Latin America have been significantly impacted. These restrictions continued to negatively impact our net sales in the first nine months of 2021. The timing and success of efforts to distribute and administer COVID-19 vaccines to these locations and to broad portions of the worldwide population, enabling widespread immunity to COVID-19, will continue to have an impact on the duration and extent of the pandemic and its effect on demand for our products.

Because the severity, magnitude, and duration of the COVID-19 pandemic and its economic consequences continue to be uncertain, the pandemic’s impact on our operations and financial performance, as well as its impact on our ability to execute our business strategies and initiatives successfully, remains uncertain and difficult to predict. Procedural delays from the further resurgence of COVID-19 infections and the emergence of new, more contagious variant strains of COVID-19, as well as ~~labor~~staffing shortages within healthcare facilities, have and may continue to negatively impact demand for our products, net sales, gross profit margin and operating expenses as a percentage of net sales. ~~In addition,~~

While we expect the COVID-19 pandemic and related impacts will continue to negatively impact our performance to an extent, we continue to believe our long-term fundamentals remain strong and we intend to manage through these challenges with strategic focus and the winning spirit of our global team.

Economic Trends

Economic conditions created in part by the COVID-19 pandemic, ~~the economic recovery that has followed in many areas~~have had, and ~~other macroeconomic factors~~are expected to continue to have, ~~led to~~ a ~~challenging labor market in which we compete, which affects~~negative impact on our ~~ability to retain and attract new talent as well as put inflationary pressure on certain operational costs due to wage increases. Further, we~~business. We face and ~~may~~expect to continue to face, increases in the cost and limited availability of raw materials, components, and other inputs necessary to manufacture and distribute our products due to constraints and inflation within the global supply chain, as well as increases in the cost and time to distribute our products.

~~We continue~~ Further, other macroeconomic factors have led to ~~focus~~a challenging labor market in which we compete, which impacts in some cases, our ~~efforts~~ability to retain and attract new talent as well as put inflationary pressure on certain operational costs due to wage increases. Uncertainty around inflationary pressures, rising interest rates and monetary policy, could potentially cause new, or exacerbate existing, economic challenges that we may face. These conditions could worsen, or others could arise, if the ~~health~~U.S. and ~~safety of patients, healthcare providers and employees, while executing our mission of transforming lives through innovative medical solutions~~global economies were to improve the health of patients around the world. Since the onset of the COVID-19 pandemic, our global crisis management team has focused on protecting our employees and customers, optimizing our operations and securing our supply chain. We have successfully implemented business continuity plans including establishing a medical advisory group for employees, leveraging work from home infrastructureenter recessionary periods, triggered or exacerbated by monetary policy designed to facilitate social distancing and accelerating capabilities to provide remote physician support. In certain locations where the COVID-19 transmission rates are low or moderate, as defined by public health experts, employees are returning to the office. We will continue to be guided by our values and mission and monitor our return-to-office strategy based on science and data for the

~~Table of Contents~~

~~health and safety of our employees. While we expect the COVID-19 pandemic will continue to negatively impact our 2021 performance to an extent,we continue to believe our long-term fundamentals remain strong and we will manage through these challenges with strategic focus and the winning spirit of our global team.~~curb inflation.

Corporate Sustainability

Our sustainable ~~economic,~~ environmental, social and ~~social~~governance practices underpin all aspects of our global business. Our approach is aligned with the United Nations Sustainable Development Goals and our material topics and practices are informed by a broad range of internal and external stakeholders – locally, nationally and globally. Our employees around the world work with suppliers and other organizations that share our commitment to these practices that help address issues related to health inequity, economic disparity, climate change and environmental protection. These efforts are supported by our cross-functional Corporate Social Responsibility Steering Committee, our Corporate Social Responsibility Council, our Environmental Health and Safety teams and policies, our Global Council for Inclusion, as well as our local, regional and national employee and community engagement programs. ~~Key examples~~In addition, our 2021 annual bonus plan included performance measured against environmental targets, employee engagement goals and human capital metrics targets, including global gender and U.S. (inclusive of ~~our programs include setting measurable, transparent diversity, equity and inclusion (DE&I)~~Puerto Rico) multicultural goals. Our “3UP by 2023” initiative furthers our focus on increasing the representation of women and multicultural talent at the supervisor and manager level by three percentage points or more by December 31, 2022. Our DE&I progress has been recognized in 2021 whenIn 2022 we were ~~ranked in~~named to the ~~Top 10~~Forbes 2022 list of America's Best Employers for Diversity, as well as ranked number one among Health Care Equipment companies on renewable energy use by ~~Forbes, named~~JUST Capital. We were also ranked on the ~~JUST Capital Top 100~~ list of ~~Companies Supporting Healthy Families~~100 best Corporate Citizens of 2022 by 3BL Media. For additional information on our sustainability efforts, as well as our Diversity, Equity and ~~Communities and recognized as a "Best Place~~Inclusion (DE&I) initiatives, refer to ~~Work~~our most recent Annual Report on Form 10-K. For additional information on our annual bonus plan, refer to our Proxy Statement for Disability Inclusion", achieving top marks on Disability:IN’s 2021 Disability Equality Index (DEI). We are also proactively addressing ways to minimize energy consumption, carbon emissions, waste management and water use. We are focused on a “C3” strategy: Cutting energy use, Converting to renewable energy sources and Compensating with carbon offset projects where needed. We are on track to carbon neutrality in our manufacturing and key distribution sites by 2030, and expect to fully source or generate our electricity from renewable sources by 2024.the 2022 Annual Meeting of Shareholders.

Table of Contents

Financial Summary

Three Months Ended ~~September~~June 30, ~~2021~~2022

Our net sales for the ~~third~~second quarter of ~~2021~~2022 were ~~$2.932~~$3.244 billion, as compared to ~~$2.659~~$3.077 billion for the ~~third~~second quarter of ~~2020.~~2021. This increase of ~~$274~~$167 million, or ~~10.3~~5.4 percent, included operational1 net sales growth of ~~9.7~~9.6 percent and the ~~positive~~negative impact of 60420 basis points from foreign currency ~~fluctuations, and includes net sales from our recent acquisitions following the respective dates of acquisition.~~1fluctuations. The increase in our net sales was primarily driven by recent acquisitions as well as the ~~recovery~~strength and diversity of ~~elective~~our product portfolio coupled with growth in the underlying markets in which we compete and ~~semi-emergent procedure volumes compared to the prior year when the COVID-19 pandemic had significant impact on our net sales.~~strong commercial execution. Refer to Quarterly Results and Business Overview for a discussion of our net sales by global business.

Our reported net income available to common stockholders for the ~~third~~second quarter of ~~2021~~2022 was ~~$405~~$246 million, or ~~$0.28~~$0.17 per diluted share. Our reported results for the ~~third~~second quarter of ~~2021~~2022 included certain charges and/or credits totaling ~~$176~~$389 million (after-tax), or ~~$0.12~~$0.27 per diluted share. Excluding these items, adjusted net income available to common stockholders ~~for the third quarter of 2021~~1 was ~~$581~~$635 million, or ~~$0.41~~$0.44 per diluted share.~~1, 2~~

Our reported net ~~loss~~income available to common stockholders for the ~~third~~second quarter of ~~2020~~2021 was ~~$169~~$172 million, or ~~$(0.12)~~$0.12 per diluted share. Our reported results for the ~~third~~second quarter of ~~2020~~2021 included certain charges and/or credits totaling ~~$698~~$405 million (after-tax), or ~~$0.48~~$0.28 per diluted share. Excluding these items, adjusted net income available to common stockholders ~~for the third quarter of 2020~~1 was ~~$530~~$577 million, or ~~$0.37~~$0.40 per diluted share.

1Operational net sales growth rates, which exclude the impact of foreign currency fluctuations, and other adjusted measures, which exclude certain items required by generally accepted accounting principles in the United States (U.S. GAAP) are not prepared in accordance with U.S. GAAP and should not be considered in isolation from, or as a replacement for, the most directly comparable GAAP measure. Refer to Additional Information for a discussion of management’s use of these non-GAAP financial measures.

2In May 2020, we completed an offering of 10,062,500 shares of 5.50% Mandatory Convertible Preferred Stock, Series A (MCPS) at a price to the public and liquidation preference of $100 per share. Refer to the reconciliations below for the impact of the MCPS cumulative preferred stock dividends on our calculations of earnings per share (EPS).

4037

Table of Contents

The following is a reconciliation of our results of operations prepared in accordance with U.S. GAAP to those adjusted results considered by management. Refer to Quarterly Results and Business Overview and Additional Information for a discussion of these reconciling items:


		Three Months Ended September 30, 2021												Three Months Ended June 30, 2022
(in millions, except per share data)	(in millions, except per share data)	Income (Loss) Before Income Taxes		Income Tax Expense (Benefit)		Net Income (Loss)		Preferred Stock Dividends		Net Income (Loss) Available to Common Stockholders		Impact per Share(3)			(in millions, except per share data)	Income (Loss) Before Income Taxes		Income Tax Expense (Benefit)		Net Income (Loss)		Preferred Stock Dividends		Net Income (Loss) Available to Common Stockholders		Impact per Share(2)
Reported	Reported	$	483	$	64	$	419	$	(14)	$	405	$	0.28		Reported	$	345	$	85	$	260	$	(14)	$	246	$	0.17
Non-GAAP adjustments:	Non-GAAP adjustments:														Non-GAAP adjustments:
Amortization expense	Amortization expense	184		16		168		—		168		0.12			Amortization expense	204		29		175		—		175		0.12
Intangible asset impairment charges		128		19		109		—		109		0.08
Goodwill and other intangible asset impairment charges															Goodwill and other intangible asset impairment charges	7		—		7		—		7		0.00
Acquisition/divestiture-related net charges (credits)	Acquisition/divestiture-related net charges (credits)	(232)		(2)		(230)		—		(230)		(0.16)			Acquisition/divestiture-related net charges (credits)	91		(5)		95		—		95		0.07
Restructuring and restructuring-related net charges (credits)	Restructuring and restructuring-related net charges (credits)	44		5		39		—		39		0.03			Restructuring and restructuring-related net charges (credits)	35		5		30		—		30		0.02
Litigation-related net charges (credits)	Litigation-related net charges (credits)	—		—		—		—		—		(0.00)			Litigation-related net charges (credits)	42		10		33		—		33		0.02
Investment portfolio net losses (gains)	Investment portfolio net losses (gains)	26		8		19		—		19		0.01			Investment portfolio net losses (gains)	4		2		2		—		2		0.00
European Union (EU) Medical device regulation (MDR) implementation costs	European Union (EU) Medical device regulation (MDR) implementation costs	13		1		12		—		12		0.01			European Union (EU) Medical device regulation (MDR) implementation costs	17		2		14		—		14		0.01

Debt extinguishment charges															Debt extinguishment charges	0		0		0		—		0		0.00
Deferred tax expenses (benefits)	Deferred tax expenses (benefits)	—		(43)		43		—		43		0.03			Deferred tax expenses (benefits)	—		(34)		34		—		34		0.02
Discrete tax items	Discrete tax items	—		(17)		17		—		17		0.01			Discrete tax items	—		1		(1)		—		(1)		(0.00)
Adjusted	Adjusted	$	646	$	51	$	595	$	(14)	$	581	$	0.41		Adjusted	$	744	$	95	$	649	$	(14)	$	635	$	0.44

~~(3)~~


	Three Months Ended June 30, 2021
(in millions, except per share data)	Income (Loss) Before Income Taxes		Income Tax Expense (Benefit)		Net Income (Loss)		Preferred Stock Dividends		Net Income (Loss) Available to Common Stockholders		Impact per Share(2)
Reported	$	149	$	(37)	$	186	$	(14)	$	172	$	0.12
Non-GAAP adjustments:
Amortization expense	180		19		161		—		161		0.11
Goodwill and other intangible asset impairment charges	45		6		39		—		39		0.03
Acquisition/divestiture-related net charges (credits)	(64)		1		(65)		—		(65)		(0.05)
Restructuring and restructuring-related net charges (credits)	39		4		35		—		35		0.02
Litigation-related net charges (credits)	298		69		229		—		229		0.16
Investment portfolio net losses (gains)	6		1		5		—		5		0.00
European Union (EU) Medical device regulation (MDR) implementation costs	12		1		11		—		11		0.01
Deferred tax expenses (benefits)	—		(25)		25		—		25		0.02
Discrete tax items	—		35		(35)		—		(35)		(0.02)
Adjusted	$	665	$	74	$	591	$	(14)	$	577	$	0.40

(2) For the ~~third~~second quarter and first six months of 2022 and 2021, the effect of assuming the conversion of MCPS into shares of common stock was anti-dilutive, and therefore excluded from the calculation of EPS. Accordingly, GAAP Net incomeand Adjusted net income were reduced by cumulative Preferred stock dividends, as presented in our unaudited consolidated statements of operations, for purposes of calculating GAAP Net income available to common stockholders.

Three Months Ended September 30, 2020
(in millions, except per share data) Income (Loss) Before Income Taxes Income Tax Expense (Benefit) Net Income (Loss) Preferred Stock Dividends Net Income (Loss) Available to Common Stockholders
Impact per Share(4)
Reported $ (227) $ (72) $ (155) $ (14) $ (169) $ (0.12)
Non-GAAP adjustments:
Amortization expense 197 21 176 — 176 0.12
Intangible asset impairment charges 219 30 189 — 189 0.13
Acquisition/divestiture-related net charges (credits) 111 24 87 — 87 0.06
Restructuring and restructuring-related net charges (credits) 23 3 21 — 21 0.01
Litigation-related net charges (credits) 260 5 255 — 255 0.18
Investment portfolio net losses (gains) (65) (15) (50) — (50) (0.03)
European Union (EU) Medical device regulation (MDR) implementation costs 8 1 7 — 7 0.00
Deferred tax expenses (benefits) — (18) 18 — 18 0.01
Discrete tax items — 3 (3) — (3) (0.00)
Adjusted $ 525 $ (18) $ 543 $ (14) $ 530 $ 0.37

~~(4) For the third quarter of 2020, the effect of assuming the conversion of MCPS into shares of common stock was anti-dilutive, and therefore excluded from the calculation of EPS. Accordingly, GAAP~~ ~~Net loss~~ ~~and Adjusted net loss were reduced by cumulative~~ ~~Preferred stock dividends~~, as presented in our unaudited consolidated statements of operations, for purposes of calculating EPS. We have assumed dilution of 13.6 million common stock equivalents related to employee stock options for all or a portion of the non-GAAP adjustments, which were anti-dilutive for GAAP purposes due to our ~~Net loss~~ ~~position.~~

4138

Table of Contents

~~Nine~~Six Months Ended ~~September~~June 30, ~~2021~~2022

Our net sales for the first ~~nine~~six months of ~~2021~~2022 were ~~$8.761~~$6.270 billion, as compared to ~~$7.204~~$5.829 billion for the first ~~nine~~six months of ~~2020.~~2021. This increase of ~~$1.557 billion,~~$441 million, or ~~21.6~~7.6 percent, included operational1 net sales growth of ~~19.3~~11.1 percent and the ~~positive~~negative impact of ~~230~~350 basis points from foreign currency ~~fluctuations, and includes net sales from our recent acquisitions following the date of acquisition.~~fluctuations. The increase in our net sales was primarily driven by recent acquisitions as well as the ~~recovery~~strength and diversity of ~~elective~~our product portfolio coupled with growth in the underlying markets in which we compete and ~~semi-emergent procedure volumes compared to the prior year when the COVID-19 pandemic had significant impact on our net sales.~~strong commercial execution. Refer to Quarterly Results and Business Overview for a discussion of our net sales by global business.

Our reported net income available to common stockholders for the first ~~nine~~six months of ~~2021~~2022 was ~~$905~~$342 million, or ~~$0.63~~$0.24 per diluted share. Our reported results for the first ~~nine~~six months of ~~2021~~2022 included certain charges and/or credits totaling ~~$778~~$854 million (after-tax), or ~~$0.54~~$0.59 per diluted share. Excluding these items, adjusted net income available to common stockholders1 for the first ~~nine~~six months of ~~2021~~2022 was ~~$1.683~~$1.197 billion, or ~~$1.17~~$0.83 per diluted share.

Our reported net ~~loss~~income available to common stockholders for the first ~~nine~~six months of ~~2020~~2021 was ~~$311~~$500 million, or ~~$(0.22)~~$0.35 per diluted share. Our reported results for the first ~~nine~~six months of ~~2020~~2021 included certain charges and/or credits totaling ~~$1.351 billion~~$602 million (after-tax), or ~~$0.95~~$0.42 per diluted share. Excluding these items, adjusted net income available to common stockholders1 for the first ~~nine~~six months of ~~2020~~2021 was ~~$1.040~~$1.102 billion, or ~~$0.73~~$0.77 per diluted share.

Table of Contents

Nine Months Ended September 30, 2021
(in millions, except per share data) Income (Loss) Before Income Taxes Income Tax Expense (Benefit) Net Income (Loss) Preferred Stock Dividends Net Income (Loss) Available to Common Stockholders
Impact per Share(5)
Reported $ 957 $ 10 $ 946 $ (42) $ 905 $ 0.63
Non-GAAP adjustments:
Amortization expense 549 53 496 — 496 0.35
Intangible asset impairment charges 173 25 148 — 148 0.10
Acquisition/divestiture-related net charges (credits) (444) 5 (449) — (449) (0.31)
Restructuring and restructuring-related net charges (credits) 133 15 118 — 118 0.08
Litigation-related net charges (credits) 302 69 233 — 233 0.16
Investment portfolio net losses (gains) 178 43 136 — 136 0.09
European Union (EU) Medical device regulation (MDR) implementation costs 35 3 32 — 32 0.02
Deferred tax expenses (benefits) — (86) 86 — 86 0.06
Discrete tax items — 21 (21) — (21) (0.01)
Adjusted $ 1,883 $ 158 $ 1,725 $ (42) $ 1,683 $ 1.17


	Six Months Ended June 30, 2022
(in millions, except per share data)	Income (Loss) Before Income Taxes		Income Tax Expense (Benefit)		Net Income (Loss)		Preferred Stock Dividends		Net Income (Loss) Available to Common Stockholders		Impact per Share(2)
Reported	$	501	$	131	$	370	$	(28)	$	342	$	0.24
Non-GAAP adjustments:
Amortization expense	402		56		345		—		345		0.24
Intangible asset impairment charges	7		—		7		—		7		0.00
Acquisition/divestiture-related net charges (credits)	163		(5)		167		—		167		0.12
Restructuring and restructuring-related net charges (credits)	64		9		55		—		55		0.04
Litigation-related net charges (credits)	42		10		33		—		33		0.02
Investment portfolio net losses (gains)	11		4		7		—		7		0.00
European Union (EU) Medical device regulation (MDR) implementation costs	33		5		28		—		28		0.02
Debt extinguishment charges	194		45		149		—		149		0.10
Deferred tax expenses (benefits)	—		(63)		63		—		63		0.04
Discrete tax items	—		—		—		—		—		0.00
Adjusted	$	1,416	$	191	$	1,224	$	(28)	$	1,197	$	0.83

(5) For the first nine months of 2021, the effect of assuming the conversion of MCPS into shares of common stock was anti-dilutive, and therefore excluded from the calculation of EPS. Accordingly, GAAP


	Six Months Ended June 30, 2021
(in millions, except per share data)	Income (Loss) Before Income Taxes		Income Tax Expense (Benefit)		Net Income (Loss)		Preferred Stock Dividends		Net Income (Loss) Available to Common Stockholders		Impact per Share(2)
Reported	$	474	$	(53)	$	527	$	(28)	$	500	$	0.35
Non-GAAP adjustments:
Amortization expense	365		37		328		—		328		0.23
Goodwill and other intangible asset impairment charges	45		6		39		—		39		0.03
Acquisition/divestiture-related net charges (credits)	(212)		7		(219)		—		(219)		(0.15)
Restructuring and restructuring-related net charges (credits)	88		10		79		—		79		0.05
Litigation-related net charges (credits)	302		69		233		—		233		0.16
Investment portfolio net losses (gains)	152		35		117		—		117		0.08
European Union (EU) Medical device regulation (MDR) implementation costs	23		2		20		—		20		0.01
Deferred tax expenses (benefits)	—		(43)		43		—		43		0.03
Discrete tax items	—		38		(38)		—		(38)		(0.03)
Adjusted	$	1,237	$	108	$	1,129	$	(28)	$	1,102	$	0.77

~~Net loss~~

~~and Adjusted net income were reduced by cumulative~~ ~~Preferred stock dividends, as presented in our unaudited consolidated statements of operations, for purposes of calculating GAAP~~ ~~Net income available to common stockholders~~.

~~Table of Contents~~

Nine Months Ended September 30, 2020
(in millions, except per share data) Income (Loss) Before Income Taxes Income Tax Expense (Benefit) Net Income (Loss) Preferred Stock Dividends Net Income (Loss) Available to Common Stockholders
Impact per Share(6)
Reported $ (386) $ (94) $ (292) $ (19) $ (311) $ (0.22)
Non-GAAP adjustments:
Amortization expense 595 62 533 — 533 0.38
Intangible asset impairment charges 452 68 384 — 384 0.27
Acquisition/divestiture-related net charges (credits) 148 48 100 — 100 0.07
Restructuring and restructuring-related net charges (credits) 77 10 66 — 66 0.05
Litigation-related net charges (credits) 260 5 255 — 255 0.18
Investment portfolio net losses (gains) (65) (15) (50) — (50) (0.04)
European Union (EU) Medical device regulation (MDR) implementation costs 20 2 17 — 17 0.01
Deferred tax expenses (benefits) — (26) 26 — 26 0.02
Discrete tax items — (20) 20 — 20 0.01
Adjusted $ 1,100 $ 41 $ 1,059 $ (19) $ 1,040 $ 0.73

(6) For the first nine months of 2020, the effect of assuming the conversion of MCPS into shares of common stock was anti-dilutive, and therefore excluded from the calculation of EPS. Accordingly, GAAP ~~Net loss~~ ~~and Adjusted net income were reduced by cumulative~~ ~~Preferred stock dividends~~, as presented in our unaudited consolidated statements of operations, for purposes of calculating EPS. We have assumed dilution of 14.1 million common stock equivalents related to employee stock options for all or a portion of the non-GAAP adjustments, which were anti-dilutive for GAAP purposes due to our ~~Net loss~~ ~~position.~~

~~Cash provided by operating activities was $1,392 million for the first nine months of~~ ~~2021. As of September 30, 2021, we had total debt outstanding of $9.085 billion net of unamortized debt issuance discounts and deferred financing costs,~~ ~~Cash and cash equivalents~~ ~~of $1.947 billion and working capital of $2.207 billion. Refer to~~ ~~Liquidity and Capital Resources~~ ~~for further discussion.~~

4340

Table of Contents

Quarterly Results and Business Overview

In the first quarter of 2022, we reorganized our operational structure and have aggregated our core businesses, each of which generate revenues from the sale of medical devices (Medical Devices), into two reportable segments: MedSurg and Cardiovascular. Within the Cardiovascular segment, the newly formed Cardiology division represents the combined former Rhythm Management and Interventional Cardiology divisions. We have revised prior periods to conform to the current year presentation. The following section describes our net sales and results of operations by reportable segment and business unit. For additional information on our businesses and product offerings, ~~see~~refer to Item 1. Business of our most recent Annual Report on Form 10-K.


		Three Months Ended September 30,									Three Months Ended June 30,
(in millions)	(in millions)	2021		2020		Change	(in millions)	2022	2021				Increase/(Decrease)
Endoscopy	Endoscopy	$	533	$	475	12.1%				Endoscopy	$	560		$	551	1.6%
Urology and Pelvic Health	Urology and Pelvic Health	384		350		9.9%				Urology and Pelvic Health	450			397		13.4%
Neuromodulation										Neuromodulation	239			247		(3.4)%
MedSurg	MedSurg	917		825		11.2%				MedSurg	1,248			1,195		4.5%
Cardiac Rhythm Management		512		465		10.1%
Electrophysiology		86		76		13.6%
Neuromodulation		221		216		2.4%
Rhythm and Neuro		819		757		8.2%
Interventional Cardiology		744		586		26.9%

Cardiology										Cardiology	1,517			1,410		7.6%
Peripheral Interventions	Peripheral Interventions	452		416		8.8%				Peripheral Interventions	478			473		1.2%
Cardiovascular	Cardiovascular	1,196		1,002		19.4%				Cardiovascular	1,996			1,883		6.0%
Medical Devices	Medical Devices	2,932		2,584		13.5%				Medical Devices	3,244			3,077		5.4%
Specialty Pharmaceuticals(7)		—		74		(100.0)%

Net Sales	Net Sales	$	2,932	$	2,659	10.3%				Net Sales	$	3,244		$	3,077	5.4%

											Six Months Ended June 30,
(in millions)										(in millions)	2022			2021		Increase/(Decrease)
Endoscopy										Endoscopy	$	1,091		$	1,050	3.9%
Urology and Pelvic Health										Urology and Pelvic Health	863			758		13.9%
Neuromodulation										Neuromodulation	448			444		0.7%
MedSurg										MedSurg	2,402			2,252		6.6%

Cardiology										Cardiology	2,925			2,658		10.0%
Peripheral Interventions										Peripheral Interventions	944			906		4.2%
Cardiovascular										Cardiovascular	3,868			3,564		8.6%
Medical Devices										Medical Devices	6,270			5,816		7.8%
Specialty Pharmaceuticals(3)										Specialty Pharmaceuticals(3)	—			13		(100.0)%
Net Sales										Net Sales	$	6,270		$	5,829	7.6%

(3)

Nine Months Ended September 30,
(in millions) 2021 2020 Change
Endoscopy $ 1,583 $ 1,265 25.1%
Urology and Pelvic Health 1,142 910 25.5%
MedSurg 2,725 2,175 25.3%
Cardiac Rhythm Management 1,505 1,253 20.1%
Electrophysiology 265 202 31.4%
Neuromodulation 666 529 25.7%
Rhythm and Neuro 2,436 1,985 22.7%
Interventional Cardiology 2,230 1,714 30.1%
Peripheral Interventions 1,358 1,148 18.3%
Cardiovascular 3,588 2,862 25.4%
Medical Devices 8,748 7,021 24.6%
Specialty Pharmaceuticals(7)
13 183 (92.7)%
Net Sales $ 8,761 $ 7,204 21.6%

~~(7)~~ On March 1, 2021, we completed the divestiture of the Specialty Pharmaceuticals business. Our consolidated net sales include Specialty Pharmaceuticals up to the date of the closing of the transaction.

4441

Table of Contents

MedSurg

Endoscopy

Our Endoscopy business develops and manufactures devices to diagnose and treat a broad range of gastrointestinal (GI) and pulmonary conditions with innovative, less-invasive technologies. Our net sales of Endoscopy products were ~~$533~~$560 million for the ~~third~~second quarter ~~of 2021~~ and ~~$1.583~~$1.091 billion for the first ~~nine~~six months of ~~2021~~2022, and represented 1817 percent of our consolidated net sales in both ~~the third quarter and first nine months of 2021.~~periods. Our Endoscopy net sales increased ~~$57~~$9 million, or ~~12.1~~1.6 percent, in the ~~third~~second quarter ~~of 2021~~ and increased ~~$318~~$41 million, or ~~25.1~~3.9 percent, in the first ~~nine~~six months of ~~2021,~~2022, compared to the prior year periods. In the ~~third~~second quarter of ~~2021,~~2022, this increase included operational net sales growth of ~~11.4~~5.8 percent and a ~~positive~~negative impact of 60430 basis points from foreign currency fluctuations, compared to the prior year period. In the first ~~nine~~six months of ~~2021,~~2022, this increase included operational net sales growth of ~~22.6~~7.3 percent and a ~~positive~~negative impact of ~~250~~340 basis points from foreign currency fluctuations, compared to the prior year period.

~~Operational net sales~~ This growth ~~in the third quarter and first nine months of 2021~~ was primarily driven by our ~~biliary,~~ single-use imaging franchise led by our EXALTTM D Single-use Duodenoscope and our biliary franchise led by our AXIOSTM Stent and Delivery System, as well as our hemostasis and infection prevention franchises due to the recovery of elective and semi-emergent procedure volumes compared to the prior year, particularly in the first half, when the COVID-19 pandemic had a significant negative impact on our net sales.franchises.

Urology and Pelvic Health

Our Urology and Pelvic Health business develops and manufactures devices to treat various urological and pelvic conditions for both male and female anatomies. Our net sales of Urology and Pelvic Health products were ~~$384~~$450 million for the ~~third~~second quarter ~~of 2021~~ and ~~$1.142 billion~~$863 million for the first ~~nine~~six months of ~~2021,~~2022, representing 1314 percent of our consolidated net sales in both ~~the third quarter and first nine months of 2021.~~periods. Our Urology and Pelvic Health net sales increased ~~$35~~$53 million, or ~~9.9~~13.4 percent, in the ~~third~~second quarter ~~of 2021~~ and increased ~~$232~~$105 million, or ~~25.5~~13.9 percent, in the first ~~nine~~six months of ~~2021,~~2022, compared to the prior year periods. In the ~~third~~second quarter of ~~2021,~~2022, this increase included operational net sales growth of ~~9.4~~16.2 percent and a ~~positive~~negative impact of 50280 basis points from foreign currency fluctuations, compared to the prior year period. In the first ~~nine~~six months of ~~2021,~~2022, this increase included operational net sales growth of ~~23.7~~16.1 percent and a ~~positive~~negative impact of ~~180~~220 basis points from foreign currency fluctuations, compared to the prior year period.

Operational net sales growth included organic net sales growth of ~~6.6~~7.0 percent in the second quarter of 2022 and 7.0 percent in the first six months of 2022, and the positive impact of 920 basis points in both periods, from our acquisition of the surgical business of Lumenis, LTD. (Lumenis) in the third quarter of 2021 and 23.6 percent in the first nine months of 2021, and the positive impact of 280 basis points in the third quarter of 2021 and 20 basis points in the first nine months of 2021 due to our Lumenis, LTD. (Lumenis) acquisition and the divestiture of the Intrauterine Health business in the second quarter of 2020. In the third quarter of 2021, we completed the acquisition of the global surgical business of Lumenis, a privately held company that develops and commercializes energy-based medical solutions, including innovative laser systems, fibers and accessories used for urology and otolaryngology procedures.2021. Organic net sales growth was driven by strong performance across our ~~stone management~~key products, including our LithoVue™ Single-Use Digital Flexible Ureteroscopes and prostate health franchises and, during the first nine months of 2021, our prosthetic urology franchise due to the recovery of elective and semi-emergent procedure volumes compared to the prior year when the COVID-19 pandemic had a significant negative impact on our net sales.

~~Rhythm and Neuro~~

~~Cardiac Rhythm Management~~

Our Cardiac Rhythm Management (CRM) business develops and manufactures a variety of implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities. Our net sales of CRM products were $512 million for the third quarter of 2021 and $1.505 billion for the first nine months of 2021, representing 17 percent of our consolidated net sales in both the third quarter and first nine months of 2021. Our CRM net sales increased $47 million, or 10.1 percent, in the third quarter of 2021 and increased $252 million, or 20.1 percent, in the first nine months of 2021, compared to the prior year periods. In the third quarter of 2021, this increase included operational net sales growth of 9.6 percent and a positive impact of 50 basis points from foreign currency fluctuations, compared to the prior year period. In the first nine months of 2021, this increase included operational net sales growth of 17.7 percent and a positive impact of 240 basis points from foreign currency fluctuations, compared to the prior year period.

Operational net sales growth included organic net sales declines of (0.3) percent in the third quarter of 2021 and growth of 8.8 percent for the first nine months of 2021, and the positive impact of 990 basis points in the third quarter of 2021 and 890 basis points for the first nine months of 2021 from the acquisition of Preventice Solutions, adding to our CRM business a full

~~Table of Contents~~

portfolio of mobile cardiac health solutions and services, ranging from ambulatory cardiac monitors, to cardiac event monitors and mobile cardiac telemetry. During the third quarter of 2021, organic sales performance was driven by a decline in net sales from our defibrillator franchise partially offset by growth in our pacemaker franchise and cardiac diagnostics franchise, led by our LUX-Dx™ Insertable Cardiac Monitor (ICM) system. For the first nine months of 2021, organic net sales growth was attributable to our defibrillator and pacemaker franchises, due to the recovery of semi-emergent and emergent procedure volumes compared to the prior year, particularly in the first half, when the COVID-19 pandemic had a significant negative impact on our net sales,SpaceOAR™ Hydrogel Systems, as well as ~~our cardiac diagnostics franchise, led by our ICM system.~~

~~Electrophysiology~~

Our Electrophysiology business develops and manufactures less-invasive medical technologies used in the diagnosis and treatment of rate and rhythm disorders of the heart. Our net sales of Electrophysiology products were $86 million for the third quarter of 2021 and $265 million for the first nine months of 2021, representing three percent of our consolidated net sales in both the third quarter and first nine months of 2021. Our Electrophysiology net sales increased $10 million, or 13.6 percent, in the third quarter of 2021 and increased $63 million, or 31.4 percent, in the first nine months of 2021, compared to the prior year periods. In the third quarter of 2021, this increase included operational net sales growth of 13.2 percent and a positive impact of 40 basis points from foreign currency fluctuations, compared to the prior year period. In the first nine months of 2021, this increase included operational net sales growth of 27.8 percent and a positive impact of 350 basis points from foreign currency fluctuations, compared to the prior year period.

Operational net sales growth was driven primarily by the recovery of elective procedure volumes compared to the prior year, particularly in the first half, when the COVID-19 pandemic had a significant negative impactcontinued focus on ~~our net sales, as well as the success of our ongoing POLARx™ Cryoablation System and Stablepoint Force-Sensing Catheter international launches.~~globalization.

Neuromodulation

Our Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Our net sales of Neuromodulation products were ~~$221~~$239 million for the ~~third~~second quarter ~~of 2021~~ and ~~$666~~$448 million for the first ~~nine~~six months of ~~2021,~~2022, representing ~~eight~~7 percent of our consolidated net sales in both ~~the third quarter and first nine months of 2021.~~periods. Our Neuromodulation net sales ~~increased $5~~decreased $8 million, or ~~2.4~~3.4 percent in the ~~third~~second quarter ~~of 2021~~ and increased ~~$136~~$3 million, or ~~25.7~~0.7 percent in the first ~~nine~~six months of ~~2021,~~2022, compared to the prior year periods. In the ~~third~~second quarter of ~~2021,~~2022, this ~~increase~~decrease included an operational net sales ~~growth~~decline of ~~2.1~~1.0 percent and a ~~positive~~negative impact of 30240 basis points from foreign currency fluctuations, compared to the prior year period. In the first ~~nine~~six months of ~~2021,~~2022, this increase included operational net sales growth of ~~24.1~~2.8 percent and a ~~positive~~negative impact of ~~160~~210 basis points from foreign currency fluctuations, compared to the prior year period.

Operational net sales declines for the second quarter of 2022 were primarily due to very strong procedural volumes in the second quarter of 2021 associated with sharp recovery from the COVID-19 pandemic as well as the U.S. launch of our WaveWriter Alpha™ SCS and Vercise Genus™ DBS systems. Operational net sales growth for the first six months of 2022 was primarily driven by the first quarter performance of our spinal cord stimulation (SCS) ~~systems, led by our next generation WaveWriter Alpha™ SCS System. During the first nine months~~systems.

Table of 2021, growth was driven by sales of both our SCS systems and our deep brain stimulation (DBS) systems, including our Vercise Genus™ DBS System, due to the recovery of elective procedure volumes in the first half of 2021 compared to the prior year when the COVID-19 pandemic had a more significant negative impact on our net sales. During the third quarter of 2021, procedure volumes continued to be negatively impacted by the COVID-19 pandemic due to their elective nature.Contents

Cardiovascular

~~Interventional~~ Cardiology

Our ~~Interventional~~ Cardiology business develops and manufactures devices and medical technologies for diagnosing and treating ~~coronary artery disease~~a variety of diseases and ~~structural heart conditions.~~abnormalities of the heart. Our net sales of ~~Interventional~~ Cardiology products were ~~$744 million~~$1.517 billion for the ~~third~~second quarter ~~of 2021~~ and ~~$2.230~~$2.925 billion for the first ~~nine~~six months of ~~2021,~~2022, representing 2547 percent of our consolidated net sales in both ~~the third quarter and first nine months of 2021.~~periods. Our ~~Interventional~~ Cardiology net sales increased ~~$158~~$108 million, or ~~26.9~~7.6 percent, in the ~~third~~second quarter ~~of 2021~~ and ~~increased $516~~$266 million, or ~~30.1~~10.0 percent in the first ~~nine~~six months of ~~2021,~~2022, compared to the prior year periods. In the ~~third~~second quarter of ~~2021,~~2022, this increase included operational net sales growth of ~~26.0~~12.5 percent and a ~~positive~~negative impact of 90480 basis points from foreign currency fluctuations, compared to the prior year period. In the first ~~nine~~six months of ~~2021,~~2022, this increase included operational net sales growth of ~~27.4~~14.1 percent and a ~~positive~~negative impact of ~~270~~410 basis points from foreign currency fluctuations, compared to the prior year period. Operational net sales growth included organic net sales growth of 8.5 percent in the second quarter of 2022 and 9.7 percent for the first six months of 2022, and the positive impact of 400 and 440 basis points, respectively, from our acquisitions of Preventice Solutions, Inc. (Preventice), Farapulse, Inc. and Baylis Medical in the first and third quarter of 2021 and the first quarter of 2022, respectively.

~~In the third quarter and first nine months of 2021, operational~~Organic net sales growth was primarily driven by ~~our WATCHMAN FLX™~~continued market expansion of Left Atrial Appendage Closure (LAAC) procedures with our WATCHMAN™ FLX LAAC Device, as well as performance of our percutaneous coronary intervention guidance ~~(PCIG)~~and subcutaneous implantable cardiac defibrillator (S-ICD) franchises. Organic net sales growth was also driven by our diagnostics franchise, ~~and~~led by our ~~drug-eluting~~

~~Table of Contents~~

~~stent (DES) systems due to the recovery of procedure volumes compared to the prior year, particularly~~LUX-Dx™ Insertable Cardiac Monitor (ICM) system, as well as our wearable ambulatory electrocardiograph portfolio. In addition, sales growth in the first ~~half, when the COVID-19 pandemic had a significant negative impact on~~six months of 2022 was driven by our ~~net sales. In addition, growth was positively impacted~~structural heart valve franchise led by ~~reserves recorded in the third quarter of 2020 primarily related to~~ our conversion to a consignment inventory model for our LAAC franchise with the launch of our WATCHMAN FLX™ Device in the U.S. These increases were partially offset by the discontinuation of our LOTUS Edge™ACURATE neo2™ Aortic Valve System in the fourth quarter of 2020, general price declines associated with our DES systems and the unfavorable impact of China tender pricing on both DES systems and balloon catheter net sales following a reduction in prices in the first quarter of 2021.Systems.

Peripheral Interventions

Our Peripheral Interventions business develops and manufactures products to diagnose and treat peripheral arterial and venous diseases, as well as products to diagnose, treat and ease various forms of cancer. Our net sales of Peripheral Interventions products were ~~$452~~$478 million for the ~~third~~second quarter ~~of 2021~~ and ~~$1.358 billion~~$944 million for the first ~~nine~~six months of ~~2021,~~2022, representing 15 percent of our consolidated net sales in both ~~the third quarter and first nine months of 2021.~~periods. Our Peripheral Interventions net sales increased ~~$36~~$6 million, or ~~8.8~~1.2 percent, in the ~~third~~second quarter ~~of 2021~~ and increased ~~$210~~$38 million, or ~~18.3~~4.2 percent, in the first ~~nine~~six months of ~~2021,~~2022, compared to the prior year periods. In the ~~third~~second quarter of ~~2021,~~2022, this increase included operational net sales growth of ~~8.1~~5.7 percent and a ~~positive~~negative impact of 70450 basis points from foreign currency fluctuations, compared to the prior year period. In the first ~~nine~~six months of ~~2021,~~2022, this increase included operational net sales growth of ~~16.1~~7.8 percent and a ~~positive~~negative impact of ~~220~~360 basis points from foreign currency fluctuations, compared to the prior year period.

Operational net sales growth was primarily driven by ~~the Interventional Oncology~~our drug eluting franchise ~~including~~led by our RangerTM Drug-Coated Balloon and EluviaTM Drug-Eluting Stent System within our arterial portfolio as well as our interventional oncology franchise led by our TheraSphere™ Y-90 Radioactive Glass Microspheres, which received U.S. Food and Drug Administration approval in the first quarter of 2021 after 20 years as a humanitarian device exemption (HDE). In addition, growth was driven by our drug-eluting portfolio, including the Eluvia™ Drug-Eluting Stent and Ranger™ Drug-Coated Balloon due to the recovery of procedure volumes compared to the prior year, particularly in the first half, when the COVID-19 pandemic had a significant negative impact on our net sales, as well as continued worldwide commercial execution and adoption in recently approved countries. In the first quarter of 2021, we received approval from Japan’s Ministry of Health, Labor and Welfare (MHLW) for our Ranger Drug-Coated Balloon and initiated a full launch.Microspheres.

Specialty Pharmaceuticals

On March 1, 2021, we completed the divestiture of the Specialty Pharmaceuticals business for a purchase price of approximately $800 million. Our consolidated net sales include Specialty Pharmaceuticals up to the date of the closing of the transaction.

Emerging Markets

As part of our strategic imperative to drive global expansion, we are seeking to grow net sales and market share by expanding our global presence, including in Emerging Markets. We define Emerging Markets as the 20 countries that we believe have strong growth potential based on their economic conditions, healthcare sectors and our global capabilities. Periodically, we assess our list of Emerging Markets countries, ~~and effective January 1, 2021, modified our list to include~~which currently includes the following countries: Brazil, Chile, China, Colombia, Czech Republic, India, Indonesia, Malaysia, Mexico, Philippines, Poland, Russia, Saudi Arabia, Slovakia, South Africa, South Korea, Taiwan, Thailand, Turkey and Vietnam. ~~We have revised prior period amounts to conform to the current year's presentation which had an immaterial impact on previously reported Emerging Markets net sales.~~ Our Emerging Markets net sales represented 1213 percent of our consolidated net sales in ~~both~~ the ~~third~~second quarter and first ~~nine~~six months of ~~2021, 11 percent in the third quarter of 2020,~~2022, and 12 percent in the second quarter and first ~~nine~~six months of ~~2020.~~2021. In the ~~third~~second quarter of ~~2021,~~2022, our Emerging Markets net sales grew ~~21.9~~18.9 percent on a reported basis, which included operational net sales growth of ~~17.8~~26.0 percent and a ~~positive~~negative impact of ~~410~~710 basis points from foreign currency fluctuations, compared to the prior year period. In the first ~~nine~~six months of ~~2021,~~2022, our Emerging Markets net sales grew ~~23.8~~20.8 percent on a reported basis, which included operational net sales growth of ~~18.9~~27.3 percent and a ~~positive~~negative impact of ~~490~~650 basis points from foreign currency fluctuations, compared to the prior year period. The ~~growth~~increase in the ~~third~~second quarter ~~and first nine months~~ of ~~2021~~2022 compared to the prior year ~~periods~~period was driven primarily by ~~our net sales~~growth in ~~China, which have largely recovered from the impact of the COVID-19 pandemic~~India and Brazil as we continue to focus on ~~procedural volumes.~~

globalization

4743

Table of Contents

of our products. We experienced sequentially lower growth in China in the second quarter of 2022 due to decreased procedural volumes related to the recent increase of COVID-19 cases and associated public health measures implemented. The increase in the first six months of 2022 compared to the prior year period was driven primarily by growth in China, India and Brazil.

Gross Profit

Our Gross profit was ~~$2.032~~$2.233 billion for the ~~third~~second quarter of 2022, $2.132 billion for the second quarter of 2021, ~~$1.790~~$4.304 billion ~~for the third quarter of 2020, $6.022 billion for the~~ first ~~nine~~six months of ~~2021~~2022 and ~~$4.740~~$3.990 billion ~~for the~~ first ~~nine~~six months of ~~2020.~~2021. As a percentage of net sales, our Gross profit ~~increased~~decreased to 68.8 percent in the second quarter of 2022, as compared to 69.3 percent in the ~~third~~second quarter of 2021 ~~as compared~~and increased to ~~67.3 percent in the third quarter of 2020 and 68.7~~68.6 percent in the first ~~nine~~six months of ~~2021,~~2022, as compared to ~~65.8~~68.4 percent in the first ~~nine~~six months of ~~2020.~~2021. The following is a reconciliation of our gross profit margin and a description of the drivers of the changes from period to period:

Percentage of Net Sales
Three Months Nine Months
Gross profit margin - period ended September 30, 2020 67.3% 65.8%
Abnormal production variances 0.5 1.4
Sales pricing, volume and mix 0.4 1.3
Inventory charges 0.9 0.4
All other, including other expenses 0.2 (0.1)
Gross profit margin - period ended September 30, 2021 69.3% 68.7%


	Percentage of Net Sales
	Three Months	Six Months
Gross profit margin - period ended June 30, 2021	69.3%	68.4%


Sales pricing, volume and mix	(0.3)	0.1


Net impact of foreign currency fluctuations	1.1	1.0

All other, including other period expenses	(1.3)	(0.8)
Gross profit margin - period ended June 30, 2022	68.8%	68.6%

The primary factors contributing to the ~~increase~~decrease in our gross profit margin in the ~~third~~second quarter ~~and first nine months~~ of ~~2021,~~2022, as compared to the same ~~periods~~period in ~~2020, were higher sales volumes and favorable product mix associated with the resumption of procedures using higher-margin products, as well as~~ the prior year, ~~impact~~were the impacts of abnormal production variances attributable to manufacturing plant shut-downs and excess and obsolete inventory charges due to lower forecasted demand for certain of our products driven by the COVID-19 pandemic in the prior year. These improvements were partially offset by price declines related primarily to sales of our coronary drug-eluting stent systems and foreign currency fluctuations. In addition, inflation ~~has put pressure~~ on ~~our gross profit margin, particularly with increases in~~ costs of certain raw materials, direct labor and ~~freight.~~freight, as well as inefficiencies in our manufacturing plants due to constraints in material availability, which were partially offset by the favorable impact of foreign currency fluctuations and the realization of standard cost improvements. As expected, these macro-economic factors have negatively impacted our gross profit margin, and we expect continued negative impact throughout 2022 while these factors persist. Despite the challenging macro-economic environment, we experienced an overall increase in our gross profit margin in first six months of 2022, as compared to the same period in the prior year, due to increased sales of higher-margin products and the favorable impact of foreign currency fluctuations, which offset the macro-economic factors that became more pronounced in the second quarter of 2022.

Operating Expenses

The following table provides a summary of certain of our operating expenses:


		Three Months Ended September 30,								Nine Months Ended September 30,									Three Months Ended June 30,								Six Months Ended June 30,
		2021				2020				2021				2020					2022				2021				2022				2021
(in millions)	(in millions)	$		% of Net Sales		$		% of Net Sales		$		% of Net Sales		$		% of Net Sales		(in millions)	$		% of Net Sales		$		% of Net Sales		$		% of Net Sales		$		% of Net Sales
Selling, general and administrative (SG&A) expenses		$	1,066	36.4	%	$	984	37.0	%	$	3,206	36.6	%	$	2,760	38.3	%
Research and development (R&D) expenses		310		10.6	%	315		11.9	%	884		10.1	%	857		11.9	%
Selling, general and administrative expenses																		Selling, general and administrative expenses	$	1,165	35.9	%	$	1,121	36.4	%	$	2,225	35.5	%	$	2,139	36.7	%
Research and development expenses																		Research and development expenses	335		10.3	%	298		9.7	%	654		10.4	%	574		9.9	%
Royalty expense	Royalty expense	14		0.5	%	12		0.4	%	38		0.4	%	32		0.4	%	Royalty expense	11		0.3	%	12		0.4	%	23		0.4	%	24		0.4	%

Selling, general and administrative expenses (SG&A ~~Expenses~~Expenses)

In the ~~third~~second quarter of ~~2021, our~~2022, SG&A expenses increased ~~$83~~$45 million, or 84 percent, as compared to the ~~third quarter of 2020~~prior year period and were 6050 basis points lower as a percentage of net sales. In the first ~~nine~~six months of ~~2021, our~~2022, SG&A expenses increased ~~$445~~$86 million, or 164 percent, as compared to the ~~first nine months of 2020~~prior year period and were ~~170~~120 basis points lower as a percentage of net sales. The ~~increase~~increases in SG&A expenses ~~for the third quarter and first nine months of 2021, as compared to the same period in the prior year, was~~were primarily due to higher selling costs driven by higher global net ~~sales and the targeted lifting of spending controls implemented during the first nine months of 2020 in response to the escalating COVID-19 pandemic. In addition,~~ ~~SG&A expenses~~ ~~in the first nine months of 2021 were further impacted by higher restructuring-related spend and acquisition-related charges.~~sales.

Research and development expenses (R&D ~~Expenses~~Expenses)

We remain committed to advancing medical technologies and investing in meaningful R&D projects across our businesses. In the ~~third~~second quarter of ~~2021, our~~2022, R&D expenses ~~decreased $5~~increased $36 million, or 212 percent, as compared to the ~~third quarter of 2020~~prior year period and were ~~130~~60 basis points ~~lower~~higher as a percentage of net ~~sales due to higher one-time charges in the prior year.~~sales. In the first ~~nine~~six months of ~~2021,~~2022, our R&D expenses increased ~~$27~~$79 million, or ~~3 percent, as compared to the first nine months of 2020, and were~~

4844

Table of Contents

~~180~~14 percent, as compared to the prior year period, and were 60 basis points ~~lower~~higher as a percentage of net sales. R&D expenses increased in both the second quarter and first ~~nine~~six months of ~~2021, as compared to the same period in the prior year,~~2022 as a result of investments across our businesses in order to maintain a pipeline of new products that we believe will contribute to profitable sales growth.

~~Royalty Expense~~

~~In the third quarter of 2021, our~~ ~~Royalty expense~~ ~~increased $2 million, or 17 percent as compared to the third quarter of 2020 and remained relatively flat as a percentage of net sales. In the first nine months of 2021, our~~ ~~Royalty expense~~ increased $6 million, or 19 percent, as compared to the first nine months of 2020, and remained flat as a percentage of net sales, primarily due to global net sales growth in the third quarter and first nine months of 2021 as compared to the third quarter and first nine months of 2020.

Other Operating Expenses

The following table provides a summary of certain of our other operating expenses, which are excluded by management for purposes of evaluating operating ~~performance, refer~~performance. Refer to Additional Information for a further description of certain operating expenses:


		Three Months Ended September 30,				Nine Months Ended September 30,					Three Months Ended June 30,				Six Months Ended June 30,
(in millions)	(in millions)	2021		2020		2021		2020		(in millions)	2022		2021		2022		2021
Amortization expense	Amortization expense	$	184	$	197	$	549	$	595	Amortization expense	$	204	$	180	$	402	$	365
Intangible asset impairment charges	Intangible asset impairment charges	128		219		173		452		Intangible asset impairment charges	7		45		7		45
Contingent consideration net expense (benefit)	Contingent consideration net expense (benefit)	(26)		6		(117)		(102)		Contingent consideration net expense (benefit)	36		(85)		48		(91)
Restructuring charges (credits)	Restructuring charges (credits)	9		3		18		16		Restructuring charges (credits)	11		3		14		8
Litigation-related net charges (credits)	Litigation-related net charges (credits)	—		260		302		260		Litigation-related net charges (credits)	42		298		42		302
Gain on disposal of businesses and assets	Gain on disposal of businesses and assets	(40)		—		(48)		—		Gain on disposal of businesses and assets	—		(2)		—		(9)

Amortization Expense

In the ~~third~~second quarter of ~~2021, our~~2022, Amortization expense ~~decreased $13~~increased $24 million, or 713 percent, as compared to ~~third quarter of 2020.~~the prior year period. In the first ~~nine~~six months of ~~2021, our~~2022, Amortization expense ~~decreased $47~~increased $37 million, or 810 percent, as compared to first ~~nine~~six months of ~~2020.~~2021. The ~~decrease~~increase in Amortization expense in both the ~~third~~second quarter and first ~~nine~~six months of ~~2021, as compared to the same period in the prior year,~~2022 was driven ~~by the divestiture of the Specialty Pharmaceuticals business partially offset~~ by the addition of amortizable intangible assets associated with our recent acquisitions.

Intangible Asset Impairment Charges

We recorded Intangible asset impairment charges of ~~$128~~$7 million in the ~~third~~second quarter and first six months of ~~2021, $219~~2022, and $45 million in the ~~third~~second quarter ~~of 2020, $173 million in the~~and first ~~nine~~six months of ~~2021 and $452 million in the first nine months of 2020.~~2021. The impairment charges recorded in ~~the third quarter of~~ 2021 were primarily ~~associated with amortizable technology-related intangible assets that were initially established following our acquisition of VENITI, Inc.,~~attributable to incremental time and in the first nine months of 2021 also included the partial impairment of one of our acquired IPR&D assets. In the third quarter of 2020, impairment charges were primarily associated with IPR&D acquired with Apama Medical, Inc. and in the first nine months of 2020 also included charges primarily associated with amortizable technology-related intangible assets that were initially established following our acquisition of nVision Medical Corporation. Each of these charges were recorded as a result of management’s decision to change commercial launch plans or discontinue certain commercial or R&D programs based on cost to complete ~~or remediate, time to market, overall economic viability or, specific to nVision, our understanding of the clinical evidence necessary to commercialize the technology.~~an acquired in-process research and development (IPR&D) project. Refer to Note C – Goodwill and Other Intangible Assets to our unaudited consolidated financial statements contained in Item 1 of this Quarterly Report on Form 10-Q and Critical Accounting Estimates in Item 7 of our most recent Annual Report on Form 10-K for additional details and a discussion of key assumptions used in our goodwill and intangible asset impairment testing and future events that could have a negative impact on the recoverability of our goodwill and intangible assets.

~~Table of Contents~~

Contingent Consideration Net Expense (Benefit)

To recognize changes in the fair value of our contingent consideration liability, we recorded net ~~benefits~~charges of ~~$26~~$36 million and ~~$117~~$48 million in the ~~third~~second quarter and first ~~nine~~six months of 2022, respectively, and net benefits of $85 million and $91 million in the in the second quarter and first six months of 2021, ~~respectively, a~~respectively. The net ~~expense of $6 million in the third quarter of 2020 and a net benefit of $102 million~~charges recorded in the first ~~nine~~six months of ~~2020.~~2022 related to an increase in expected payments for achievement of commercialization-based milestones and revenue-based payments as a result of over-performance. In addition, we made payments of $314 million associated with prior acquisitions during the first six months of 2022, following the achievement of revenue and/or regulatory milestones. The net benefits recorded in the first ~~nine~~six months of 2021 ~~and 2020~~ related to a reduction in the contingent consideration liability for certain prior acquisitions for which we reduced the probability of achievement of associated revenue and/or regulatory milestones upon which payment is conditioned, or, in the case of nVision, for milestones that would not be achieved due to management's discontinuation of the R&D program. In addition, we made payments of $14 million associated with prior acquisitions during the first ~~nine~~six months of 2021, following the achievement of a revenue-based milestone. Refer to Note B – Acquisitions, Divestitures and Strategic Investments to our unaudited consolidated financial statements contained in Item 1 of this Quarterly Report on Form 10-Q for additional details related to our contingent consideration arrangements.

Restructuring Charges (Credits)

In November 2018, our Board of Directors approved, and we committed to, a new global restructuring program (the 2019 Restructuring Plan). ~~The 2019 Restructuring Plan, for which~~In addition, on February 22, 2022, our Board of Directors approved ~~an extension and expansion in February 2021, is~~increased cost estimates to complete

Table of Contents

additional activities identified under the program, which are expected to result in total pre-tax charges of approximately $450 million to $500 million, and approximately $375 million to ~~$475 million and approximately $340 million to $440~~$425 million of these charges are expected to result in cash outlays. We expect the majority of activity associated with our 2019 Restructuring Plan ~~including the extension,~~ to be substantially complete by the end of 2022. A substantial portion of the savings are being reinvested in strategic growth initiatives. Pursuant to this program, restructuring charges were $9$11 million in the ~~third~~second quarter of ~~2021,~~2022, $3 million in the ~~third~~second quarter of ~~2020, $15~~2021, $14 million in the first ~~nine~~six months of ~~2021~~2022 and ~~$16~~$6 million in the first ~~nine~~six months of ~~2020.~~2021. Restructuring-related charges were ~~$34~~$24 million in the ~~third~~second quarter of 2022, $35 million in the second quarter of 2021, ~~$20 million in the third quarter of 2020, $98~~$49 million in the first ~~nine~~six months of ~~2021~~2022 and ~~$61~~$64 million in the first ~~nine~~six months of ~~2020~~2021, and were recorded primarily in Cost of products sold and SG&A expenses.

In addition, on November 17, 2020, we announced a global, voluntary recall of all unused inventory of our LOTUS ~~Edge™~~EdgeTM Aortic Valve System and our decision to retire the entire ~~LOTUS™~~LOTUSTM Valve platform. We ~~recorded immaterial restructuring and restructuring-related charges associated with the product discontinuation in the third quarter of 2021 and~~ recorded $2 million of restructuring charges and ~~$17~~$16 million of restructuring-related charges associated with the product discontinuation in the first ~~nine~~six months of 2021. The ~~product discontinuation~~restructuring activities were completed in 2021 and resulted in total pre-tax restructuring and restructuring-related net charges of approximately $80 million. ~~We substantially completed the restructuring activities in the first quarter of 2021.~~

Refer to Note H – Restructuring-related Activities to our audited financial statements contained in Item 8 of our most recent Annual Report on Form 10-K for additional information.

Litigation-related net charges (credits)

We ~~did not record any~~recorded litigation-related net charges of $42 million during the ~~third~~second quarter and first six months of ~~2021~~2022. We recorded litigation-related net charges of $298 million during the second quarter and ~~recorded~~ $302 million during ~~the~~ first ~~nine~~six months of 2021, primarily related ~~primarily~~ to transvaginal surgical mesh products. ~~During the first nine months of 2021 we~~We increased the accrual associated with this matter to account for increased, post-COVID-19 ~~pandemic~~ settlement and litigation activity related to the remaining cases and claims the Company faces, our revision of the per-case settlement amount for these cases is based on recent settlement and litigation activity and changes to our expectations regarding the rate of incoming cases and claims. We recorded litigation-related net charges of $260 million during the third quarter and first nine months of 2020, primarily related to transvaginal mesh products, inclusive of a reserve related to claims made by a coalition of state attorneys general. We record certain legal and product liability charges, credits and costs of defense, which we consider to be unusual or infrequent and significant as Litigation-related net charges (credits) inwithin our accompanying unaudited consolidated financial statements. All other legal and product liability charges, credits and costs are recorded within SG&A expenses.

We continue to assess certain litigation and claims to determine the amounts, if any, that management believes will be paid as a result of such claims and litigation, and therefore, additional losses may be accrued and paid in the future, which could materially adversely impact our operating results, cash flows and/or our ability to comply with the financial covenant required by our credit arrangements. Refer to Note H – Commitments and Contingencies to our unaudited consolidated financial statements contained in Item 1 of this Quarterly Report on Form 10-Q for discussion of our material legal proceedings.

~~Table of Contents~~

Interest Expense

The following table provides a summary of our Interest expense and average borrowing rate:


		Three Months Ended September 30,						Nine Months Ended September 30,							Three Months Ended June 30,						Six Months Ended June 30,
		2021			2020			2021			2020				2022			2021			2022			2021
Interest expense (in millions)	Interest expense (in millions)	$	(86)		$	(86)		$	(254)		$	(265)		Interest expense (in millions)	$	(64)		$	(86)		$	(343)		$	(168)
Average borrowing rate	Average borrowing rate	3.6		%	3.4		%	3.6		%	3.4		%	Average borrowing rate	2.7		%	3.6		%	7.2		%	3.6		%

Interest expense and our average borrowing rate ~~remained relatively flat~~decreased in the ~~third~~second quarter ~~and first nine months~~ of ~~2021, as~~2022 compared to the ~~same periods~~prior year period, due to the issuance of euro-denominated bonds in the first quarter of 2022, which carry lower interest rates than our prior ~~year. During~~period debt portfolio. Interest expense and our average borrowing rate increased in the first ~~nine~~six months of ~~2020, we took proactive steps~~2022 compared to ~~manage~~ the ~~potential impact~~prior year period due to $194 million of charges associated with the ~~COVID-19 pandemic on~~early extinguishment of $3.275 billion of certain of our short-term liquidity and refinanced existing term loans and outstanding commercial paper with proceeds from new term loans and our 2018 Revolving Credit Facility. We refinanced this short-term, variable-rate debt in May 2020 with our issuances of $500 million 1.900% senior notes, ~~due June 2025~~including payment of tender premiums and ~~$1.200 billion 2.650% senior notes due June 2030. During~~ the ~~third quarter~~acceleration of ~~2020, we prepaid the remaining $250 million outstanding under our February 2021 Term Loan and terminated the facility.~~unamortized debt issuance costs. Refer to Liquidity and Capital Resources and Note E – Contractual Obligations and Commitments to our unaudited consolidated financial statements contained in Item 1 of this Quarterly Report on Form 10-Q for information regarding our debt obligations.

Table of Contents

Other, net

The following are the components of Other, net:


		Three Months Ended September 30,				Nine Months Ended September 30,					Three Months Ended June 30,				Six Months Ended June 30,
(in millions)	(in millions)	2021		2020		2021		2020		(in millions)	2022		2021		2022		2021
Interest income	Interest income	$	1	$	1	$	3	$	3	Interest income	$	1	$	1	$	5	$	3
Net foreign currency gain (loss)	Net foreign currency gain (loss)	(8)		(1)		(17)		(13)		Net foreign currency gain (loss)	1		(7)		(7)		(9)
Net gains (losses) on investments	Net gains (losses) on investments	186		48		208		14		Net gains (losses) on investments	(16)		(14)		(36)		22

Other income (expense), net	Other income (expense), net	3		16		(3)		6		Other income (expense), net	(0)		(7)		(7)		(5)
		$	181	$	64	$	192	$	9		$	(14)	$	(26)	$	(46)	$	11

In ~~the third quarter and first nine months of 2021, in~~ connection with the ~~acquisitions~~acquisition of ~~Farapulse and~~ Preventice in the first quarter of 2021, we remeasured the fair value of our previously-held ~~interests in the acquired companies,~~equity interest, which resulted in a ~~$222 million and~~ $195 million gain ~~respectively,~~ recognized within Other, net~~. In addition,~~ in the ~~third~~first six months of 2021. In the second quarter and first ~~nine~~six months of 2021, we also recorded losses of ~~$24~~$8 million and ~~$178~~$154 million, respectively, on our investment in Pulmonx Corporation presented in Other, net associated with the partial disposition of our ownership and remeasurement of our remaining investment ~~during the period~~ to fair value based on observable market ~~prices, as well as the disposition of our remaining ownership.~~prices. The Preventice ~~and Farapulse gains are~~gain is included within Acquisition/divestiture-related net charges (credits) and the Pulmonx loss is included in Investment portfolio net losses (gains)presented in the reconciliation of our results of operations prepared in accordance with U.S. GAAP to those adjusted results considered by management. Refer to Financial Summary for the reconciliation and Additional Information for a discussion of management's use of non-GAAP financial measures.

Tax ~~Rates~~Rate

Our effective tax rate from continuing operations is presented below:

Three Months Ended September 30, Nine Months Ended September 30,
2021 2020 2021 2020
Effective tax rate from continuing operations 13.2 % 31.7 % 1.1 % 24.3 %


	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Effective tax rate from continuing operations	24.7	%	(24.9)	%	26.1	%	(11.2)	%

~~Table of Contents~~

~~divestiture-related~~ net charges, as well as certain discrete tax items primarily related to ~~an IRS audit settlement~~changes in ~~the third quarter of 2020.~~

~~Economic stimulus legislation has been enacted~~tax laws, unrecognized tax benefits, changes in ~~many countries in response to the COVID-19 pandemic. In the U.S., the CARES Act, enacted on March 27, 2020, provided an estimated $2.2 trillion in COVID-19 pandemic-related relief,~~valuation allowance and included tax relief and government loans, subsidies and other relief for entities in affected industries. While we have not applied for government loans, we have taken advantage of the benefits offered in multiple jurisdictions, including the U.S. provision allowing taxpayers to defer payment of the employer portion of certain payroll taxes incurred in 2020. This allowed us to preserve cash generated from operations to service our debt obligations and other near-term commitments and is expected to be paid in full by the end of 2022 as permitted by the legislation.foreign return-to-provision adjustments.

Critical Accounting Policies and Estimates

Our financial results are affected by the selection and application of accounting policies and methods. In the second quarter and first ~~nine~~six months of ~~2021,~~2022, there were no material changes to the application of critical accounting policies previously disclosed in our most recent Annual Report on Form 10-K.

Liquidity and Capital Resources

Due to the uncertainty of the impact of the COVID-19 pandemic on our business, we took proactive steps in 2020 to reduce costs and ensure we are in a strong position to support customers and patients as healthcare systems recover and elective and semi-emergent procedures resume. These actions included taking steps to manage outstanding borrowings and increase available liquidity, and preemptively amending our financial covenant requirement for our outstanding credit arrangements.

Based on our current business plan, we believe our existing balance of Cash and cash equivalents, future cash generated from operations, access to capital markets and existing credit facilities will be sufficient to fund our operations, invest in our infrastructure, pay our legal-related liabilities, pay taxes due, service and repay our existing debt and fund possible acquisitions for ~~at least~~ the next 12 ~~months. We expect to fund~~months and for the previously announced definitive agreements to acquire Devoro Medical, Inc. and Baylis Medical Company, Inc. using cash on hand on the closing date of the transactions, expected in the fourth quarter of 2021 and the first quarter of 2022, respectively. Please refer to ~~Contractual Obligations and Commitments~~ ~~below for additional details on our future payment obligations and commitments.~~foreseeable future.

As of ~~September~~June 30, ~~2021,~~2022, we had ~~$1.947 billion~~$276 million of unrestricted Cash and cash equivalents on hand, comprised of ~~$1.537 billion~~$36 million invested in money market funds and time deposits and ~~$410~~$240 million in interest bearing and non-interest-bearing bank accounts. We invest excess cash on hand in short-term financial instruments that earn at market interest rates while mitigating principal risk through instrument and counterparty diversification, as well as what we believe to be prudent instrument selection. We limit our direct exposure to securities in any one industry or issuer.

Table of Contents

In 2021, we entered into a new $2.750 billion revolving credit facility (2021 Revolving Credit Facility) with a global syndicate of commercial banks and terminated our previous facility (2018 Revolving Credit Facility). The 2021 Revolving Credit Facility will mature on May 10, 2026, with one-year extension options, subject to certain conditions. This facility provides backing for our commercial paper program, and outstanding commercial paper directly reduces borrowing capacity under the 2021 Revolving Credit Facility. As of ~~September~~June 30, ~~2021,~~2022, we had no$155 million of commercial paper debt outstanding, resulting in an additional ~~$2.750~~$2.595 billion of available ~~liquidity.~~liquidity under the 2021 Revolving Credit Facility.

For additional details related to our debt obligations, including our financial covenant requirement, refer to Note E – Contractual Obligations and Commitments to our unaudited consolidated financial statements contained in Item 1 of this Quarterly Report on Form 10-Q.

The following provides a summary and description of our net cash inflows (outflows):


		Nine Months Ended September 30,					Six Months Ended June 30,
(in millions)	(in millions)	2021		2020		(in millions)	2022		2021
Cash provided by (used for) operating activities	Cash provided by (used for) operating activities	$	1,392	$	835	Cash provided by (used for) operating activities	$	249	$	927
Cash provided by (used for) investing activities	Cash provided by (used for) investing activities	(1,136)		(264)		Cash provided by (used for) investing activities	(1,603)		71
Cash provided by (used for) financing activities	Cash provided by (used for) financing activities	(87)		1,112		Cash provided by (used for) financing activities	(350)		(93)

Operating Activities

In the first ~~nine~~six months of ~~2021,~~2022, cash provided by operating activities ~~increased $557~~decreased $678 million as compared to the ~~first nine months of 2020,~~prior year period primarily due to changes in working capital partially offset by comparatively higher net sales and operating ~~income compared to the same period in the prior year.~~

~~Table of Contents~~

income.

Investing Activities

In the first ~~nine~~six months of 2022, cash used for investing activities included a net cash payment of $1.471 billion for the acquisition of Baylis Medical. In the first six months of 2021, cash provided by investing activities included proceeds of $801 million from the divestiture of the Specialty Pharmaceuticals business and ~~$329~~$92 million of proceeds from ~~the sale of~~(payments for) investments and ~~disposition~~acquisitions of certain ~~assets,~~technologies, partially offset by a net cash payment of ~~$2.014 billion~~$706 million for the ~~acquisitions~~acquisition of ~~Preventice, Lumenis and Farapulse.~~Preventice. For more information, refer to Note B – Acquisitions, Divestitures and Strategic Investments to our unaudited consolidated financial statements contained in Item 1 of this Quarterly Report on Form 10-Q. In addition, we made purchases of property, plant and equipment and internal use software of ~~$288~~$226 million in the first ~~nine~~six months of ~~2021~~2022 and ~~$217~~$181 million in the first ~~nine~~six months of ~~2020.~~2021.

Financing Activities

In the first ~~nine~~six months of 2022, we completed a public offering (the Offering) of €3.000 billion in aggregate principal amount of euro-dominated senior notes. The Offering resulted in cash proceeds of $3.270 billion, net of investor discounts and issuance costs. We used the net proceeds from the Offering to fund the tender offer and early redemption of combined aggregate principal amount of $3.275 billion of certain of our outstanding senior notes, as well as to pay accrued interest, tender premiums, fees and expenses. Cash used for financing activities in the first six months of 2022 also included payments on short-term borrowings of $250 million, payment of contingent consideration previously established in purchase accounting of $283 million and an increase (decrease) in commercial paper of $154 million. For more information, refer to Note E – Contractual Obligations and Commitments to our unaudited consolidated financial statements contained in Item 1 of this Quarterly Report on Form 10-Q. In the first six months of 2022 and 2021, cash used for financing activities ~~primarily~~also included cash payments associated with the settlement of employee equity awards ~~dividends paid to shareholders of our mandatory convertible preferred stock~~ and payments for royalty rights associated with the Zytiga™ Drug. On May 10, 2021 we entered into a new $2.750 billion revolving credit facility (2021 Revolving Credit Facility) with a global syndicate of commercial banks and terminated our previous facility (2018 Revolving Credit Facility). The 2021 Revolving Credit Facility will mature on May 10, 2026, with one-year extension options, subject to certain conditions. We have not made any borrowings against the 2021 Revolving Credit Facility.

In the first nine months of 2020, we took proactive steps to manage the potential impact of the emerging COVID-19 pandemic on our short-term liquidity and refinanced our existing term loans and outstanding commercial paper with proceeds from new term loans, borrowings against our 2018 Revolving Credit Facility, a senior notes offering and public equity offerings of preferred and common stock.

~~Please refer to~~ ~~Note F – Contractual Obligations and Commitments~~ to our audited financial statements contained in Item 8 of our most recent Annual Report on Form 10-K for additional information regarding financing activities for the year ended December 31, 2020, including the full repayment of amounts borrowed against our credit facility and partial repayment of amounts borrowed under term loans in the first nine months of 2020.

Financial Covenant

As of ~~and through September~~June 30, ~~2021,~~2022, we were in compliance with the financial covenant required by the ~~credit facilities.~~2021 Revolving Credit Facility described below.

Table of Contents

acquisition occurs, the maximum permitted leverage ratio is 4.75 times. The maximum permitted ratio steps down for the fifth, sixth and seventh succeeding quarters to 4.50 times, 4.25 times and 4.00 times, respectively. Thereafter, a maximum leverage ratio of 3.75 times is required through the remaining term of the 2021 Revolving Credit Facility. We have not elected to increase the maximum permitted leverage ratio for the recently completed ~~acquisition of Lumenis~~qualified acquisitions due to the funding ~~of the acquisition~~ using cash on hand. We believe that we have the ability to comply with the financial covenant for the next 12 months.

~~Table of Contents~~

Contractual Obligations and Commitments

Certain of our acquisitions involve the payment of contingent consideration. ~~See~~Refer to Note B – Acquisitions, Divestitures and Strategic Investments to our unaudited consolidated financial statements contained in Item 1 of this Quarterly Report on Form 10-Q for further details regarding the estimated potential amount of future contingent consideration we could be required to pay associated with our acquisitions. There have been no other material changes to our contractual obligations and commitments as ~~reported in our most recent Annual Report filed on Form 10-K.~~of June 30, 2022.

Equity

On May 27, 2020, we completed an offering of 10,062,500 shares of 5.50% Mandatory Convertible Preferred Stock, Series A (MCPS) at a price to the public and liquidation preference of $100 per share. The net proceeds from the MCPS offering were approximately $975 million after deducting underwriting discounts and commissions and offering expenses. On May 27, 2020, we also completed an offering of 29,382,500 shares of common stock at a public offering price of $34.25 per share. The net proceeds from the common stock offering were approximately $975 million after deducting underwriting discounts and commissions and offering expenses.

We received ~~$102~~$58 million in the first ~~nine~~six months of ~~2021~~2022 and ~~$107~~$38 million in the first ~~nine~~six months of ~~2020~~2021 in proceeds from stock issuances related to our stock option and employee stock purchase plans. Proceeds from the exercise of employee stock options and employee stock purchases vary from period to period based upon, among other factors, fluctuations in the trading price of our common stock and in the exercise and stock purchase patterns of our employees.

We did not repurchase any shares of our common stock in the second quarter or first ~~nine~~six months of ~~2021~~2022 or ~~2020.~~2021. On December 14, 2020, our Board of Directors approved a new stock repurchase program authorizing the repurchase of up to $1.000 billion of our common stock. As of ~~September~~June 30, ~~2021,~~2022, we had the full amount remaining available under the authorization.

Legal Matters

For a discussion of our material legal proceedings ~~see~~refer to Note H – Commitments and Contingencies to our unaudited consolidated financial statements contained in Item 1 of this Quarterly Report on Form 10-Q and Note K – Commitments and Contingencies to our audited financial statements contained in Item 8 of our most recent Annual Report on Form 10-K.

Recent Accounting Pronouncements

Information regarding new accounting pronouncements implemented since December 31, ~~2020 is included in~~ ~~Note A – Basis of Presentation~~2021 and ~~information regarding~~ new accounting pronouncements to be implemented is included in Note N – New Accounting Pronouncements to our unaudited consolidated financial statements contained in Item 1 of this Quarterly Report on Form 10-Q.

Additional Information

Cybersecurity

We have established controls and procedures to escalate enterprise level issues, including cybersecurity matters, to the appropriate management levels within our organization and our Board of Directors, or members or committees thereof, as appropriate. Under our framework, cybersecurity issues are analyzed by subject matter experts and a crisis committee for potential financial, operational, and reputational risks, based on, among other factors, the nature of the matter and breadth of impact. Matters determined to present potential material impacts to the Company’s financial results, operations, and/or reputation are immediately reported by management to the Board of Directors, or individual members or committees thereof, as appropriate, in accordance with our escalation framework. In addition, we have established procedures to ensure that management responsible for overseeing the effectiveness of disclosure controls is informed in a timely manner of known cybersecurity risks and incidents that may materially impact our operations and that timely public disclosure is made or updated, as appropriate.

5449

Table of Contents

The conflict between Russia and Ukraine raises cybersecurity risks on a global basis. While there is significant uncertainty around implications of cybersecurity attacks resulting from the conflict, we have taken steps to better understand our readiness, including the resilience of our critical business functions, with the goal of reducing the impact if such an event were to occur.

Stock Trading Policy

Our directors and executive officers are subject to our Stock Trading Policy, which is designed to facilitate compliance with insider trading laws and governs transactions in our common stock and related derivative securities. Our policy designates certain regular periods, dictated by release of financial results, in which trading is restricted for individuals in information-sensitive positions, including directors and executive officers. In addition, additional periods of trading restriction may be imposed as determined by the President and Chief Executive Officer, General Counsel, or Chief Financial Officer in light of material pending developments. Further, during permitted windows, individuals in information-sensitive positions are required to seek pre-clearance for trades from the General Counsel, who assesses whether there are any important pending developments, including cybersecurity matters, which need to be made public before the individual may participate in the market.

Periodically, certain of our executive officers adopt written stock trading plans in accordance with Rule 10b5-1 under the Exchange Act and our own Stock Trading Policy. A Rule 10b5-1 Trading Plan is a written document that pre-establishes the amount, prices and dates (or formulas for determining the amounts, prices and dates) of future purchases or sales of our stock, including shares issued upon exercise of stock options or vesting of deferred stock units. These plans are entered into at a time when the person is not in possession of material non-public information about the Company. We disclose details regarding individual Rule 10b5-1 Trading Plans on the Investor Relations section of our website.

Table of Contents

Use of Non-GAAP Financial Measures

To supplement our unaudited consolidated financial statements presented on a GAAP basis, we disclose certain non-GAAP financial measures, including adjusted net income (loss), adjusted net income (loss) available to common stockholders and adjusted net income (loss) per share (EPS) that exclude certain ~~amounts;~~charges (credits); operational net sales, which exclude the impact of foreign currency fluctuations; and organic net sales, which exclude the impact of foreign currency fluctuations as well as the impact of certain acquisitions and divestitures with less than a full period of comparable net sales. These non-GAAP financial measures are not in accordance with generally accepted accounting principles in the United States and should not be considered in isolation from or as a replacement for the most directly comparable GAAP financial measures. Further, other companies may calculate these non-GAAP financial measures differently than we do, which may limit the usefulness of those measures for comparative purposes.

To calculate adjusted net income (loss), adjusted net income (loss) available to common stockholders and adjusted net income (loss) per share we exclude certain charges (credits) ~~from GAAP~~, which include amortization expense, goodwill and intangible asset impairment charges, acquisition/divestiture-related net ~~income (loss)~~charges (credits), investment portfolio gains and ~~GAAP~~losses, restructuring and restructuring-related net ~~income (loss) available to common stockholders.~~charges (credits); and certain litigation-related net charges (credits), EU MDR implementation costs, debt extinguishment charges, deferred tax expenses (benefits) and discrete tax items. Amounts are presented after-tax ~~using~~at our effective tax rate, unless the amount is a significant unusual or infrequently occurring item in accordance with Financial Accounting Standards Board ~~(FASB)~~ Accounting Standards Codification ~~(ASC) section~~Topic 740-270-30, "General Methodology and Use of Estimated Annual Effective Tax Rate." Please refer to Part II, Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations in our most recent Annual Report filed on Form 10-K filed with the Securities and Exchange Commission ~~(SEC)~~ for an explanation of each of these adjustments and the reasons for excluding each item.

The GAAP financial measures most directly comparable to adjusted net income (loss), adjusted net income (loss) available to common stockholders and adjusted net income (loss) per share are GAAP net income (loss), GAAP net income (loss) available to common stockholders and GAAP net income (loss) per common share - assuming dilution, respectively.

To calculate operational net sales growth rates, which exclude the impact of foreign currency fluctuations, we convert actual net sales from local currency to U.S. dollars using constant foreign currency exchange rates in the current and prior periods. To calculate organic net sales growth rates, we also remove the impact of acquisitions and divestitures with less than a full period of comparable net sales. The GAAP financial measure most directly comparable to operational net sales and organic net sales is net sales on a GAAP basis.

Reconciliations of each of these non-GAAP financial measures to the corresponding GAAP financial measure are included in the relevant sections of this Quarterly Report.

Management uses these supplemental non-GAAP financial measures to evaluate performance period over period, to analyze the underlying trends in our business, to assess our performance relative to our competitors and to establish operational goals and forecasts that are used in allocating resources. In addition, management uses these non-GAAP financial measures to further its understanding of the performance of our operating segments. The adjustments excluded from our non-GAAP financial measures are consistent with those excluded from our operating segments’ measures of net sales and profit or loss. These adjustments are excluded from the segment measures reported to our chief operating decision maker that are used to make operating decisions and assess performance.

~~Table of Contents~~

We believe that presenting adjusted net income (loss), adjusted net income (loss) available to common stockholders, adjusted net income (loss) per share, operational net sales and organic net sales growth rates, in addition to the corresponding GAAP financial measures, provides investors greater transparency to the information used by management for its operational decision-making and allows investors to see our results “through the eyes” of management. We further believe that providing this information assists our investors in understanding our operating performance and the methodology used by management to evaluate and measure such performance.

Table of Contents

Safe Harbor for Forward-Looking Statements

Certain statements that we may make from time to time, including statements contained in this Quarterly Report on Form 10-Q and information incorporated by reference herein, constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like “anticipate,” “expect,” “project,” “believe,” “plan,” “may,”, “estimate,” “intend,” ~~“aim”~~“aim,” "goal," "target," "continue," "hope" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements.

The forward-looking statements in this Quarterly Report on Form 10-Q are based on certain risks and uncertainties, including the risk factors described in Part I, Item 1A. Risk Factors in our most recent Annual Report on Form 10-K and the specific risk factors discussed herein and in connection with forward-looking statements throughout this Quarterly Report on Form 10-Q, which could cause actual results to vary materially from the expectations and projections expressed or implied by our forward-looking statements. These risks and uncertainties, in some cases, have affected and in the future could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this Quarterly ~~Report.~~Report on Form 10-Q. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements. Risks and uncertainties that may cause such differences include, among other things: the impact of the ongoing COVID-19 pandemic on our operations and financial results; the impact of foreign currency fluctuations; future U.S. and global economic, political, competitive, reimbursement and regulatory ~~conditions;~~conditions, including as a result of the ongoing conflict between Russia and Ukraine; manufacturing, distribution and supply chain disruptions and cost increases; disruptions caused by cybersecurity events; disruptions caused by extreme weather or other climate change-related events; labor shortages and increases in labor costs; new product introductions and the market acceptance of those products; markets for our products; expected pricing environment; expected procedural volumes; the closing and integration of acquisitions; clinical trial results; demographic trends; intellectual property rights; litigation; financial market conditions; the execution and effect of our restructuring program; the execution and effect of our business strategy, including our cost-savings and growth initiatives; our ability to achieve environmental, social and governance goals and commitments; and future business decisions made by us and our competitors. New risks and uncertainties may arise from time to time and are difficult to predict, including those that have emerged or have increased in significance or likelihood as a result of the COVID-19 pandemic. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, ~~see~~refer to Part I, Item 1A. Risk Factors in our most recent Annual Report on Form 10-K filed with the SEC, which we may update in Part II, Item 1A. Risk Factors in subsequent Quarterly Reports on Form 10-Q that we will file ~~hereafter, and Part II, Item 1A.~~ ~~Risk Factors~~ ~~in this Quarterly Report on Form 10-Q.~~hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this Quarterly Report.

The following are some of the important risk factors that could cause our actual results to differ materially from our expectations in any forward-looking statements. For further discussion of these and other risk factors, ~~see~~refer to Part I, Item 1A. Risk Factors in our most recent Annual Report on Form ~~10-K and Part II, Item 1A.~~ ~~Risk Factors~~ ~~in this Quarterly Report on Form 10-Q.~~10-K.

Our Businesses

•The impact of the COVID-19 pandemic on the worldwide economy and financial markets, and developments related to the disease,

•The impact of the COVID-19 pandemic on our global manufacturing and distribution system, including disruption in the ~~time it will take for vaccines~~manufacture or supply of certain components, materials or products, or the failure to ~~be broadly produced, distributed and administered worldwide,~~secure in a timely manner alternative manufacturing or additional or replacement components, materials or products,

•Labor shortages and the ~~effectiveness~~impact of ~~such vaccines in slowing or stopping~~inflation on the ~~spread~~cost of ~~COVID-19~~raw materials and ~~variants thereof and mitigating~~direct labor, including as a result of the economic effects of the COVID-19 pandemic,

•The impact of the COVID-19 pandemic upon the scheduling of elective and semi-emergent procedures,

~~Table of Contents~~

•~~The impact of the COVID-19 pandemic on our global manufacturing and distribution system, including the quality of our products, availability and cost of raw materials and direct labor,~~

•~~Our ability to recover from the impact of the COVID-19 pandemic on our business and increase net sales, expand the markets in which we participate, capture market share and adapt to market volatility,~~

•The impact of natural disasters, climate change, additional future public health crises and other catastrophic events on our ability to manufacture, distribute and sell our products,

Table of Contents

•Competitive offerings and related declines in average selling prices for our products,

•The ongoing impact on our business of physician alignment to hospitals, governmental investigations and audits of hospitals and other market and economic conditions on the overall number of procedures performed,

•The performance of, and physician and patient confidence in, our products and technologies or those of our competitors,

•The impact and outcome of ongoing and future clinical trials and market studies undertaken by us, our competitors or other third parties or perceived product performance of our or our competitors' products,

•Variations in clinical results, reliability or product performance of our and our competitors' products,

•Our ability to acquire or develop, launch and supply new or next-generation products and technologies worldwide and in line with our commercialization strategies in a timely and successful manner and with respect to our recent acquisitions,

•The effect of consolidation and competition in the markets in which we do business or plan to do business,

•Disruption in the manufacture or supply of certain components, materials or products, or the failure to secure in a timely manner alternative manufacturing or additional or replacement components, materials or products,

•Our ability to achieve our projected level or mix of product sales, as some of our products are more profitable than others,

•Our ability to attract and retain talent, including key personnel ~~including those~~ associated with recent acquisitions, and to maintain our robust corporate culture, ~~especially in light of the remote working conditions imposed by the COVID-19 pandemic, and execute plans to return employees to offices in jurisdictions where safe and feasible,~~

•The inability of certain of our employees to return to work ~~full time~~full-time due to impacts of the COVID-19 pandemic, or our inability to recruit personnel into direct labor roles for the duration of the pandemic,

•The impact of enhanced requirements to obtain and maintain regulatory approval in the U.S. and around the world, including EU MDR and the associated timing and cost of product approval,

•The impact of increased pressure on the availability and rate of third-party reimbursement for our products and procedures in the U.S. and around the world, including with respect to the timing and costs of creating and expanding markets for new products and technologies,

•The issuance of new or revised accounting standards by the Financial Accounting Standards Board or the Securities and Exchange Commission, and

•The impact of potential goodwill and intangible asset impairment charges on our results of operations.

Regulatory Compliance, Litigation and Data Protection

•The impact of healthcare policy changes and legislative or regulatory efforts in the U.S., the EU and around the world to modify product approval or reimbursement processes, including a trend toward demonstrating clinical outcomes, comparative effectiveness and cost efficiency, as well as the impact of other healthcare reform legislation,

~~Table of Contents~~

•Risks associated with our regulatory compliance and quality systems and activities in the U.S., the EU and around the world, including meeting regulatory standards applicable to manufacturing and quality processes,

•The effect of global legal, regulatory or market responses to ~~global~~ climate change, including increased compliance burdens and costs to meet regulatory obligations,

•Our ability to minimize or avoid future field actions or FDA warning letters relating to our products and processes and the ongoing inherent risk of potential physician advisories related to our or our competitors' products,

•The impact of increased scrutiny of and heightened global regulatory enforcement facing the medical device industry arising from political and regulatory changes, economic pressures or otherwise, including under U.S. Anti-Kickback

Table of Contents

Statute, U.S. False Claims Act and similar laws in other jurisdictions, U.S. Foreign Corrupt Practices Act (FCPA) and similar laws in other jurisdictions, and U.S. and foreign export control, trade embargo and customs laws,

•Costs and risks associated with current and future asserted litigation,

•The effect of our litigation and risk management practices, including self-insurance and compliance activities on our loss contingencies, legal ~~provision~~provisions and cash flows,

•The impact of, diversion of management attention as a result of, and costs to cooperate with, litigate and/or resolve governmental investigations and our class action, product liability, contract and other legal proceedings,

•The possibility of failure to protect our intellectual property rights and the outcome of patent litigation,

•Our ability to operate properly our information systems that support our business operations and protect our data integrity and products from a cyber-attack or other breach that has a material adverse effect on our business, reputation or results of operationsincluding increased risks as an indirect result of the ongoing conflict between Russia and Ukraine, and

•The potential impact to internal control over financial reporting relating to potential restrictions to access to consigned inventory at customer locations for our inventory count procedures.

Innovation and Certain Growth Initiatives

•The timing, size and nature of our strategic growth initiatives and market opportunities, including with respect to our internal research and development platforms and externally available research and development platforms and technologies and the ultimate cost and success of those initiatives and opportunities,

•Our ability to complete planned clinical trials successfully, obtain regulatory approvals and launch new and next generation products in a timely manner consistent with cost estimates, including the successful completion of projects from in-process research and development,

•Our ability to identify and prioritize our internal research and development project portfolio and our external investment portfolio on profitable net sales growth opportunities as well as to maintain the estimated timing and costs of such projects and expected revenue levels for the resulting products and technologies,

•Our ability to develop, manufacture and market new products and technologies successfully and in a timely manner and the ability of our competitors and other third parties to develop products or technologies that render our products or technologies noncompetitive or obsolete,

•Our ability to execute appropriate decisions to discontinue, write-down or reduce the funding of any of our research and development projects, including projects from in-process research and development from our acquisitions, in our growth adjacencies or otherwise,

•Our dependence on acquisitions, alliances or investments to introduce new products or technologies and to enter new or adjacent growth markets and our ability to fund them or to fund contingent payments with respect to those acquisitions, alliances and investments, and

•The potential failure to successfully integrate and realize the expected benefits, including cost synergies, from the strategic acquisitions, alliances and investments we have consummated or may consummate in the future.

~~Table of Contents~~

International Markets

•Our dependency on international net sales to achieve growth, including in emerging markets,

•The timing and collectability of customer payments, as well as our ability to continue factoring customer receivables where we have factoring arrangements, or to enter new factoring arrangements with favorable terms,

•The impact on pricing due to national and regional tenders,

Table of Contents

•Geopolitical and economic conditions, including civil unrest, terrorist activity, governmental changes, restrictions on the ability to transfer capital across borders, tariffs and other protectionist measures,

•The impact of the ~~United Kingdom’s departure from~~Russia/Ukraine conflict,and related, downstream effects thereof, including the ~~European Union,~~impact of sanctions on U.S. manufacturers doing business in these regions,

•Protection of our intellectual property,

•Our ability to comply with established and developing U.S. and foreign legal and regulatory requirements, including FCPA, EU MDR and similar laws in other jurisdictions,

•Our ability to comply with U.S. and foreign export control, trade embargo and customs laws,

•The impact of changes in reimbursement practices and policies,

•The impact of significant developments or uncertainties stemming from changes in the U.S. ~~administration~~government following ~~the 2020~~ presidential and congressional elections, including changes in U.S. trade policies, tariffs and the reaction of other countries thereto, particularly China,

•Our ability to maintain or expand our worldwide market positions in the various markets in which we compete or seek to compete, including through investments in product diversification and emerging markets such as Brazil, Russia, India and China,

•Our ability to execute and realize anticipated benefits from our investments in emerging markets, and

•The potential effect of foreign currency fluctuations and interest rate fluctuations on our net sales, expenses and resulting margins.

Liquidity

•Our ability to generate sufficient cash flow to fund operations, capital expenditures, global expansion initiatives, any litigation settlements and judgments, share repurchases and strategic investments and acquisitions as well as maintaining our investment grade ratings and managing our debt levels and financial covenant compliance, ~~particularly in light of the COVID-19 pandemic and lower demand for our products,~~

•Our ability to access the public and private capital markets when desired and to issue debt or equity securities on terms reasonably acceptable to us,

•The unfavorable resolution of open tax matters, exposure to additional tax liabilities and the impact of changes in U.S. and international tax laws,

•The unfavorable resolution of open litigation matters, exposure to additional loss contingencies and legal provisions,

•The impact of examinations and assessments by domestic and international taxing authorities on our tax ~~provision,~~provisions, financial condition or results of operations,

•The possibility of counterparty default on our derivative financial instruments, and

•Our ability to collect outstanding and future receivables and/or sell receivables under our factoring programs.

~~Table of Contents~~

Cost Reduction and Optimization Initiatives

•Risks associated with changes made or expected to be made to our organizational and operational structure, pursuant to our restructuring plans as well as any further restructuring or optimization plans we may undertake in the future and our ability to recognize benefits and cost reductions from such programs and

Table of Contents

•Business disruption and employee distraction as we execute our global compliance program, restructuring and optimization plans and divestitures of assets or businesses and implement our other strategic and cost reduction initiatives.

6056

Table of Contents

ITEM 3.QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We develop, manufacture and sell medical devices globally and our earnings and cash flows are exposed to market risk from changes in currency exchange rates and interest rates. We address these risks through a risk management program that includes the use of derivative financial instruments. We operate the program pursuant to documented corporate risk management policies. We do not enter derivative transactions for speculative purposes. Gains and losses on derivative financial instruments substantially offset losses and gains on underlying hedged exposures. Furthermore, we manage our exposure to counterparty risk on derivative instruments by entering into contracts with a diversified group of major financial institutions and by actively monitoring outstanding positions.

Our currency risk consists primarily of foreign currency denominated firm commitments, forecasted foreign currency denominated intercompany and third-party transactions and net investments in certain subsidiaries. We use both nonderivative (primarily European manufacturing operations) and derivative instruments to manage our earnings and cash flow exposure to changes in currency exchange rates. We had currency derivative instruments outstanding in the contract amount of ~~$9.675~~$6.920 billion as of ~~September~~June 30, ~~2021~~2022 and ~~$10.481~~$8.381 billion as of December 31, ~~2020.~~2021. A ten percent appreciation in the U.S. dollar’s value relative to the hedged currencies would increase the derivative instruments’ fair value by ~~$333~~$264 million as of ~~September~~June 30, ~~2021~~2022 as compared to ~~$333~~$298 million as of December 31, ~~2020.~~2021. A ten percent depreciation in the U.S. dollar’s value relative to the hedged currencies would decrease the derivative instruments’ fair value by ~~$408~~$323 million as of ~~September~~June 30, ~~2021~~2022 as compared to ~~$407~~$364 million as of December 31, ~~2020.~~2021. Any increase or decrease in the fair value of our currency exchange rate sensitive derivative instruments would be substantially offset by a corresponding decrease or increase in the fair value of the hedged underlying asset, liability or forecasted transaction, resulting in minimal impacts on our unaudited consolidated statements of operations.

Our interest rate risk relates primarily to U.S. dollar borrowings partially offset by U.S. dollar cash investments. We have historically used interest rate derivative instruments to manage our earnings and cash flow exposure to changes in interest rates. We had no interest rate derivative instruments outstanding as of ~~September~~June 30, ~~2021~~2022 and December 31, ~~2020.~~2021. As of ~~September~~June 30, ~~2021, $9.143~~2022, $8.878 billion in aggregate principal amount of our outstanding debt obligations ~~were~~was at fixed interest rates, representing approximately ~~100~~98 percent of our total debt, on an amortized cost basis. As of ~~September~~June 30, ~~2021,~~2022, our outstanding debt obligations at fixed interest rates were comprised of senior notes.

Refer to Note D – Hedging Activities and Fair Value Measurements to our unaudited consolidated financial statements contained in Item 1 of this Quarterly Report on Form 10-Q for further information regarding our derivative financial instruments.

6157

Table of Contents

ITEM 4.CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer (CEO) and our Chief Financial Officer (CFO), evaluated the effectiveness of our disclosure controls and procedures as of ~~September~~June 30, ~~2021~~2022 pursuant to Rule 13a-15(b) of the Securities Exchange Act of 1934, as amended (the Exchange Act). Disclosure controls and procedures are designed to ensure that material information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that such material information is accumulated and communicated to our management, including our CEO and CFO, as appropriate, to allow timely decisions regarding required disclosure. Based on their evaluation, our CEO and CFO concluded that, as of ~~September~~June 30, ~~2021,~~2022, our disclosure controls and procedures were effective.

Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting in the ~~third~~second quarter or first six months of ~~2021~~2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. ~~Further, while many~~

A multi-year implementation of a new global enterprise resource planning (ERP) system is in progress and will replace our ~~employees continued~~existing ERP system. The implementation is expected to ~~work remotely~~occur in phases over the next several years. As the phased implementation occurs, it will result in changes to ~~adhere~~our processes and procedures which will include changes to ~~COVID-19 social distancing requirements, this did not affect~~ our ~~ability to maintain financial reporting systems,~~ internal controls over financial ~~reporting or disclosure controls and procedures. Prior to the COVID-19 pandemic,~~reporting. As such changes occur, we ~~were leveraging electronic tools to facilitate~~will evaluate quarterly whether they materially affect our global close process and to connect our physically dispersed team of finance professionals in offices around the world. While the quarterly close cycle was performed remotely, fundamentally, the work performed, and the processes and controls executed did not change.internal control over financial reporting.

6258

Table of Contents

PART II

OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

~~See~~Refer to Note G – Income Taxes and Note H – Commitments and Contingencies to our unaudited consolidated financial statements contained in Item 1 of this Quarterly Report on Form 10-Q, which is incorporated herein by reference.

ITEM 1A. RISK FACTORS

In addition to other information contained elsewhere in this report, you should carefully consider the factors discussed in Part I, Item 1A. Risk Factors in our most recent Annual Report filed on Form 10-K, which could materially affect our business, financial condition or future results.

ITEM 6. EXHIBITS (* documents filed or furnished with this ~~report,)~~report)






4.1						~~Second Supplemental~~ Indenture dated as of ~~April 21, 2006 between~~March 8, 2022, among American Medical Systems Europe B.V., Boston Scientific Corporation and ~~The~~U.S. Bank ~~of New York Mellon Trust Company, N.A., as successor to J.P. Morgan~~ Trust Company, National Association, as Trustee (incorporated ~~herein~~ by reference to Exhibit ~~99.6,~~4.1, Current Report on Form 8-K dated ~~April 21, 2006,~~March 8, 2022, File No. 1-11083)

4.2						0.750% Senior Notes due March 8, 2025 (incorporated herein by reference to Exhibit 4.2, Current Report on Form 8-K dated March 8, 2022, File No. 1-11083)

4.3						1.375% Senior Notes due March 8, 2028 (incorporated herein by reference to Exhibit 4.3, Current Report on Form 8-K dated March 8, 2022, File No. 1-11083)

4.4						1.625% Senior Notes due March 8, 2031 (incorporated herein by reference to Exhibit 4.4, Current Report on Form 8-K dated March 8, 2022, File No. 1-11083)

4.5						1.875% Senior Notes due March 8, 2034 ((incorporated herein by reference to Exhibit 4.5, Current Report on Form 8-K dated March 8, 2022, File No. 1-11083)

10.1						Form of EC Non-CEO Change in Control Agreement (incorporated herein by reference to Exhibit 10.1, Current Report on Form 8-K dated May 6, 2022, File No. 1-11083)

10.2						Boston Scientific Corporation Employee Stock Purchase Plan, Amended and Restated Effective as of July 1, 2022 (incorporated by reference herein to Exhibit 10.2, Current Report on Form 8-K dated May 6, 2022, File No. 1-11083)

22








						Subsidiary Issuer of Guaranteed Securities

31.1*						Certification of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2*						Certification of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32.1*						Certification of the Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

32.2*						Certification of the Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101.SCH*						XBRL Taxonomy Extension Schema Document.

Table of Contents


101.CAL*						XBRL Taxonomy Extension Calculation Linkbase Document.

101.DEF*						XBRL Taxonomy Extension Definition Linkbase Document.

101.LAB*						XBRL Taxonomy Extension Label Linkbase Document.

101.PRE*						XBRL Taxonomy Extension Presentation Linkbase Document.

104						Cover Page Interactive Data File (embedded within the Inline XBRL document and contained in Exhibit 101).

6360

Table of Contents

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized on ~~November~~August 4, ~~2021.~~2022.


BOSTON SCIENTIFIC CORPORATION
By:	/s/ Daniel J. Brennan

	Name:	Daniel J. Brennan
	Title:	Executive Vice President and Chief Financial Officer

6461


		Page No.

PART I	FINANCIAL INFORMATION	3

ITEM 1.	Consolidated Financial Statements	3

	Consolidated Statements of Operations (Unaudited)	3

	Consolidated Statements of Comprehensive Income (Loss) (Unaudited)	4

	Consolidated Balance Sheets (Unaudited as of ~~September~~June 30 ~~2021)~~ 2022)	5

	Consolidated Statements of Stockholders' Equity (Unaudited)	6

	Consolidated Statements of Cash Flows (Unaudited)	7

	Notes to the Consolidated Financial Statements (Unaudited)	9

ITEM 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	4036

ITEM 3.	Quantitative and Qualitative Disclosures About Market Risk	6257

ITEM 4.	Controls and Procedures	6358

PART II	OTHER INFORMATION	6459

ITEM 1.	Legal Proceedings	6459

ITEM 1A.	Risk Factors	6459



ITEM 6.	Exhibits	6459

SIGNATURE		6561


(in millions)	Preventice		Lumenis		Farapulse		Total
Payment for acquisition, net of cash acquired	$	706	$	1,039	$	268	$	2,014
Fair value of contingent consideration	221		—		162		384
Fair value of prior interest	269		—		222		491
	$	1,197	$	1,039	$	653	$	2,889


	Three Months Ended September 30,				Nine Months Ended September 30,
Geographic Regions	2021		2020		2021		2020
U.S.	$	1,726	$	1,496	$	5,103	$	4,005
EMEA (Europe, Middle East and Africa)	590		540		1,855		1,507
APAC (Asia-Pacific)	517		472		1,511		1,292
LACA (Latin America and Canada)	99		77		279		217
Medical Devices	2,932		2,584		8,748		7,021
U.S.	—		65		10		162
International	—		10		4		21
Specialty Pharmaceuticals	—		74		13		183
Net Sales	$	2,932	$	2,659	$	8,761	$	7,204

Emerging Markets(1)	$	354	$	291	$	1,030	$	832


	Three Months Ended September 30, 2020
(in millions, except per share data)	Income (Loss) Before Income Taxes		Income Tax Expense (Benefit)		Net Income (Loss)		Preferred Stock Dividends		Net Income (Loss) Available to Common Stockholders		Impact per Share(4)
Reported	$	(227)	$	(72)	$	(155)	$	(14)	$	(169)	$	(0.12)
Non-GAAP adjustments:
Amortization expense	197		21		176		—		176		0.12
Intangible asset impairment charges	219		30		189		—		189		0.13
Acquisition/divestiture-related net charges (credits)	111		24		87		—		87		0.06
Restructuring and restructuring-related net charges (credits)	23		3		21		—		21		0.01
Litigation-related net charges (credits)	260		5		255		—		255		0.18
Investment portfolio net losses (gains)	(65)		(15)		(50)		—		(50)		(0.03)
European Union (EU) Medical device regulation (MDR) implementation costs	8		1		7		—		7		0.00
Deferred tax expenses (benefits)	—		(18)		18		—		18		0.01
Discrete tax items	—		3		(3)		—		(3)		(0.00)
Adjusted	$	525	$	(18)	$	543	$	(14)	$	530	$	0.37


	Nine Months Ended September 30, 2021
(in millions, except per share data)	Income (Loss) Before Income Taxes		Income Tax Expense (Benefit)		Net Income (Loss)		Preferred Stock Dividends		Net Income (Loss) Available to Common Stockholders		Impact per Share(5)
Reported	$	957	$	10	$	946	$	(42)	$	905	$	0.63
Non-GAAP adjustments:
Amortization expense	549		53		496		—		496		0.35
Intangible asset impairment charges	173		25		148		—		148		0.10
Acquisition/divestiture-related net charges (credits)	(444)		5		(449)		—		(449)		(0.31)
Restructuring and restructuring-related net charges (credits)	133		15		118		—		118		0.08
Litigation-related net charges (credits)	302		69		233		—		233		0.16
Investment portfolio net losses (gains)	178		43		136		—		136		0.09
European Union (EU) Medical device regulation (MDR) implementation costs	35		3		32		—		32		0.02

Deferred tax expenses (benefits)	—		(86)		86		—		86		0.06
Discrete tax items	—		21		(21)		—		(21)		(0.01)
Adjusted	$	1,883	$	158	$	1,725	$	(42)	$	1,683	$	1.17


	Nine Months Ended September 30, 2020
(in millions, except per share data)	Income (Loss) Before Income Taxes		Income Tax Expense (Benefit)		Net Income (Loss)		Preferred Stock Dividends		Net Income (Loss) Available to Common Stockholders		Impact per Share(6)
Reported	$	(386)	$	(94)	$	(292)	$	(19)	$	(311)	$	(0.22)
Non-GAAP adjustments:
Amortization expense	595		62		533		—		533		0.38
Intangible asset impairment charges	452		68		384		—		384		0.27
Acquisition/divestiture-related net charges (credits)	148		48		100		—		100		0.07
Restructuring and restructuring-related net charges (credits)	77		10		66		—		66		0.05
Litigation-related net charges (credits)	260		5		255		—		255		0.18
Investment portfolio net losses (gains)	(65)		(15)		(50)		—		(50)		(0.04)
European Union (EU) Medical device regulation (MDR) implementation costs	20		2		17		—		17		0.01
Deferred tax expenses (benefits)	—		(26)		26		—		26		0.02
Discrete tax items	—		(20)		20		—		20		0.01
Adjusted	$	1,100	$	41	$	1,059	$	(19)	$	1,040	$	0.73


	Percentage of Net Sales
	Three Months	Nine Months
Gross profit margin - period ended September 30, 2020	67.3%	65.8%
Abnormal production variances	0.5	1.4

Sales pricing, volume and mix	0.4	1.3
Inventory charges	0.9	0.4





All other, including other expenses	0.2	(0.1)
Gross profit margin - period ended September 30, 2021	69.3%	68.7%